Bangladesh Mayer Hashi II 2015 Baseline Survey Report

August 2017

TR-17-183





Bangladesh Mayer Hashi II 2015 Baseline Survey Report

August 2017

TR-17-183

MEASURE Evaluation

University of North Carolina at Chapel Hill 400 Meadowmont Village Circle, 3rd Floor Chapel Hill, North Carolina 27517 *Phone:* +1-919-445-9350 • measure@unc.edu

www.measureevaluation.org

This publication was produced with the support of the United States Agency for International Development (USAID) under the terms of MEASURE Evaluation cooperative agreement AID-OAA-I-14-00004. MEASURE Evaluation is implemented by the Carolina Population Center, University of North Carolina at Chapel Hill in partnership with ICF International; John Snow, Inc.; Management Sciences for Health; Palladium; and Tulane University. Views expressed are not necessarily those of USAID or the United States government. TR-17-183 ISBN: 978-1-9433-6461-9





CONTENTS

1. Introduction and Background 1 1. 1. Purpose of the 2015 Baseline Survey 1 1.2. Country Context 1 1.3. Project Description 3 1.4. Evaluation Design 7 1.5. Evaluation Questions 9 1.6. Sample Design of 2015 MH-II Baseline Survey 10 1.6.1. Household Survey 10 1.6.2. Facility Readiness and Provider Surveys 11 1.8. Survey Instruments 11 1.8.3. Provider Questionnaire 12 1.8.4. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 13 1.9.1. Training and Fieldwork 13 1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 17 2.1. Primary Outcomes 17 2.1. Contraceptive Use and Method Mix 17 <	Abbreviations	ix
1.2. Country Context 1 1.3. Project Description 3 1.4. Evaluation Design 7 1.5. Evaluation Questions 9 1.6. Sample Design of 2015 MtHI Baseline Survey 10 1.6.1. Household Survey 10 1.6.2. Facility Readiness and Provider Surveys 11 1.7. Implementation of the Survey. 11 1.8. Survey Instruments 11 1.8.1. Household Listing Schedule. 11 1.8.2. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.9.7. Training and Fieldwork for Household Listing 13 1.9.1. Training and Fieldwork for the Usehold and Women's Survey 13 1.9.2. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 17 2.1. Primary Outcomes 17 2.1. Primary Outcomes 17 2.1. Provider Training 20 2.2. Intermedicite/Process Outcomes 20 2.2.1. Provider Knowledge and Self-Reported	1. Introduction and Background	1
1.3. Project Description 3 1.4. Evaluation Design 7 1.5. Evaluation Questions 9 1.6. Sample Design of 2015 MH-II Baseline Survey 10 1.6.1. Household Survey 10 1.6.2. Facility Readiness and Provider Surveys 11 1.7. Implementation of the Survey. 11 1.8. Survey Instruments 11 1.8.1. Household Listing Schedule. 11 1.8.2. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.8.7. Training and Fieldwork 13 1.9.9.1. Training Aretesting and Fieldwork for Household Listing 13 1.9.1. Training /Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.0. Data Processing 13 1.11. Response Rates 13 2.1. Primary Outcomes 17 2.1. Primary Outcomes 17 2.1. Provider Training 20 2.2. Intermediate/Process Outcomes 20 2.2.1. Provider Knowledge and Self-Reported Practice 23 2.3.	1.1. Purpose of the 2015 Baseline Survey	1
1.4. Evaluation Design 7 1.5. Evaluation Questions 9 1.6. Sample Design of 2015 MH-II Baseline Survey 10 1.6.1. Household Survey 10 1.6.2. Facility Readiness and Provider Surveys 10 1.6.1. Household Survey 10 1.6.2. Facility Readiness and Provider Surveys 11 1.7. Implementation of the Survey. 11 1.8. Survey Instruments 11 1.8.1. Household Listing Schedule. 11 1.8.2. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork for Household Listing 13 1.9.1. Training and Fieldwork for Household and Women's Survey 13 1.9.2. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 17 2.1. Primary Outcomes 17 2.1.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use and Method Mix 17	1.2. Country Context	1
1.5. Evaluation Questions 9 1.6. Sample Design of 2015 MH-II Baseline Survey 10 1.6. 1. Household Survey 10 1.6. 2. Facility Readiness and Provider Surveys 11 1.7. Implementation of the Survey. 11 1.8. Survey Instruments 11 1.8. Survey Instruments 11 1.8. 1. Household Listing Schedule. 11 1.8. 2. Household and Women's Questionnaire 12 1.8. 3. Provider Questionnaire 12 1.8. 4. Facility Readiness Questionnaire 12 1.8. 4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork 13 1.9. 2. Training /Pretesting and Fieldwork for Household Listing 13 1.9. 3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.9. 3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2.1. Primary Outcomes 17 2.1. 1. Contraceptive Use and Method Mix 17 2.1. 2. Contraceptive Use and Method Mix 17 2.1. 2. Contraceptive Use and Method Mix 17 <	1.3. Project Description	3
1.6. Sample Design of 2015 MH-II Baseline Survey 10 1.6.1. Household Survey 10 1.6.2. Facility Readiness and Provider Surveys 11 1.7. Implementation of the Survey. 11 1.8. Survey Instruments 11 1.8. Survey Instruments 11 1.8.1. Household Listing Schedule. 11 1.8.2. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork for Household Listing 13 1.9.1. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.2. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2.1. Primary Outcomes 17 2.1. Primary Outcomes 17 2.1. Provider Training 20 2.2. Intermediate/Process Outcomes 20 2.2.1. Provider Training 20 2.2.2. Provider Knowledge and Self-Reported Practice 23 2.2.3. Quality of Care 23	1.4. Evaluation Design	7
1.6.1. Household Survey 10 1.6.2. Facility Readiness and Provider Surveys 11 1.7. Implementation of the Survey. 11 1.8. Survey Instruments 11 1.8.2. Household Listing Schedule. 11 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.8.5. Training and Fieldwork 13 1.9. Training and Fieldwork for Household Listing 13 1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2.1. Primary Outcomes 17 2.1. Primary Outcomes 17 2.1. Contraceptive Use and Method Mix 17 2.1. Contraceptive Use and Method Mix 17 2.1. Contraceptive Use and Self-Reported Practice 23 2.2.1. Provider Training 20 2.2.2. P	1.5. Evaluation Questions	9
1.6.2. Facility Readiness and Provider Surveys 11 1.7. Implementation of the Survey. 11 1.8. Survey Instruments 11 1.8. Household Listing Schedule. 11 1.8. Fracility Readiness Questionnaire 12 1.8. Facility Readiness Questionnaire 12 1.8. Fraining and Fieldwork 13 1.9. Training and Fieldwork for Household Listing 13 1.9.1. Training /Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2.1. Primary Outcomes 17 2.1. Primary Outcomes 17 2.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use and Self-Reported Practice 23 2.2.3. Quality of Care	1.6. Sample Design of 2015 MH-II Baseline Survey	10
1.7. Implementation of the Survey. 11 1.8. Survey Instruments 12 1.8. Automative Questionnaire 12 1.8. Facility Readiness Questionnaire 12 1.8. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork for Household Listing 13 1.9.1. Training and Fieldwork for Household Listing 13 1.9.2. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2.1. Primary Outcomes 17 2.1. Primary Outcomes 17 2.1. Contraceptive Use and Method Mix 17 2.1. 2. Contraceptive Use and Method Mix 17 2.1. 2. Contraceptive Use and Self Reported Practice 23 2.2.1. Provider Training 20 2.2.2. Provider Knowledge and Self Reported Practice 23 2.3. Analysis of Evaluation Design Assumpti	1.6.1. Household Survey	10
1.8. Survey Instruments 11 1.8. Survey Instruments 11 1.8.1. Household Listing Schedule. 11 1.8.2. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork for Household Listing 13 1.9.2. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.1.0. Data Processing 13 1.1.1. Response Rates 13 2.1.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 18 2.2.1. Provider Training 20 2.2.2. Pr	1.6.2. Facility Readiness and Provider Surveys	11
1.8.1. Household Listing Schedule. 11 1.8.2. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork 13 1.9.1. Training and Fieldwork for Household Listing 13 1.9.2. Training AP Freesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2. Key Findings 17 2.1. Primary Outcomes 17 2.1. Contraceptive Use and Method Mix 17 2.1.1. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 20 2.2.1. Provider Training 20 2.2.2. Intermediate/Process Outcomes 20 2.2.3. Quality of Care 23 2.2.4. Behavior Change and Behavior Change Communication Activities 25 2.3. Analysis of Evaluation Design Assumptions 31 2.1.1. Timing of Baseline Data Collection 31 2.1.2. Comparability of Phase 1 and Phase III Areas 3	1.7. Implementation of the Survey	11
1.8.2. Household and Women's Questionnaire 12 1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork 13 1.9.1. Training and Fieldwork for Household Listing 13 1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2. Key Findings 17 2.1. Primary Outcomes 17 2.1. Contraceptive Use and Method Mix 17 2.1.1. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 20 2.2.1. Provider Training 20 2.2.2. Intermediate/Process Outcomes 20 2.2.3. Quality of Care 23 2.2.4. Behavior Change and Behavior Change Communication Activities 25 2.3. Analysis of Evaluation Design Assumptions 31 2.1.1. Timing of Baseline Data Collection 31 2.1.2. Comparability of Phase I and Phase III Areas 32 2.1.3. Parallel Trend Assumption 34 <td>1.8. Survey Instruments</td> <td>11</td>	1.8. Survey Instruments	11
1.8.3. Provider Questionnaire 12 1.8.4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork 13 1.9.1. Training and Fieldwork for Household Listing 13 1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2. Key Findings 17 2.1. Primary Outcomes 17 2.1.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 18 2.2.1. Intermediate/Process Outcomes 20 2.2.2. Provider Training 20 2.2.3. Quality of Care 23 2.2.4. Behavior Change and Behavior Change Communication Activities 25 2.3. Analysis of Evaluation Design Assumptions 31 2.1.1. Timing of Baseline Data Collection 31 2.1.2. Comparability of Phase I and Phase III Areas 32 2.1.3. Parallel Trend Assumption 34 References 35 <t< td=""><td>1.8.1. Household Listing Schedule</td><td>11</td></t<>	1.8.1. Household Listing Schedule	11
1.8.4. Facility Readiness Questionnaire 12 1.9. Training and Fieldwork 13 1.9.1. Training and Fieldwork for Household Listing 13 1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2. Key Findings 17 2.1. Primary Outcomes 17 2.1.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 18 2.2.1. Provider Training 20 2.2.2. Provider Knowledge and Self-Reported Practice 23 2.2.3. Quality of Care 23 2.2.4. Behavior Change and Behavior Change Communication Activities 25 2.3. Analysis of Evaluation Design Assumptions 31 2.1.1. Timing of Baseline Data Collection 31 2.1.2. Comparability of Phase I and Phase III Areas 32 2.1.3. Parallel Trend Assumption 34 References 35 Appendix A. Additional Tables 37	1.8.2. Household and Women's Questionnaire	12
1.9. Training and Fieldwork131.9.1. Training and Fieldwork for Household Listing131.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey131.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey131.10. Data Processing131.11. Response Rates132. Key Findings172.1. Primary Outcomes172.1.1. Contraceptive Use and Method Mix172.1.2. Contraceptive Use among Young Married Women182.1.3. Postpartum Contraceptive Counseling and Use182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	1.8.3. Provider Questionnaire	12
1.9. Training and Fieldwork131.9.1. Training and Fieldwork for Household Listing131.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey131.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey131.10. Data Processing131.11. Response Rates132. Key Findings172.1. Primary Outcomes172.1.1. Contraceptive Use and Method Mix172.1.2. Contraceptive Use among Young Married Women182.1.3. Postpartum Contraceptive Counseling and Use182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	1.8.4. Facility Readiness Questionnaire	12
1.9.1. Training and Fieldwork for Household Listing 13 1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2. Key Findings 17 2.1.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 18 2.2.1. Provider Training 20 2.2.2. Provider Knowledge and Self-Reported Practice 23 2.2.3. Quality of Care 23 2.2.4. Behavior Change and Behavior Change Communication Activities 25 2.3. Analysis of Evaluation Design Assumptions 31 2.1.1. Timing of Baseline Data Collection 31 2.1.2. Comparability of Phase I and Phase III Areas 32 2.1.3. Parallel Trend Assumption 34 References 35 Appendix A. Additional Tables 37		
1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey 13 1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2. Key Findings 17 2.1. Primary Outcomes 17 2.1.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 18 2.2.1. Provider Training 20 2.2.2. Provider Knowledge and Self-Reported Practice 23 2.2.4. Behavior Change and Behavior Change Communication Activities 25 2.3. Analysis of Evaluation Design Assumptions 31 2.1.2. Comparability of Phase I and Phase III Areas 32 2.1.3. Parallel Trend Assumption 34 References 35 Appendix A. Additional Tables 37		
1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey 13 1.10. Data Processing 13 1.11. Response Rates 13 2. Key Findings 17 2.1. Primary Outcomes 17 2.1.1. Contraceptive Use and Method Mix 17 2.1.2. Contraceptive Use among Young Married Women 18 2.1.3. Postpartum Contraceptive Counseling and Use 18 2.2.1. Intermediate/Process Outcomes 20 2.2.2. Provider Training 20 2.2.3. Quality of Care 23 2.2.4. Behavior Change and Behavior Change Communication Activities 25 2.3. Analysis of Evaluation Design Assumptions 31 2.1.1. Timing of Baseline Data Collection 31 2.1.2. Comparability of Phase I and Phase III Areas 32 2.1.3. Parallel Trend Assumption 34 References 35 Appendix A. Additional Tables 37		
1.10. Data Processing131.11. Response Rates132. Key Findings172.1. Primary Outcomes172.1.1. Contraceptive Use and Method Mix172.1.2. Contraceptive Use among Young Married Women182.1.3. Postpartum Contraceptive Counseling and Use182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37		
2. Key Findings172.1. Primary Outcomes172.1.1. Contraceptive Use and Method Mix172.1.2. Contraceptive Use among Young Married Women182.1.3. Postpartum Contraceptive Counseling and Use182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37		
2.1. Primary Outcomes172.1.1. Contraceptive Use and Method Mix172.1.2. Contraceptive Use among Young Married Women182.1.3. Postpartum Contraceptive Counseling and Use.182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	1.11. Response Rates	13
2.1.1. Contraceptive Use and Method Mix172.1.2. Contraceptive Use among Young Married Women182.1.3. Postpartum Contraceptive Counseling and Use182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2. Key Findings	17
2.1.2. Contraceptive Use among Young Married Women182.1.3. Postpartum Contraceptive Counseling and Use182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.1. Primary Outcomes	17
2.1.3. Postpartum Contraceptive Counseling and Use.182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.1.1. Contraceptive Use and Method Mix	17
2.1.3. Postpartum Contraceptive Counseling and Use.182.2. Intermediate/Process Outcomes202.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.1.2. Contraceptive Use among Young Married Women	18
2.2.1. Provider Training202.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.1.3. Postpartum Contraceptive Counseling and Use	18
2.2.2. Provider Knowledge and Self-Reported Practice232.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.2. Intermediate/Process Outcomes	20
2.2.3. Quality of Care232.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.2.1. Provider Training	20
2.2.4. Behavior Change and Behavior Change Communication Activities252.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.2.2. Provider Knowledge and Self-Reported Practice	23
2.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.2.3. Quality of Care	23
2.3. Analysis of Evaluation Design Assumptions312.1.1. Timing of Baseline Data Collection312.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.2.4. Behavior Change and Behavior Change Communication Activities	25
2.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37		
2.1.2. Comparability of Phase I and Phase III Areas322.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37	2.1.1. Timing of Baseline Data Collection	31
2.1.3. Parallel Trend Assumption34References35Appendix A. Additional Tables37		
References		
Appendix A. Additional Tables	•	

Household Survey	37
Women's Survey	
Client-Provider Contact in the Past Six Months	
Quality of Care	
, Knowledge of LARCs/PMs	
Knowledge of Postpartum Family Planning	
Method Mix	
Source of Current Contraceptive Method	51
Postpartum Family Planning	53
Discussion of LARCs/PMs in Past Six Months	55
Intention to Use LARC/PM in Next 12 Months	55
Appendix A.2. Provider Survey Tables	
Provider Training	57
Provider's Knowledge and Practice: IUDs	58
Provider's Knowledge and Practice: Implants	
Provider's Knowledge and Practice: Female Sterilization	
Provider Knowledge of Postpartum Family Planning Policies	
Appendix A.3. Facility Readiness Survey Tables	68
Services Available at Facilities	68
Quality of Care Assessment and Feedback Mechanisms	70
Facility Infrastructure	
Behavior Change Communication Materials Available in Facilities	72
Availability of Equipment and Supplies	72
Appendix B. Balance Test Tables	75
Appendix C. Mayer Hashi II Questionnaires	79
Appendix C.1. Household and Women's Questionnaire	79
Appendix C.2. Questionnaire for FWA, Service Promoter, and Community Health Worker	112
Appendix C.3. Questionnaire for FWV, SACMO, Nurse, Nurse Midwife, and Paramedic	126
Appendix C.4. Questionnaire for MO (MCH-FP), Medical Officer, RMO, and Clinic Manager	144
Appendix C.5. Questionnaire for Obstetrician/Gynecologist (OB/GYN)	162
Appendix C.6. Facility Readiness Questionnaire	175

Figures and Tables

Figure 1.1: Trends in current contraceptive use by method
Table 1.1: Trends in modern contraceptive method mix
Figure 1.2: Map of Bangladesh districts by phase of Mayer Hashi II project implementation 6
Figure 1.3: Pathways through which MH-II interventions can affect contraceptive behavior
Table 1.2: Mayer Hashi II key indicators 9
Table 1.3: Results of interviews with households and women14
Table 1.4: Results of interviews with health facilities by type of facility15
Table 1.5: Results of interviews with health service providers
Figure 2.1: Percentage of currently married women ages 15–49 who use contraceptive methods, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey17
Figure 2.2: Use of contraceptive methods by women under 25 years of age who have been married for two years or less by type of contraceptive method used, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey
Figure 2.3A: Facility delivery, counseling, and use of postpartum family planning among women who gave birth between January 2012 and September 2013, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey
Figure 2.3B: Facility delivery, counseling, and use of postpartum family planning among women who have given birth since October 2013, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey
Figure 2.4: Percentage of providers who received training in LARCs/PMs since 2014 by type of provider, by Phase I and Phase III areas, 2015 MH-II survey21
Figure 2.5: Percentage of providers who received training on postpartum family planning since 2014 by type of provider, by Phase I and Phase III areas, 2015 MH-II survey
Figure 2.6: Percentage of providers who received training on behavior change communication since 2014 by type of provider, by Phase I and Phase III areas, 2015 MH-II survey22
Figure 2.7: Percentage of facilities with minimal equipment and supplies to provide LARC/PM services by facility type and method, by Phase I and Phase III areas, 2015 MH-II survey24
Figure 2.8: Indicators of quality of family planning care reported among women ages 15–49 who are not pregnant and are using female sterilization, IUDs, or implants, by Phase I and Phase III areas, 2015 MH-II survey
Figure 2.9: Availability of various behavior change communication materials at each type of health facility, by Phase I and Phase III areas, 2015 MH-II survey
Figure 2.10: Percentage of married women ages 15–49 who had heard/saw/read about LARCs/PMs in the six months preceding the survey, by Phase I and Phase III areas, 2015 MH-II survey
MH-II survey
Figure 2.12: Perceptions of male and female sterilization among women ages 15–49 by Phase I and Phase III areas, 2015 MH-II survey
Figure 2.13: Intention to use LARCs/PMs in the next 12 months among women ages 15–49 who are not pregnant, are not using LARCs/PMs, and do not want any more children or are undecided about wanting more children, by Phase I and Phase III areas, 2015 MH-II survey30

Table 2.1: Summary results of the balance tests for similarity between Phase I and Phase III districts, 2015 MH-II survey	33
Figure 2.14: Trends in prevalence of LARC/PM use among married women ages 15–49, 2010–2015, by Phase I and Phase III districts	35

Appendix A

Table A.1.1: Household composition	37
Table A.1.2: Housing characteristics and land ownership	
Table A.1.3: Sociodemographic characteristics	
Table A.1.4: Client-provider contact in family planning care in the past six months	
Table A.1.5: Family planning services received at home	
Table A.1.6: Family planning services received at a government health facility	
Table A.1.7: Family planning services received at a private/NGO health facility	
Table A.1.8: Family planning services received at a satellite clinic	
Table A.1.9: Behavior change communication materials during family planning services	
Table A.1.10: Quality of family planning care	
Table A.1.11: Knowledge of LARC/PM	
Table A.1.12: Knowledge of postpartum family planning	
Table A.1.12: Knowledge of postpartum IUDs Table A.1.13: Sources of knowledge of postpartum IUDs	
Table A.1.14: Sources of knowledge of postpartum female sterilization	
Table A.1.15: Perceptions of male and female sterilizations	
Table A.1.16: Use of contraception by method	
Table A.1.17: Last source of current family planning method	
Table A.1.18: Contraceptive use by young recently married women	
Table A.1.19: Use of postpartum family planning among women who had given birth between	
January 2012 and September 2013	53
Table A.1.20: Use of postpartum family planning among women who had given birth since	
October 2013	54
Table A.1.21: Discussion of LARCs/PMs in the past six months	55
Table A.1.22: Intention to use LARC/PM	55
Table A.1.23: Duration of current LARC/PM use	56
Table A.2.1: Type of respondents	56
Table A.2.2: Training since 2014	57
Table A.2.3: Training on behavior change communication since 2014	58
Table A.2.4: Pre-counseling elements for IUD clients	58
Table A.2.5: Conditions for accepting an IUD	59
Table A.2.6: Conditions for not accepting an IUD	59
Table A.2.7: Possible side effects of IUDs	60
Table A.2.8: Provision of care to IUD clients with excessive bleeding	60
Table A.2.9: Provision of care to IUD clients with abdominal pain	61
Table A.2.10: Pre-counseling elements for implant clients	61

Table A.2.11: Conditions for accepting an implant	62
Table A.2.12: Possible side effects of implants	62
Table A.2.13: Provision of care to implant clients with excessive bleeding	63
Table A.2.14: Provision of care to implant clients with amenorrhea	63
Table A.2.15: Pre-counseling for female sterilization	64
Table A.2.16: Post-counseling for female sterilization	65
Table A.2.17: Conditions for accepting female sterilization	66
Table A.2.18: Follow-up with female sterilization clients	66
Table A.2.19: Counseling at the time of follow-up with female sterilization clients	67
Table A.2.20: Awareness of government policies regarding postpartum IUDs and female	
sterilization	
Table A.3.1: Types of facilities	68
Table A.3.2: Availability of LARC/PM services	68
Table A.3.3: Availability of delivery services	69
Table A.3.4: Availability of postpartum family planning services	69
Table A.3.5: Routine assessment of quality of services	70
Table A.3.6: Facility infrastructure	71
Table A.3.7: Availability of behavior change communication materials	72
Table A.3.8: Availability of basic equipment	72
Table A.3.9: Availability and functionality of operation theater	73
Table A.3.10: Availability of equipment and supplies for providing LARCs/PMs	74

Appendix B

Table B.1: Balance test results for household characteristics	.75
Table B.2: Balance test results for women's background characteristics	.76
Table B.3: Balance test results for women's knowledge and practice of reproductive health services	77
Table B.4: Balance test results for health providers' characteristics and exposure to the program	.78
Table B.5: Balance test results for health facilities' characteristics	.78

Abbreviations

BDHSBangladesh Demographic and Health SurveyBMMSBangladesh Maternal Mortality and Health Care SurveyCMWRAcurrently married women of reproductive ageCPRcontraceptive prevalence rateDHdistrict hospitalDIDdifference-in-differencesDGFPdirectorate general of family planningEH/MHengender health/mayer hashiFPfamily planningFWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCH0maternal and child healthMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnogovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSUMsubassistant community medical officerSUMprimary sampling unitRMOresident medical officerSUMsubassistant community medical officerSUMsubassistant commu	BCC	behavior change communication
CMWRAcurrently married women of reproductive ageCPRcontraceptive prevalence rateDHdistrict hospitalDIDdifference-in-differencesDGFPdirectorate general of family planningEH/MHengender health/mayer hashiFPfamily planningFWAfamily velfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHomedical college hospitalMCWCmaternal and child healthMCHomedical officerMoHFWMinistry of Health and Family WelfareMRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPPpostpartum family planningPSUprimary sampling unitRMOresident methodPFPApostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSuply-Enabling Environment-DemandUHCupazila health complex	BDHS	C C
CMWRAcurrently married women of reproductive ageCPRcontraceptive prevalence rateDHdistrict hospitalDIDdifference-in-differencesDGFPdirectorate general of family planningEH/MHengender health/mayer hashiFPfamily velfare assistantFWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCH0medical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOoperation theaterPMoperation theaterPMpermanent methodNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubasistant community medical officerSEEDSuply-Enabling Environment-DemandUHCupazia health complex	BMMS	Bangladesh Maternal Mortality and Health Care Survey
DHdistrict hospitalDIDdifference-in-differencesDGFPdirectorate general of family planningEH/MHengender health/mayer hashiFPfamily planningFWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmartried women of reproductive ageNGOobstetrician/gynecologistOToperation theaterPMpermanent methodSUPORTSottertician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOresident metical officerSACMOsubassistant community medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupzila health complex	CMWRA	-
DIDdifference-in-differencesDGFPdirectorate general of family planningEH/MHengender health/mayer hashiFPfamily planningFWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCH0medical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOsubassistant community medical officerSACMOsubassistant community medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	CPR	contraceptive prevalence rate
DGFPdirectorate general of family planningEH/MHengender health/mayer hashiFPfamily planningFWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCK0medical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpirmary sampling unitRMOresident methodPFPsubassistant community medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupzila health complex	DH	district hospital
EH/MHengender health/mayer hashiFPfamily planningFWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCCWmaternal and child welfare centerM&Emonitoring and evaluationMOmedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnogovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	DID	difference-in-differences
FPfamily planningFWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCKOmedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOsubassistant community medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupzila health complex	DGFP	directorate general of family planning
FWAfamily welfare assistantFWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCH0medical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	EH/MH	engender health/mayer hashi
FWCfamily welfare centerFWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCHomedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMRAmarried women of reproductive ageNGOnogovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUsitient methcal officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	FP	family planning
FWVfamily welfare visitorGOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCHomedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOsubassistant community medical officerSACMOSupply-Enabling Environment-DemandUHCupazila health complex	FWA	family welfare assistant
GOBGovernment of BangladeshIUDintrauterine deviceLARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCHomedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOsubassistant community medical officerSACMOsupply-Enabling Environment-DemandUHCupazila health complex	FWC	family welfare center
IUDintrauterine deviceIARClong-acting reversible contraceptivesIAPMlong-acting and permanent methodMCHmaternal and child healthMCHomedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnogovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUresident methodal officerSACMOsubassistant community medical officerSACMOSupply-Enabling Environment-DemandUHCupazila health complex	FWV	family welfare visitor
LARClong-acting reversible contraceptivesLAPMlong-acting and permanent methodMCHmaternal and child healthMCHomedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	GOB	Government of Bangladesh
LAPMlong-acting and permanent methodMCHmaternal and child healthMCHomedical college hospitalMCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUprimary sampling unitRMOsubassistant community medical officerSACMOSupply-Enabling Environment-DemandUHCupazila health complex	IUD	intrauterine device
MCHmaternal and child healthMCHomedical college hospitalMCWcmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUprimary sampling unitRMOsubassistant community medical officerSACMOSupply-Enabling Environment-DemandUHCupazila health complex	LARC	long-acting reversible contraceptives
MCHomedical college hospitalMCWCmaternal and child welfare centerMQWCmonitoring and evaluationMQmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	LAPM	long-acting and permanent method
MCWCmaternal and child welfare centerM&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUprimary sampling unitRMOsubassistant community medical officerSACMOSupply-Enabling Environment-DemandUHCupazila health complex	MCH	maternal and child health
M&Emonitoring and evaluationMOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPSUpostpartum family planningPSUresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	MCHo	medical college hospital
MOmedical officerMOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageMGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOSupassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	MCWC	maternal and child welfare center
MOHFWMinistry of Health and Family WelfareMWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOSubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	M&E	monitoring and evaluation
MWRAmarried women of reproductive ageNGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	MO	medical officer
NGOnongovernmental organizationNIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	MOHFW	Ministry of Health and Family Welfare
NIPORTNational Institute of Population, Research and TrainingOB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	MWRA	married women of reproductive age
OB/GYNobstetrician/gynecologistOToperation theaterPMpermanent methodPPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	NGO	nongovernmental organization
OToperation theaterPMpermanent methodPPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	NIPORT	National Institute of Population, Research and Training
PMpermanent methodPPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	OB/GYN	obstetrician/gynecologist
PPFPpostpartum family planningPSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	OT	operation theater
PSUprimary sampling unitRMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	PM	permanent method
RMOresident medical officerSACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	PPFP	postpartum family planning
SACMOsubassistant community medical officerSEEDSupply-Enabling Environment-DemandUHCupazila health complex	PSU	primary sampling unit
SEEDSupply-Enabling Environment-DemandUHCupazila health complex	RMO	resident medical officer
UHC upazila health complex	SACMO	subassistant community medical officer
1 1	SEED	Supply-Enabling Environment-Demand
USAID US Agency for International Development	UHC	upazila health complex
	USAID	U.S. Agency for International Development

1. INTRODUCTION AND BACKGROUND

1.1. Purpose of the 2015 Baseline Survey

An external impact evaluation of the Mayer Hashi Phase II (MH-II) project was requested by the U.S. Agency for International Development (USAID)/Bangladesh. MH-II, which is a follow-on project to the previous Mayer Hashi (MH-I) project, was awarded to EngenderHealth in September 2013. It will be conducted between October 2013 and September 2017. The 2015 Baseline Mayer Hashi Phase II Evaluation Survey is the first of two surveys to evaluate the impact of MH-II in increasing the use of effective family planning (FP) and reproductive health services among the population in Bangladesh. The baseline survey has three main objectives. First, it is designed to provide baseline estimates of the primary and secondary outcomes in areas where MH-II initiated its activities at different times. Second, it aims to assess baseline differences in the outcomes among areas with different lengths of exposure to the project. Third, with an end-line survey planned in early 2017, the baseline survey is designed to support evaluation of project impact through a difference-in-differences (DID) approach comparing pre-post differences in outcomes between areas with different lengths of exposure to the project.

1.2. Country Context

Bangladesh has made substantial improvements in recent decades in social, economic, and health conditions, demonstrating solid progress toward achieving the United Nation's Millennium Development Goals. Poverty has been reduced; child mortality and maternal mortality have declined; school enrollment has increased, and gender equality has been achieved in primary and secondary school enrollment; and malarial deaths have been reduced (General Economics Division, 2015).

One of the most considerable transitions in Bangladesh has been observed in its fertility level. The total fertility rate has declined rapidly from 6.3 in the early 1970s to 2.3 in 2009–2011 and 2012–2014 (NIPORT, 2016). As Bangladesh is one of the most densely populated countries with a high rate of population growth, one of its development priorities since its independence has been to reduce fertility to replacement level, to achieve sustainable population growth. Recognizing voluntary FP as a priority approach, the government of Bangladesh (GOB), in close collaboration with development partners, has strengthened efforts to improve access to FP and reproductive health services throughout the country and especially among low-income populations and geographic areas. Contraceptive prevalence among currently married women of reproductive age (CMWRA) has increased substantially from 7.7 percent in the 1970s to 62.4 percent in 2014 (NIPORT, 2016).

However, there has been differential fertility decline across geographic areas and populations. The latest Bangladesh Demographic and Health Surveys (BDHSs) suggest that fertility has increased slightly in Dhaka Division—the most populous division in the country—from 2.2 to 2.3 births per woman. However, in all the other divisions it remained the same or declined between the 2011 BDHS and 2014 BDHS. Fertility has remained higher in Sylhet Division (2.9 births per woman) than in other divisions where fertility approaches 2.0 births per woman (NIPORT, 2016). There are observed differentials in fertility by socio-economic status of women as well; women in lower wealth quintiles or with low educational attainment have higher fertility than their wealthier or highly educated counterparts (NIPORT, 2016). As a result, fertility remains slightly above replacement level.

Despite the decline in fertility, unintended births and unmet need for FP among women remain a concern in Bangladesh. Twelve percent of CMWRA have an unmet need for FP, which represents 16 percent of the total demand for FP (NIPORT, 2016). Approximately one-fourth of births in the five years before the 2014 BDHS were reported as mistimed or unwanted. The wanted fertility rate in 2014 was 1.6 births among women of reproductive age, which is lower (by approximately 30 percent) than the observed fertility rate of 2.3 births per woman, suggesting that some women have exceeded their fertility preferences.

Although a high proportion of CMWRA desire to limit childbearing (63%), their contraceptive use is mostly reliant on short-acting methods, including oral contraceptive pills, injectables, and condoms (NIPORT, 2016).

Figure 1.1 presents the trends in contraceptive use in the past two decades, obtained from a series of BDHSs, among CMWRA by method. The methods are long-acting and permanent methods (LAPMs) including intrauterine devices (IUDs), implants, and female or male sterilizations; short-acting modern methods including oral contraceptive pills, condoms, and injectables; and traditional methods including abstinence and withdrawal. The total rate of use for all three categories combined therefore represents the current prevalence for all contraceptive methods. Although total current contraceptive use has increased from 49 percent to 62 percent among CMWRA, the increase has resulted largely from a substantial increase in the use of short-acting modern methods (from 31 percent to 46 percent). The level of LAPM use decreased from 10.6 percent in 1996/97 to 7.2 percent in 2004 and has since increased slightly, to 8.1 percent in 2014.




Figure 1.1: Trends in current contraceptive use by method

Note: The sum of contraceptive uses by method may not add up to the total contraceptive use reported in the 2014 BDHS due to rounding errors. The estimates from the three earlier BDHSs (1996-97, 1999-2000, and 2004) are based on currently married women ages 10-49; estimates from the three latest BDHSs (2007, 2011, and 2014) are based on currently married women ages 15-49.

Source: 2014 BDHS (NIPORT, 2016)

Table 1.1 presents the trends in modern contraceptive method mix by specific short-acting method and LAPM among CMWRA. Oral contraceptive pills are the most popular method used by CMWRA (27%), followed by injectables (12%) and condoms (6%). The use of each of the shortacting methods has increased over time. Among LAPMs, female sterilization is the most commonly adopted method (5%), followed by implants (2%), male sterilization (1%), and IUDs (1%). Implants (which have been introduced relatively recently) are the only LAPM that has increased its share of contraceptive use; the use of other LAPMs has plateaued or declined. The low use of LAPMs is also reflected in low intention to use LAPMs in the future. Although 58 percent of CMWRA who are not using contraception intend to use a contraceptive method in the future, only 3 percent of them prefer to use LAPMs (NIPORT, 2016).

	Percentage of CMWRA currently using each method						
	1996-97	1999-2000	2004	2007	2011	2014	
Contraceptive methods	BDHS	BDHS	BDHS	BDHS	BDHS	BDHS	
Short-acting methods							
Pills	20.8	23.0	26.2	28.5	27.2	27.0	
Injectables	6.2	7.2	9.7	7.0	11.2	12.4	
Condoms	3.9	4.3	4.2	4.5	5.5	6.4	
LAPMs							
Female sterilization	7.6	6.7	5.2	5.0	5.0	4.6	
Male sterilization	1.1	0.5	0.6	0.7	1.2	1.2	
IUD	1.8	1.2	0.6	0.9	0.7	0.6	
Implants	0.1	0.5	0.8	0.7	1.1	1.7	

Table 1.1: Trends in modern contraceptive method mix

Source: 2014 BDHS (NIPORT, 2016)

Note: The estimates from the three earlier BDHSs (1996-97, 1999-2000, and 2004) are based on currently married women ages 10-49, whereas those from the three latest BDHSs (2007, 2011, and 2014) are based on currently married women ages 15-49.

The low use of LAPMs highlights a potential gap between fertility preferences and FP practices among couples. LAPMs are effective for an extended period; require minimum action, if any, from users; and because of their low maintenance, are considered cost-effective for both the health system and individual users. These characteristics make LAPMs a good option for many women who want to limit childbearing.

1.3. Project Description

The previous MH-I project aimed to increase the demand for and use of voluntary FP services with an emphasis on LAPMs and selected components of maternal health services, such as postpartum hemorrhage care. The project was conducted in 21 districts between 2009 and 2013, and provided technical assistance to the directorate general of FP (DGFP) of the Ministry of Health and Family Welfare (MOHFW) of Bangladesh.

MH-II was awarded to EngenderHealth in September 2013 and is planned to run from October 1, 2013 to September 30, 2017. The overall objective of MH-II is to increase the use of effective FP and reproductive health services, with a focus on the informed and voluntary use of long-acting reversible contraceptives (LARCs) and permanent methods (PMs). In contrast to MH-I, MH-II has increased attention on urban areas and slums, and gives new attention to private-sector provision of LARCs. In addition, there is particular attention given to postpartum FP (PPFP), and to young married couples to delay first birth.

MH-II defines three primary objectives, with corresponding secondary objectives, as follows:

- Effective and high-quality FP services delivered nationwide
 - Capacity of public and private sectors' service providers to provide LARCs/PMs increased
 - o Training, support, and performance improvement mechanisms institutionalized
- Demand for FP services, especially LARCs/PMs, increased
 - Communication strategies promoting social norms for delaying, spacing, and limiting births implemented
 - Accurate knowledge of FP, especially LARCs and PMs, increased among community leaders, families, and clients
 - o Client identification and referrals increased
- Supporting an enabling environment that advances access to LARCs, PMs, and other FP/ reproductive health services
 - Key policy barriers to LARCs and PMs removed
 - National standards, guidelines, and policies implemented by personnel at teaching institutions and service delivery points

The MH-II model is grounded in the Supply-Enabling Environment-Demand (SEED) Programming Model (EngenderHealth, 2011; USAID, 2014). It is designed to apply a range of approaches, which can be grouped broadly into the following types of activities:

- Use of mobile teams to provide LARCs and PMs
- Training of the GOB, nongovernmental organizations (NGOs), and other private providers in LARCs and PMs through training centers and training of trainers at the district level. The activity includes training on service provision but also supervision and quality assurance processes.
- Collaboration with the GOB, NGOs, and other private providers to increase availability of LARCs and PMs. The activity includes training providers, as noted above, but also other types of support for commodities, supplies, and resources (e.g., support for satellite clinics in slum areas, support for workplace clinics, especially in the garment sector).
- Application of a comprehensive, multi-channel behavior change communication (BCC) strategy that includes mass media messages, community-level BCC activities, and BCC materials at clinics. The activity also includes both provider and satisfied client champions; target audiences include potential female clients, men, and community leaders. The activity also includes collaboration with the USAID project Strengthening Health Outcomes through the Private Sector (SHOPS) and Social Marketing Company (SMC) on communications and marketing campaigns for LARCs and PMs in the private sector.

• Adoption of various policy and system-level activities aimed at influencing the regulatory environment to make LARCs and PMs available through a wider variety of outlets, including provision of injectables by Frontline Health Workers (FHWs). The activity also includes collaboration with the GOB to update and roll out clinical guidelines for LARCs and PMs.

One feature of the planned interventions is that MH-II will do little or no direct service provision (except through mobile teams). The model is to support other stakeholders actively engaged in FP service provision—the GOB, NGOs, and private-sector entities—to provide LARCs and PMs through training, technical assistance, and provision of some kinds of material support. Second, the system-level interventions that aim to make policies more supportive of LARCs and PMs and that aim to improve underlying systems, such as logistics, will potentially affect the entire system.

Another change in the project design between MH-I and MH-II is that MH-II operates in all 64 districts in Bangladesh, whereas MH-I was focused on 21 low-performing districts. MH-II activities, however, will be introduced at different times (i.e., phased in) across districts. In Year 1 (Phase I), MH-II will work in 20 districts in three divisions. In Year 2 (Phase II), the project will expand to an additional 18 districts. In the third year (Phase III), the project plans to expand to the remaining 26 districts (**Figure 1.2**). The Phase I districts were purposively selected to include a range of contraceptive prevalence rates (CPRs) and rates of LARC/PM use (high-, medium-, and low-performing districts). Other factors also influenced the decision of which districts to work in first, such as whether they had large urban or slum populations, large concentrations of underserved groups, and the presence of training centers or medical colleges or other partners. The specific selection criteria listed in the MH-II monitoring and evaluation (M&E) plan are as follows:

- Districts with a shortage of skilled providers
- Districts with a high CPR but low use of LARCs/PMs
- Districts with geographically and ethnically marginalized populations but with NGOs that could be strengthened
- Districts with a high percentage of private-sector facilities with the potential to enhance LARCs/PMs
- Districts with NGOs to scale up interventions for young married couples

Analysis of the 2010 Bangladesh Maternal Mortality and Health Care Survey (BMMS) data shows that LARC/PM use among currently married women of reproductive age (CMWRA) was 6.6 percent, 6.2 percent, and 6.6 percent in the districts where MH-II will be active in Phase I, Phase II, and Phase III districts, respectively. This indicates that the districts for the three phases are comparable in terms of LARC/PM use.




Figure 1.2: Map of Bangladesh districts by phase of Mayer Hashi II project implementation

Figure 1.3 illustrates pathways through which MH-II interventions can affect contraceptive behavior with the primary goal of improving access to, and quality and use of, LARC/PM services. To improve accessibility, providers are added to the LARC/PM service delivery system; obstetricians/gynecologists (OB/GYNs) in upazila health complexes (UHCs), district hospitals (DHs), and medical colleges are trained and allowed to provide LARC/PM services. Providers in NGO clinics and private clinics are also trained on LARCs/PMs. MH-II emphasizes information provision through various channels of BCC initiatives as well as through the project's technical assistance in the areas of policy change and logistics improvement for enhancing access to LARC/PM services. To improve quality of care, providers are trained in LARC/PM services so as to increase client satisfaction and continuation of methods. Increased access to services combined with increased client satisfaction is expected to generate greater demand for LARCs/PMs, and thus increase the use of LAPMs. In addition, it is hypothesized that increasing access to and quality of LARC/PM services will have a larger impact on the use of LARCs/PMs in relatively higher-performing districts (at baseline) due to the higher initial demand for these methods in those areas (Rahman, 2014).




Figure 1.3: Pathways through which MH-II interventions can affect contraceptive behavior

1.4. Evaluation Design

The overarching evaluation method for MH-II is based on a DID approach, which is supplemented with additional statistical analyses on relationships between intensity of exposure to interventions and outcomes of interest. DID is a quasi-experimental design adopted during the impact evaluation of MH-I. The method relies on comparing the change in outcomes between two time points in areas in which the intervention is implemented with the corresponding change in comparison areas where no intervention is implemented, thus requiring collection of baseline and end-line data in both intervention and comparison areas. The MH-II baseline survey was conducted in 2015, approximately

one and a half year after project initiation.¹ The end-line household survey is expected to be conducted in early 2017, six months before the end of project (scheduled in September 2017). The data will be collected from the same clusters at these two points in time to evaluate the extent of change in the indicators of interest across intervention and comparison areas.

The identification of comparison areas for estimating project effects requires consideration. There are no districts or areas within districts that will not be exposed to MH-II, because the project is designed to operate in all 64 districts. Although there are areas that will not receive some components of the project, they could not be used as comparison areas because they differ systematically from the intervention areas in their service environments,² or because the geographic operation plan was not determined prior to the baseline survey.³

However, the phase-in design of MH-II implies that districts will differ in their lengths of exposure to the project. The adapted DID approach proposed for MH-II will compare outcomes in Phase I districts, which will be exposed to MH-II interventions for the full period of the project, with those in Phase III districts, where interventions will be introduced in Year 3 of the project.⁴ The evaluation strategy will not be able to compare intervention districts with districts with no intervention; however, Phase III implementation districts will have had little time for the interventions to take effect, given the time needed for interventions to start having an impact at the population level. There is also likely to be variation in the intensity of implementation across districts within phases, which can potentially be measured and used to explore relationships between intervention implementation and outcomes (Victora, 2011).

The selection of districts for each implementation phase was not done randomly, implying that there are likely to be both observed and unobserved differences between early-phase and later-phase districts that could also affect change in their outcomes. Similarly, districts that implement interventions more intensively are likely to differ on both observed and unobserved characteristics when compared with districts that implement interventions less intensively. The proposed DID approach will address selection bias from observed differences by adopting a regression model including the observed characteristics as control variables. Additionally, the DID approach will address two sources of potential unobserved bias through its estimation method: time trends in the outcomes unrelated to the project, and pre-existing differences in the outcomes among districts of different phases. The estimation approach does not address time-variant unobserved differences among districts of different phases.

¹ The implications of the timing of the baseline survey compared to the project start date are discussed in Section 2.3. ² For instance, training on PPFP is only done in upazillas that have emergency obstetric care services, implying that some upazillas within districts will not receive some interventions. However, these upazillas are not suitable as comparison areas because they have a systematically different service environment than the upazillas that will receive the rolled-out training. ³ The exact rollout of some activities at the facility and client level is not totally within the control of MH-II because they operate through other partners that provide services directly (e.g., NGOs, private-sector doctors, the GOB) and make decisions about how and where to roll out the MH-II interventions. Therefore, it was not possible to identify in advance any areas that would not be exposed or be exposed to only some aspects of the MH-II interventions to serve as comparison areas. ⁴ Initially, we considered a design comparing all three implementation phases (i.e., Phase I versus Phase II versus Phase III), but that would have required specifying additional sample domains, which in turn would have increased sample size considerably. Therefore, we adjusted the design to compare only Phase I and Phase III to reduce sample size and associated costs of data collection. In addition, MH-II interventions will only have been operating for one year in Phase II districts at the time of end line. Given the cascade nature of many of the interventions, one year is likely to be too short a period to expect to see significant impact at the population level, so we determined that including Phase II districts would likely add little additional information on program impact.

1.5. Evaluation Questions

This evaluation of MH-II will address three primary and three secondary questions as follows:

Primary evaluation questions

- How much has use of LARCs and PMs increased among CMWRA in Bangladesh over the life of MH-II?
- How much has intention to use LARCs and PMs increased among CMWRA?
- Are increases in use of and intention to use LARCs and PMs among CMWRA greater in districts exposed to MH-II interventions for longer periods, or in areas with greater intensity of exposure to MH-II interventions?
- Is the duration/intensity of exposure to MH-II interventions associated with increases in intermediate outcomes among providers and CMWRA? Are changes in intermediate outcomes associated with increases in use of and intention to use LARCs/PMs?

Secondary evaluation questions

- Are increases in use of and intention to use LARCs and PMs among CMWRA greater in districts in which use of LARCs/PMs was higher before the interventions?
- Are increases in use of or intention to use LARCs/PMs different in urban versus rural areas?
- How does the source of LARCs/PMs evolve over time, and is that different in urban versus rural areas? Is the market share of the private and NGO sectors as a supplier of LARCs/PMs increasing? What is the role of fieldworkers in referring for LARCs/PMs, and how does that change over time?

Table 1.2 presents the key outcome indicators collected by survey instruments in the Phase I and Phase III districts.⁵

Indicator number	MH II-indicators
1	% of currently married women ages 15-49 who use contraception by type of contraceptive method
2	Among currently married women under 25 years of age who have been married for two years or less, % of those who adopted contraceptive methods
3	Among currently married women ages 15-49 who have given birth in the past three years, % who received PPFP services (e.g., received counseling)
4	Among women ages 15-49 who are not pregnant, not using LARCs/PMs, and do not want any more children or are undecided about wanting more children, % who intend to use IUDs/implants/female sterilization within the next 12 months
5	% of currently married women ages 15-49 who heard, saw, or read about LARCs/PMs through media in the past 6 months

Table 1.2: Mayer Hashi II key indicators

⁵ Note that the sample size is not powered to detect specific changes in all these indicators.

1.6. Sample Design of 2015 MH-II Baseline Survey

1.6.1. Household Survey

The household sample was powered to detect a change in LARC/PM prevalence among CMWRA at the population level from 9 percent to 12.6 percent in high-performing areas and from 7 percent to 9.8 percent in low-performing areas. These assumed changes may be ambitious for a two-year period, particularly in light of the slow growth in LARC/PM use in Bangladesh in the past. However, experience from operations research on the improvement of LARC/PM use suggests that 2.8–3.6 percentage points of increase in two years is possible.⁶

The 2015 baseline survey adopted a stratified multi-stage sampling design to obtain a representative sample of households and CMWRA from Phase I and Phase III districts, respectively. The sample was drawn from four survey domains: (1) Phase I high-performing districts, (2) Phase I low-performing districts, (3) Phase III high-performing districts, and (4) Phase III low-performing districts. This design allows for DID analysis designed to estimate the program impact, as well as potential additional analysis to examine differences in indicators by the level of LARC/PM use in districts.

The sampling frame was developed for each survey domain from the 2011 Bangladesh Population and Housing Census, which has information on the number of households at the level of mohollas (for urban areas) and mouzas (for rural areas). A multi-stage sampling design was adopted in each survey domain to conduct (1) selection of mohollas/mouzas, (2) household listings within selected mohollas/ mouzas, and (3) selection of households within selected mohollas/mouzas.

Selection of mobollas/mouzas

Mohollas (in urban areas) and mouzas (in rural areas) served as primary sampling units (PSUs) in each survey domain. From each of the Phase I and Phase III domains (where the Phase I domain was comprised of the Phase I high-performing district domain and the Phase I low-performing district domain, and the Phase III domain was comprised of the Phase III high-performing district domain and the Phase III low-performing district domain), 200 PSUs were selected randomly with probability proportional to the number of households obtained from the 2011 population and household census. Mohollas/mouzas were ordered by upazillas within districts for implicit stratification in each survey domain. Then systematic sampling of mohollas/mouzas was adopted to allow for sample allocation proportional to the number of households by survey domains.

Household listing within selected mohollas/mouzas

In each selected moholla/mouza, a household listing was conducted to obtain the actual number of households in the selected PSU and to construct a sampling frame for the next stage of sampling to select households. For the purpose of the survey, a household was defined as a person or group of related and unrelated people who usually live together in the same dwelling unit(s), who have common cooking and eating arrangements, and who acknowledge one adult member as head of the household. A member of the household is any person who usually lives in the household.

⁶ This was a targeted approach to improve neonatal health and the use LARCs and PMs. icddr,b: Centre for Child and Adolescent Health 2015.

Selection of households within selected mohollas/mouzas

From each selected moholla/mouza, an average of 30 households were randomly selected through a systematic random sampling from the list of households constructed through the household listing. All CMWRAs in the selected households were invited to participate in the household survey.

1.6.2. Facility Readiness and Provider Surveys

The sample for the facility readiness survey was drawn from the facilities serving the selected PSUs for the household survey, which allows linking of the facility data and the household data. The sample of facilities, therefore, was not designed to be representative of all facilities in the Phase I and Phase III districts. The sample of facilities was determined by the selection of the clusters for the household survey. For each selected cluster, the sample included each UHC, DH, or medical college hospital for the upazilla/district in which the cluster was located. One family welfare center (FWC) or NGO clinic that serves the residents of the sample cluster was randomly selected for each cluster, and one private clinic/hospital covered under MH-II was included in the sample for each district in which a selected cluster was located.

The sample of health service providers for the provider survey was drawn from health service providers within the selected higher-level facilities (i.e., UHCs, DHs, medical college hospitals). One key health provider and one provider assisting the key provider were selected from each of the facilities. The providers from different sectors were interviewed: medical officers-maternal and child health (MO-MCHs), family welfare visitors (FWVs), and female subassistant community medical officers (SACMOs) from the public sector, physicians and paramedics from NGOs, and physicians from private clinics and mobile teams, as well as OB/GYNs from those UHCs, DHs, medical college hospitals, and private clinics that were included in the training.

The end-line survey, which is planned to be conducted in early 2017, will return to the same clusters and facilities.

1.7. Implementation of the Survey

The 2015 baseline survey was implemented by Mitra and Associates, a research firm based in Dhaka. MEASURE Evaluation, a USAID-funded projected implemented by the Carolina Population Center at the University of North Carolina at Chapel Hill, provided technical assistance for the survey.

1.8. Survey Instruments

The 2015 baseline survey used five instruments: household listing schedule, household and women's questionnaire, provider questionnaire, and facility readiness questionnaire. The survey instruments were developed by MEASURE Evaluation and were reviewed by relevant stakeholders including MH-II project staff, USAID/Bangladesh, and staff at Mitra and Associates.

1.8.1. Household Listing Schedule

The household listing schedule was used to conduct household listing operations in each selected cluster to produce the sampling frame for the selection of households within the clusters.

1.8.2. Household and Women's Questionnaire

The household and women's questionnaire was designed to capture physical, demographic, and sociodemographic characteristics of the household and reproductive health and health service utilization of women through face-to-face interviews.

The household part of the questionnaire was administered to a primary household member (i.e., household head or female respondent) and was used to list all usual household members and visitors in the selected households. Basic information on each person was collected, including age, sex, marital status, and the individual's relationship to the household head. The main purpose of the household part of the questionnaire was to identify currently married women ages 13–49 for individual interviews using the women's part of the questionnaire. Additionally, information was collected about the dwelling itself, including the source of water, the type of toilet facilities, the materials used to construct the house, and ownership of various consumer goods.

The women's part of the questionnaire was administered to all currently married women ages 13–49 in the selected households, to collect information on the following topics:

- Background characteristics (e.g., age, current marital status, educational attainment, religion, exposure to mass media)
- Summary of reproductive history
- Knowledge and use of contraceptive methods, including attitudes toward LARCs/PMs
- Discussion of LARCs and PMs
- Postpartum female sterilization and IUDs from facilities (for women with a birth since 2012)

The key indicators described in **Table 1.2** were collected through the household and women's questionnaire.

1.8.3. Provider Questionnaire

The provider questionnaire was administered through face-to-face interviews with health service providers within selected health facilities. The questionnaire adopted a different set of questionnaire items for each type of provider interviewed, to reflect that they have different responsibilities.⁷ The questionnaire was designed to collect information on their readiness to provide LARC/PM services and their knowledge, skills, and practice of service provision. The questionnaire collected information on provider knowledge and practices related to LARCs/PMs and on exposure to MH-II interventions at the provider level.

1.8.4. Facility Readiness Questionnaire

The facility readiness questionnaire was administered through face-to-face interviews with key informants of health facilities. The questionnaire was designed to collect information on facility readiness to provide LARC/PM services, such as availability of essential supplies, availability of trained staff, and exposure to MH-II interventions at the facility level.

⁷ See Appendix C for the questionnaires used for the provider survey.

1.9. Training and Fieldwork

1.9.1. Training and Fieldwork for Household Listing

Training for household listing was conducted between April 8, 2015, and April 14, 2015. Fieldwork for the household listing was conducted over two months from April 15, 2015, to June 9, 2015.

1.9.2. Training/Pretesting and Fieldwork for the Household and Women's Survey

Training for data collection for the household and women's survey was conducted between May 26, 2015, and June 10, 2015. The pretest for the survey took place from May 21, 2015, to May 25, 2015, in Singair and Manikgonj Sadar Upazila. Fieldwork for the survey took place between June 11, 2015, and October 24, 2015, by deploying nine teams. Each team consisted of one male supervisor, one female editor, three female interviewers, and one field logistical assistant. In addition, six quality control officers were employed to oversee the work of the interviewing teams.

1.9.3. Training/Pretesting and Fieldwork for the Provider/Facility Readiness Survey

Training for data collection for the provider/facility readiness survey was conducted between May 26, 2015, and June 18, 2015. The pretest for the survey took place from May 21, 2015, to May 25, 2015, in Singair and Manikgonj Sadar Upazila. Fieldwork for the survey took place between June 23, 2015, and October 12, 2015, by deploying 12 interviewing teams. Each team consisted of two male interviewers. In addition, six quality control officers were employed to oversee the work of the interviewing teams.

The data collection agency Mitra and Associates had its own data-quality control mechanisms in place for fieldwork. In addition, MEASURE Evaluation staff based in Dhaka made periodic field monitoring visits. Field check tables were generated regularly during fieldwork to monitor data quality and performance of individual data collection teams. Any problems identified were shared with the data collection agency for corrective action. Debrief sessions were held at the end of each phase of fieldwork to discuss any problems encountered during data collection.

1.10. Data Processing

Editing and coding of data were done at the Dhaka central office of Mitra and Associates from June 15, 2015, to October 30, 2015. Data entry and data cleaning took place from July 6, 2015, to November 25, 2015. Data were double entered. The final dataset was delivered to MEASURE Evaluation in Dhaka on November 30, 2015.

1.11. Response Rates

Tables 1.3, 1.4, and 1.5 present the results of the interviews with households and women, health facilities, and health service providers, respectively, by Phase I and III areas. A total of 12,000 households (6,000 in Phase I and 6,000 in Phase III areas) were selected, of which 11,697 were occupied (**Table 1.3**). Of the selected households, 11,592 (96.5%) were successfully interviewed for the household survey. The principal reason for nonresponse among households was absence of household members at the time of the interview visit.

In the interviewed households, 11,346 currently married women ages 13-49 years (5,616 in Phase I and 5,730 in Phase III areas) were identified, of which 10,711 (94.4%) were successfully interviewed using the women's questionnaire. The principal reason for nonresponse among individual women was women's absence at the time of the interview visit.

A total of 937 health facilities (463 in Phase I and 474 in Phase III areas) were selected, of which 769 (82.1%) were successfully interviewed using the facility readiness questionnaire (**Table 1.4**). The principal reason for nonresponse among health facilities was unavailability of interviewees at the health facilities.

In the interviewed health facilities, 2,033 providers (996 in Phase I and 1,037 in Phase III areas) were identified, among which 1,863 (91.6%) were successfully interviewed for the provider surveys (**Table 1.5**). The principal reason for nonresponse among providers was their unavailability at the time of the interview visit.

Table 1.3: Results of interviews with households and women

Numbers and response rates of households and women, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III		
Measure	Low	High	Total	Low	High	Total	
Households							
Households selected	2,580	3,420	6,000	2,580	3,420	6,000	
Household occupied	2,503	3,329	5,832	2,500	3,365	5,865	
Household interviewed	2,475	3,286	5,761	2,476	3,345	5,821	
Household response rate (%) ¹	98.9	98.7	98.8	99.0	99.4	99.2	
Currently married women ages 13–49							
Eligible women selected	2,449	3,167	5,616	2,449	3,281	5,730	
Eligible women interviewed	2,280	3,021	5,301	2,275	3,135	5,410	
Eligible women response rate (%)	93.1	95.4	94.4	92.9	95.6	94.4	

¹ Households interviewed/households occupied

Table 1.4: Results of interviews with health facilities by type of facility

Numbers and response rates of health facilities by type of facility, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I		Phase III		
Measure	Low	High	Total	Low	High	Total
Facilities selected						
DH/MCHo	11	16	27	15	14	29
UHC/MCWC	63	78	141	85	80	165
FWC	53	66	119	62	76	138
Private/NGO	82	86	168	73	59	132
Rural dispensary	1	4	5	5	4	9
Unknown	1	2	3	1	0	1
Total	211	252	463	241	233	474
Facilities interviewed/observed						
DH/MCHo	9	12	21	14	10	24
UHC/MCWC	60	61	121	72	69	141
FWC	47	56	103	51	68	119
Private/NGO	69	57	126	56	46	102
Rural dispensary	1	4	5	4	3	7
Unknown	0	0	0	0	0	0
Total	186	190	376	197	196	393
Facility response rate (%)						
DH/MCHo	81.8	75.0	77.8	93.3	71.4	82.8
UHC/MCWC	95.2	78.2	85.8	84.7	86.3	85.5
FWC	88.7	84.8	86.6	82.3	89.5	86.2
Private/NGO	84.1	66.3	75.0	76.7	78.0	77.3
Rural dispensary	100.0	100.0	100.0	80.0	75.0	77.8
Unknown	0.0	0.0	0.0	0.0	n.a.	0.0
Total	88.2	75.4	81.2	81.7	84.1	82.9

Abbreviations: MCWC = maternal and child welfare center.

Table 1.5: Results of interviews with health service providers

Numbers and response rates of providers by type of provider, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

Measure	Phase I			Phase III		
	Low	High	Total	Low	High	Total
Providers selected						
MO (MCH-FP)	55	57	112	58	45	103
Medical officer	68	65	133	58	55	113
Clinic manager	1	1	2	2	5	7
FWV	107	108	215	120	131	251
Sacmo	7	14	21	9	14	23
Nurse	12	11	23	19	12	31
Nurse midwife	8	4	12	10	8	18
Paramedic	48	46	94	45	34	79
FWA	48	62	110	54	71	125
Service promoter	10	4	14	7	4	11
Community health worker	3	3	6	0	0	0
OB/GYN	81	76	157	91	60	151
RMO	51	46	97	70	55	125
Total	499	497	996	543	494	1,037
Providers interviewed						
MO (MCH-FP)	40	45	85	44	33	77
Medical officer	67	59	126	55	51	106
Clinic manager	1	1	2	2	3	5
FWV	106	108	214	118	127	245
SACMO	7	14	21	9	14	23
Nurse	12	11	23	18	12	30
Nurse midwife	8	4	12	10	8	18
Paramedic	48	44	92	44	34	78
FWA	47	61	108	53	70	123
Service prompter	9	4	13	7	4	11
Community health worker	3	3	6	0	0	0
OB/GYN	64	54	118	75	50	125
RMO	51	32	83	67	52	119
Total	463	440	903	502	458	960
	400	0	700	002	-100	700
Provider response rate (%) MO (MCH-FP)	72.7	78.9	75.9	75.9	73.3	74.8
Medical officer	98.5	90.8	94.7	94.8	92.7	74.8 93.8
	100.0		100.0			73.8 71.4
Clinic manager FWV	99.1	100.0 100.0	99.5	100.0 98.3	60.0 96.9	97.6
SACMO	100.0	100.0	100.0	100.0	100.0	100.0
Nurse	100.0	100.0	100.0	94.7	100.0	96.8
Nurse midwife	100.0	100.0	100.0	100.0	100.0	100.0
Paramedic	100.0	95.7	97.9	97.8	100.0	98.7
FWA	97.9	98.4	98.2	98.1	98.6	98.4
Service prompter	90.0	100.0	92.9	100.0	100.0	100.0
Community health worker	100.0	100.0	100.0	n.a.	n.a.	n.a.
OB/GYN	79.0	71.1	75.2	82.4	83.3	82.8
RMO	100.0	69.6	85.6	95.7	94.5	95.2
Total	92.8	88.5	90.7	92.4	92.7	92.6

Abbreviations: RMO = resident medical officer; FWA= family welfare assistant

2. KEY FINDINGS

This chapter presents baseline data relevant to the evaluation questions for the key outcome indicators as well as the process indicators identified in the framework (**Figure 1.2**) in Chapter 1. In addition, results of the balance tests to check the comparability of the Phase I and Phase III areas are presented. Detailed tabulations from the baseline survey are presented in Appendix A.

2.1. Primary Outcomes

2.1.1. Contraceptive Use and Method Mix

The primary outcome of interest for the MH-II project is the use of contraceptives, especially LARCs and PMs. The majority of CMWRA use some method of FP (Table A.1.16 in Appendix A). The prevalence of contraceptive use is slightly higher in Phase I districts, at 68 percent, than it is in Phase III districts, at 66 percent (**Figure 2.1**). In both phases, low-performing areas have a lower CPR than high-performing areas. The CPR is 61 percent in low-performing areas versus 73 percent in high-performing areas in Phase I districts; similarly, it is 64 percent in low-performing areas versus 71 percent in high-performing areas in Phase III districts. The use of LARCs, including IUDs and implants, is low in both areas: 2.5 percent in Phase I districts and 2.8 percent in Phase III districts, with no substantial difference between the low- and high-performing districts. Six percent of women in Phase I districts report using permanent contraceptives.






Figure 2.1: Percentage of currently married women ages 15–49 who use contraceptive methods, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey

2.1.2. Contraceptive Use among Young Married Women

A key focus population for the MH-II project is young, recently married women (Table A.1.18 in Appendix A). Among women under age 25 who have been married for less than two years, contraceptive prevalence is 51 percent in Phase I districts and 47 percent in Phase III districts (**Figure 2.2**). Across all groups, short-acting contraceptives are the method of choice, with 39 percent and 52 percent reporting use in low- and high-performing areas, respectively, in Phase I districts and 37 percent and 48 percent reporting use in low- and high-performing areas, respectively, in Phase III districts III districts. Less than 2 percent of young married women across both Phase I and Phase III districts reported the use of LARCs.






2.1.3. Postpartum Contraceptive Counseling and Use

Information on postpartum contraceptive counseling and use was collected for births in the three years before the survey, so we were able to examine postpartum contraceptive counseling and use separately for births from January 2012 to September 2013 (immediately before the start of MH-II interventions) and from October 2013 until the survey (during the first 18 months of MH-II interventions) (Tables A.1.19 and A.1.20 in Appendix A). From January 2012 to September 2013, 14 percent of women (n=738) in Phase I districts and 15 percent of women (n=758) in Phase III districts gave birth. Of these women, 34 percent in Phase I districts and 38 percent in Phase III districts gave birth in a health facility (**Figure 2.3A**). High-performing districts had substantially more health facility deliveries than low-performing districts in the Phase I area; not much difference was

seen between high- and low-performing districts in the Phase III area. **Figure 2.3A** shows that about 5 percent of women who gave birth in Phase I districts, compared with 6 percent in Phase III districts, were offered an IUD or tubectomy. Less than 2 percent of women who gave birth across all districts accepted a postpartum IUD or tubectomy.

Figure 2.3A: Facility delivery, counseling, and use of postpartum family planning among women who gave birth between January 2012 and September 2013, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey



Among the 16 percent of women (n=844) in Phase I districts and 17 percent of women (n=868) in Phase III districts who gave birth since October 2013, around 40 percent delivered at health facilities in both Phase I and Phase III areas (**Figure 2.3B**). About 6.5 percent of women who delivered since October 2013 were offered postpartum contraceptives in both Phase I and Phase III areas. In high-performing districts in the Phase I area, the percentage of women who gave birth who were offered a postpartum IUD/tubectomy increased from 5.6 percent to 8.6 percent between the period January 2012–September 2013 and the period since October 2013. There was no notable change in low-performing areas in Phase I or Phase III districts, and less than 2 percent of women who gave birth since October 2013 across all districts accepted a postpartum contraceptive method.





Figure 2.3B: Facility delivery, counseling, and use of postpartum family planning among women who have given birth since October 2013, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey

2.2. Intermediate/Process Outcomes

2.2.1. Provider Training

Training of providers in different aspects of LARCs/PMs is one of the key activities to achieve MH-II program objectives. Training of providers aims to increase their knowledge and skills on LARCs/PMs as a step toward improving the quality of care they provide for these methods.

Around a quarter of surveyed FWVs (26%), MOs (24%), and OB/GYNs (33%) in Phase I districts reported having received some training on LARCs and PMs since 2014 (**Figure 2.4**). More variation in training was reported across types of providers in Phase III districts, where 26 percent of FWVs and 21 percent of OB/GYNs reported being trained in LARCs/PMs, but only 6 percent of MOs reported being trained. Among FWAs and RMOs, low levels of training in LARCs/PMs were reported across both intervention and comparison areas. Eleven percent of FWAs in Phase I districts and 8 percent of FWAs in Phase III districts reported being trained. Only 1 percent of RMOs in Phase I districts and 3 percent in Phase III districts reported receiving any training on LARCs/PMs. Additional details about who provided the training and which groups were involved can be found in Table A.2.2 in Appendix A.





When compared with providers in Phase III districts, more providers in Phase I districts had received training in PPFP since 2014 (**Figure 2.5**): 7 percent of FWAs, 15 percent of FWVs, 12 percent of MOs (MCH-FP), and 15 percent of OB/GYNs in Phase I districts reported receiving training in PPFP. Comparatively, 6.5 percent of FWAs, 13 percent of FWVs, 5 percent of MOs (MCH-FP), and 9 percent of OB/GYNs in Phase III districts reported receiving any training in PPFP. Information on the role of MH-II in the provision of training can be found in Table A.2.2 in Appendix A.





Figure 2.5: Percentage of providers who received training on postpartum family planning since 2014 by type of provider, by Phase I and Phase III areas, 2015 MH-II survey

Less than 10 percent of any providers in Phase I and Phase III districts reported receiving any training in BCC (**Figure 2.6**). Less than 2 percent of OB/GYNs reported any BCC training in all districts. FWVs reported the highest levels of BCC training among all provider groups, at 7 percent in Phase I and 8.6 percent in Phase III districts (Table A.2.3 in Appendix A).





2.2.2. Provider Knowledge and Self-Reported Practice

Providers were asked a series of questions about their knowledge and practices related to providing IUDs, implants, and female sterilization. Different types of providers were asked different questions depending on the services they were expected to offer. Tables A.2.4 to A.2.9 in Appendix A present spontaneously reported knowledge and practices for IUDs, by provider type. Similar findings are presented for implants in Tables A.2.10 to A.2.14, and for female sterilization in Tables A.2.15 to A.2.19. There was a lot of variation in the percentage of providers spontaneously mentioning each knowledge/practice response, and there were no consistent patterns in spontaneously reported knowledge and practices between Phase I and Phase III districts.⁸

Providers were also questioned about their awareness of government policies to offer IUDs and tubectomies to women immediately after a birth at the health facility (Table A.2.20 in Appendix A). Knowledge of government policies on offering IUDs immediately after a facility birth (normal or Cesarean section) was consistently higher among all types of providers in the Phase I districts than among those in the Phase III districts. The rate of awareness of the government policy on offering tubectomies following Cesarean section was more than 89 percent for all types of providers in both Phase I and Phase III districts, but providers of all types in Phase I districts were more likely than those in Phase III districts to be aware of the policy on offering tubectomies after normal facility deliveries.


2.2.3. Quality of Care

The availability of equipment and supplies for providing LARCs/PMs was assessed in the facility readiness survey as a measure of readiness to provide high-quality LARC/PM services. Additionally, respondents to the women's questionnaire who reported that they were using a LARC/PM were asked questions about the services received at the facility where they obtained that method.

Less than 15 percent of DHs/public MCH facilities in either Phase I or Phase III districts were found to have all minimally required equipment and supplies to provide IUDs, implants, or male sterilization. Slightly more DHs/public hospitals in Phase III districts than in Phase I districts had minimally required equipment and supplies for providing implants and IUDs, while the reverse was true for male and female sterilization (**Figure 2.7, Panel A**). With the exception of equipment and supplies for providing implants in private/NGO facilities (**Figure 2.7, Panel B**), more UHCs/ MCWCs (**Figure 2.7, Panel C**) and private/NGO facilities in Phase III districts than in Phase I districts were found to have minimally required equipment and supplies for providing each LARC/ PM. However, readiness to provide LARCs/PMs was generally low in both Phase I and Phase III districts for all methods and types of facilities (**Figures 2.7**). Additional details on facility infrastructure and the availability of equipment and supplies can be found in Tables A.3.6 and A.3.8–A.3.10 in Appendix A).


⁸ Of the 99 response/provider combinations for IUD knowledge and practice, the percentage of providers spontaneously mentioning a response was more than one percentage point higher in Phase I districts for 49 cells, more than one percentage point higher in Phase III districts for 36 cells, and within one percentage point for 14 cells. The corresponding figures for implant knowledge and practice were 26, 31, and 12 (of 69 responses/provider combinations), and for female sterilization knowledge and practice were 41, 46, and 13 (of 100 response/provider combinations).

Figure 2.7: Percentage of facilities with minimal equipment and supplies to provide LARC/ PM services by facility type and method, by Phase I and Phase III areas, 2015 MH-II survey



A total of 372 women in Phase I districts and 418 women in Phase III districts reported that they were using a LARC/PM in the women's survey. Twenty-five percent of the LARC/PM users in Phase I districts and 30 percent of the LARC/PM users in Phase III districts reported that they were told about other methods before receiving their method (**Figure 2.8**). Only a quarter of LARC/PM users in both Phase I and Phase III areas reported that they were informed about potential side effects associated with their method. However, more than 90 percent felt that their confidentiality was maintained during their counseling. Seventy-seven percent of LARC/PM users in Phase I districts and 73 percent in Phase III districts were given a follow-up card. Further breakdown by high- and low-performing areas within Phase I and Phase III districts can be found in Table A.1.10 in Appendix A.

Figure 2.8: Indicators of quality of family planning care reported among women ages 15–49 who are not pregnant and are using female sterilization, IUDs, or implants, by Phase I and Phase III areas, 2015 MH-II survey




2.2.4. Behavior Change and Behavior Change Communication Activities

Comprehensive multichannel BCC through mass-media messages, community-level BCC activities, BCC materials at clinics, and BCC job-aid support to providers is a key activity outlined by the MH-II project. The availability of BCC materials at clinics was assessed in the facility readiness survey, as well as through questions in the women's survey about whether they had received relevant BCC materials during their visits to a health facility. Results are shown in **Figure 2.9**.


More than 90 percent of UHCs/MCWCs and FWCs in Phase I and Phase III areas had an FP-related billboard, banner, or poster. Fifty-two percent of DH/public MCHo facilities in Phase I districts and 46 percent in Phase III districts had an FP billboard, banner, or poster. DHs and public MCHo facilities had the lowest availability of informational materials such as booklets for clients (19 percent versus 21 percent in Phase I and Phase III areas) and job aids for providers (29 percent versus 37 percent). The percentage of other types of facilities with easily identifiable informational booklets

for clients varied from 35 percent in FWCs in Phase I areas to 52 percent in private/NGO clinics in Phase I areas, with no notable differences between Phase I and Phase III areas. Availability of job aids and flip charts for providers varied across other types of facilities, and was higher in Phase I districts than in Phase III districts. Further details on the availability of BCC materials can be found in Table A.3.7 in Appendix A.











In both Phase I and Phase III areas, less than 2 percent of non-pregnant women who were not using a LARC/PM and were visited by an FP worker in the past six months reported receiving BCC materials on LARCs/PMs during the home visit. Among non-pregnant women who were not using a LARC/PM and who sought FP care at a health facility in the past six months, fewer than 3 percent in either area reported receiving BCC materials on LARCs/PMs (Table A.1.9 in Appendix A).

Nearly three-quarters of CMWRA had ever heard about male sterilization across all low- and highperforming Phase I and Phase III districts. A higher percentage—more than 90 percent—had heard about female sterilization (Table A.1.11, in Appendix A). About 75 percent of women in both Phase I and Phase III districts reported having heard about IUDs as a contraceptive method; however, fewer women in low-performing districts reported knowledge of IUDs than did women in high-performing districts. In Phase I districts, 68 percent of women in low-performing districts versus 78 percent in high-performing districts reported IUD knowledge; in Phase III districts, 71 percent of women in low-performing districts versus 81 percent in high-performing districts reported IUD knowledge. More women reported knowledge about implants than IUDs. Ninety percent of women in Phase I districts and 88 percent of women in Phase III districts reported having heard about implants. As for IUDs, a higher percentage of women in high-performing districts than of those in low-performing districts reported knowledge of implants (Table A.1.11 in Appendix A).

Around 13 percent of women interviewed reported having heard about male sterilization as a contraceptive method in the past six months in both Phase I and Phase III areas (**Figure 2.10**). Similarly, around 21 percent of women reported they had heard of female sterilization in the past six months, 19 percent reported they had heard of IUDs, and around 29 percent reported they had heard of implants. There were no differences between Phase I and Phase III areas. In general, more women in high-performing districts than in low-performing districts reported having heard of each method in the past six months (Table A.1.11 in Appendix A).






Around 13 percent of women reported that they knew that IUDs can be adopted at the time of normal delivery in both Phase I and Phase III districts (**Figure 2.11** and Table A.1.12 in Appendix A). Slightly more women were aware that IUDs can be adopted at the time of a Cesarean section (14 percent in Phase I districts compared with 17 percent in Phase III areas). Family members, friends, and health providers were the primary sources of information among women who were aware of postpartum IUDs in both Phase I and Phase III areas (Table A.1.13 in Appendix A).

Around 28 percent of women reported that they knew that female sterilization can be adopted at the time of normal delivery in both Phase I and Phase III districts. Many more women were aware that female sterilization can be provided at the time of a Cesarean section (64 percent of women in Phase I areas and 63 percent of women in Phase III areas). Family members, friends, neighbors, and health care providers were the key sources of information; however, twice as many women reported family and friends as the source of information on postpartum sterilization than reported health providers as the source. (Table A.1.14 in Appendix A).

Figure 2.11: Knowledge of postpartum family planning among women ages 15–49 by Phase I and Phase III areas, 2015 MH-II survey



Sixty-seven percent of women in Phase I districts and 70 percent in Phase III districts believed that women become physically weak or may have other complications after having a tubectomy (**Figure 2.12**). About 46 percent of women in Phase I districts and 49 percent in Phase III districts believed that men become physically weak after a vasectomy. A higher percentage of women in Phase III districts (42%) than in Phase I districts (39%) believed that men who have a vasectomy lose their libido. Most women across both Phase I and Phase III areas disagreed that contraception is a woman's business and a man does not have to think about it. Variations by low- and high-performing areas in Phase I and Phase III districts can be found in (Table A.1.15 in Appendix A).






Figure 2.12: Perceptions of male and female sterilization among women ages 15–49 by Phase I and Phase III areas, 2015 MH-II survey

Among married women who are not pregnant, are not using a LARC/PM, and do not want any more children or are unsure whether they want any more children, just 3 percent reported intending to use a LARC or PM in the next 12 months in both Phase I and Phase III areas. About 4 percent of these women in low-performing Phase I districts intended to use a LARC or PM, compared with 2 percent in high-performing Phase I districts and 3 percent in all Phase III districts. (**Figure 2.13** and Table A.1.22 and Appendix A).





2.3. Analysis of Evaluation Design Assumptions

2.1.1. Timing of Baseline Data Collection

As noted in Section 1.4, the MH-II project had already been operating for one and a half years (since October 2013) before baseline data were collected in June–September 2015. This means that the baseline data could potentially pick up early effects of the program in Phase I districts, which could lead to underestimation of full project effects. Many activities in the first year focused on transition and start-up of the project, and therefore did not reach facilities and the population. However, the following activities had been undertaken in Phase I districts by the time of the baseline survey:

- Distribution of BCC materials to facilities in all 20 Phase I districts
- Training of GOB trainers in PPFP in all 20 districts
- Initiation of follow-up visits by MH-II staff members to facilities that had received training/ technical support from the project
- Involvement of individual private-sector providers and NGO providers in the 20 Phase I districts. For NGOs/the private sector, MH-II had invited providers from facilities that provide delivery services to training events with a focus on the use of postpartum and interval FP.
- Activities by mobile teams in one to two districts, with an estimated 600 clients reached
- Involvement of garment factories in Chittagong and Dhaka. These activities targeted demand generation and service provision among young married women in 25 factories.
- Continued operation in the MH-I focus districts by community health workers who had been trained in client counseling on LARCs and PMs during MH-I. Follow-up visits had been conducted to facilities that received support from MH-I.

The scale of activities at the provider and population levels was relatively modest at the time of the baseline survey. It is therefore unlikely that these activities had yet had a large impact in terms of affecting key population-level outcomes (e.g., prevalence of LARCs/PMs). The baseline household survey included questions on exposure to specific BCC materials to determine the extent of exposure at baseline, and the provider questionnaire included questions to determine whether and when providers received training related to LARCs/PMs, which allowed us to examine the degree of potential exposure to MH-II interventions in Phase I areas at baseline.

The analysis presented in Section 2.2.1 shows that MO-MCHs, OB/GYNs, and to a lesser extent, FWVs in Phase I districts were more likely to have been trained in LARCs/PMs since 2014 than those in Phase III districts. MO-MCHs and OB/GYNs were also more likely to have been trained in PPFP in Phase I districts than in Phase III districts. Training was low in all areas for BCC. Knowledge of government policies on offering IUDs immediately after a facility birth (i.e., normal or Cesarean section) was consistently higher among all types of providers in the Phase I districts than in the Phase III districts, and providers of all types in Phase I districts were more likely than those in Phase III districts to be aware of the policy on offering tubectomy after a normal facility delivery (Section 2.2.2). However, there were no consistent patterns in spontaneously reported knowledge and practices between Phase I and Phase III districts (Section 2.2.2), and there were no differences between Phase I and Phase III districts (Section 2.2.2), and there were no differences between Phase I and Phase III districts (Section 2.2.2). There were also few differences in the availability of BCC materials in facilities in Phase I and Phase III districts, except that UHC/MCWC, FWC, and private/NGO facilities in Phase I areas were somewhat more likely to have job aids for providers available than

those in Phase III areas. Few women who had contact with a service provider for FP in the six months before the survey reported receiving BCC materials on LARCs/PMs, and there were no differences in the percentage of women who reported hearing about LARCs/PMs in the past six months between Phase I and Phase III areas (Section 2.2.4). Mass media BCC activities had not been initiated at the time of the baseline survey.

Overall, these results suggest that there is evidence of some exposure to MH-II interventions, particularly provider training, in Phase I areas before the baseline survey. However, this exposure has not yet had a measurable effect on provider behavior or women's experiences of LARC/PM services, so has not affected demand for and uptake of LARCs/PMs.

2.1.2. Comparability of Phase I and Phase III Areas

In an impact evaluation, the intervention and comparison areas should be as similar as possible to increase the likelihood that the assumptions underlying the identification of program effects hold. Phase I and Phase III areas may differ systematically due to the mechanism by which the MH-II project was rolled out geographically over time. Districts for each implementation phase were not selected randomly, implying that there are likely both observed and unobserved differences between early-implementation and later-implementation districts that could also affect changes in outcomes.

Balance tests were performed to assess the underlying assumption for the program evaluation that the Phase I and Phase III areas are comparable in their observable characteristics that might be associated with the outcomes of interest. The statistical tests using the MH-II baseline data were performed on a total of 40 indicators related to:

- Household characteristics
- Women's background characteristics
- Women's knowledge and practice of reproductive health services
- Health providers' characteristics and exposure to the program
- Health facilities' characteristics

The differences in the estimated values of the selected indicators between the Phase I and Phase III domains were examined through statistical hypothesis testing. Specifically, adjusted Wald tests for binary or numeric outcomes and Pearson's chi-squared tests for categorical outcomes were performed, with correction and adjustment for stratification, clustering, and sampling weights,⁹ to evaluate the comparability between the two domains with a statistical significance at the level of 0.05 (two-sided). The analysis was conducted in Stata 14.1 (Stata Corp LP, College Station, Texas).

Summary results are presented in **Table 2.1** for indicators for households, women, health providers, and health facilities. Complete results of the balance tests are presented in Appendix B. Overall, the Phase III domain was statistically similar to the Phase I domain for 26 (65%) of the 40 indicators tested.

⁹ Note that the data on health providers and facilities did not have sampling weights. Analysis units were therefore unweighted for indicators related to health providers or facilities.

	Number of indicators	Indicators with sigr between Phase I and	
Indicator group	tested	Number	%
Household characteristics	10	5	50.0
Women's background characteristics	8	4	50.0
Women's knowledge and practice of reproductive health services	8	1	12.5
Health providers' characteristics and exposure to the program	6	3	50.0
Health facilities' characteristics	8	1	12.5
Total	40	14	35.0

Table 2.1: Summary results of the balance tests for similarity between Phase I and Phase III	
districts, 2015 MH-Íl survey	

For the indicators related to household characteristics, the Phase I domain was not statistically similar to the Phase III domain for 5 (50%) of the 10 indicators examined. There were statistically significant differences between the two domains for land ownership, main roof material, main wall material, main flooring material, and whether the household has a TV.

For the indicators related to women's background characteristics, the Phase I domain was not statistically similar to the Phase III domain for 4 (50%) of the 8 indicators examined. There were statistically significant differences between the two domains for total number of children ever born, wealth quintiles, whether women watch TV, and whether women cohabit with their husband.

For indicators related to women's knowledge and practice of reproductive health services, the Phase I domain was not statistically similar to the Phase III domain for 1 (12.5%) of the 8 indicators examined. There was a statistically significant difference between the two domains for whether women have heard about implants.

For indicators related to health providers' exposure to the program, the Phase I domain was not statistically similar to the Phase III domain for 3 (50%) of the 6 indicators examined. There were statistically significant differences between the two domains for training on LARCs/PMs, training on LARCs/PMs that Engender health (EH)/Mayer Hashi (MH) provided or was involved in or an EH/ MH representative was present for, and training on PPFP.

For indicators related to health facilities' characteristics and exposure to the program, the Phase I domain was not statistically similar to the Phase III domain for 1 (12.5%) of the 8 indicators examined. There was a statistically significant difference between the two domains for provision of delivery services.

Differences between the Phase I and Phase III domains for some indicators were expected due to the non-random selection of districts into different phases. Most notably, the districts in the Phase I domain were purposively selected to include a range of levels of CPRs and shares of LARCs/PMs (high-, medium-, and low-performing districts). Additionally, other factors influenced the decision as to which districts to introduce the program into under Phase I, including whether the districts had large urban or slum populations, large concentrations of underserved groups, and the presence of training centers or of medical colleges or other partners.


Overall, the results of the balance tests suggest a reasonable level of similarity between the Phase I and Phase III domains. Differences between the areas in provider exposure to the program reflect the fact that some activities were initiated in Phase I areas before the baseline survey was conducted, as discussed above in Section 2.3.1. The impact evaluation, which will use a DID analysis of the combined baseline and end-line data, is designed to control for time-invariant observed and unobserved differences between the Phase I and Phase III areas. The DID analysis will include relevant observed background characteristics of respondents in the statistical models in a regression form to account for their potential impact on the outcome indicators as well as on the baseline differences in outcome indicators.

2.1.3. Parallel Trend Assumption

The primary identifying assumption for the DID analysis is the parallel trend assumption (i.e., that the trend in the outcomes of interest in a comparison area is a valid estimate of the trend in the outcomes that would have been observed in an intervention area in the absence of the intervention). There is no way to formally test this assumption. However, it is sometimes possible to examine trends in the outcomes of interest in two areas prior to the start of the intervention; similar trends in the outcomes in intervention and comparison areas prior to the intervention support the plausibility of the parallel trend assumption.

Three external data sources were used to examine the plausibility of the parallel trend assumption for this evaluation: (1) the 2010 BMMS (National Institute of Population Research and Training (NIPORT), 2012), (2) the 2011 BDHS (National Institute of Population Research and Training (NIPORT), 2013), and (3) the 2014 BDHS (National Institute of Population Research and Training (NIPORT), 2013). Trends in the main outcome of interest and in the prevalence of LARC/PM use among CMWRA were assessed in Phase I and Phase III areas prior to the start of MH-II. The external data were collected prior to the introduction of MH-II (from the 2010 BMMS and 2011 BDHS) or in the first year of MH-II (from the 2014 BDHS).

The prevalence of LARC/PM use among CMWRA was comparable between Phase I and Phase III areas at 6.6 percent in 2010. The prevalence showed an upward trend in both domains prior to the start of the MH-II project, although there was some fluctuation in Phase III areas, most likely due to sampling errors (**Figure 2.14**). The prevalence of LARC/PM use was higher in Phase III areas than in Phase I areas in 2015, although the difference was not statistically significant. These findings support the general plausibility of the parallel trend assumption. The fact that a sharp increase in LARC/PM use was not observed in Phase I districts between 2014 and 2015 also supports our assumption that the program activities initiated prior to the baseline data collection are unlikely to have had significant impacts on population outcomes by the time of the baseline survey (see also Section 2.3.1 above).





Sources: 2010 BMMS, 2011 BDHS, 2014 BDHS, 2015 MH-II survey.

References

EngenderHealth, 2011. The SEED assessment guide for family planning programming.

General Economics Division, Planning Commission, Government of the People's Republic of Bangladesh.(2015). *Millennium Development Goals: Bangladesh progress report 2015.* Dhaka, Bangladesh: General Economics Division, Planning Commission, Government of the People's Republic of Bangladesh

National Institute of Population Research and Training (NIPORT), Mitra and Associates, and ICF International. (2013)*Bangladesh demographic and health survey 2011*. Dhaka, Bangladesh and Calverton, Maryland: NIPORT, Mitra and Associates, and ICF International.

National Institute of Population Research and Training (NIPORT), Mitra and Associates, and ICF International. (2016)*Bangladesh Demographic and Health Survey 2014.* Dhaka, Bangladesh, and Rockville, Maryland: NIPORT, Mitra and Associates, and ICF International.

National Institute of Population Research and Training (NIPORT), MEASURE Evaluation, icddr,b. (2012) . *Bangladesh Maternal Mortality and Health Care Survey 201*. Dhaka, Bangladesh: NIPORT, MEASURE Evaluation, and icddr,b.

Rahman, M., Curtis, S.L., and Haider, M.M. (2014) *Impact evaluation of the Mayer Yashi program of long-acting and permanent methods of contraception in Bangladesh.* Chapel Hill, NC: MEASURE Evaluation.

USAID.(2014). The Respond Project: Project brief.

Victora, C. G., Black, R.E., Boerma, J.T., and Bryce, J. (2011) Measuring impact in the Millennium Development Goal era and beyond: a new approach to large-scale effectiveness evaluations. *The Lancet* 377(9759), 85-95.

APPENDIX A. ADDITIONAL TABLES

Appendix A.1. Household and Women's Survey Tables

Household Survey

Table A.1.1: Household composition

Percentage distribution of households by sex of household head and household size, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III	
Characteristics	Low	High	Total	Low	High	Total
Household headship						
Male	84.6	88.6	87.0	85.7	91.7	88.0
Female	15.4	11.4	13.0	14.3	8.3	12.0
Total	100.0	100.0	100.0	100.0	100.0	100.0
Number of usual members						
1	1.7	2.3	2.1	1.7	1.9	1.7
2	8.3	10.6	9.7	8.2	9.6	8.7
3	17.0	20.5	19.1	18.9	21.9	20.0
4	23.1	32.2	28.5	25.0	29.3	26.6
5	20.2	18.7	19.3	20.2	18.8	19.6
6	13.0	8.9	10.5	12.1	10.2	11.4
7+	16.6	6.8	10.7	14.0	8.3	11.8
Total	100.0	100.0	100.0	100.0	100.0	100.0
Mean size of household	4.80	4.15	4.41	4.65	4.25	4.50
Number of households	2,475	3,286	5,761	2,476	3,345	5,821

Table A.1.2: Housing characteristics and land ownership

Percentage distribution of households by land ownership, housing characteristics, and selected household possessions, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III	
Characteristics	Low	High	Total	Low	High	Total
Household land ownership						
Only homestead land	49.5	46.7	47.8	50.5	46.8	49.1
Only cultivable land	0.3	0.5	0.4	0.1	0.5	0.3
Both homestead and cultivatable land	45.3	45.2	45.3	45.3	49.0	46.7
No land	4.9	7.6	6.5	4.1	3.6	3.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
Main roof material						
Tin	88.8	76.6	81.5	87.2	92.0	89.0
Cement/stone/bricks	10.4	20.7	16.5	10.4	7.2	9.2
Cement/ceramic tiles/tali/slate	0.8	2.7	1.9	2.4	0.8	1.8
No roof	0.0	0.0	0.0	0.0	0.0	0.0
Total	100.0	100.0	100.0	100.0	100.0	100.0
Main wall material						
Tin	50.2	30.4	38.3	49.1	52.0	50.2
Cement/stone/bricks	33.9	45.4	40.8	27.7	29.1	28.2
Mud/bamboo with mud/stone with mud	15.9	24.2	20.9	23.2	18.8	21.5
No wall	0.0	0.0	0.0	0.0	0.1	0.0
Total	100.0	100.0	100.0	100.0	100.0	100.0
Flooring material						
Earth/sand	63.4	54.3	57.9	68.6	79.4	72.7
Cement/ceramic tiles/tali/slate	36.5	44.6	41.4	30.0	20.4	26.3
Others	0.1	1.1	0.7	1.4	0.1	0.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
Source of drinking water						
Improved source ¹	99.4	99.5	99.4	99.7	99.2	99.5
Non-improved source ²	0.6	0.5	0.6	0.3	0.8	0.5
Total	100.0	100.0	100.0	100.0	100.0	100.0

Table A.1.2: Housing characteristics and land ownership (continued)

Percentage distribution of households by land ownership, housing characteristics, and selected household possessions, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase II	
Characteristics	Low	High	Total	Low	High	Total
Household sanitation facility						
Flush latrine	22.6	30.9	27.6	17.3	8.7	14.0
Improved pit latrine	34.8	31.2	32.7	33.1	33.2	33.2
Open pit latrine	39.9	35.1	37.0	47.5	56.6	51.0
Bucket/hanging/bush/others latrine	2.7	2.7	2.7	2.0	1.5	1.8
Total	100.0	100.0	100.0	100.0	100.0	100.0
Household has electricity (national grid/solar)	80.4	78.8	79.4	79.2	76.0	78.0
Household has television	43.8	50.5	47.8	42.6	35.2	39.8
Household has mobile phone	93.0	92.5	92.7	93.9	91.1	92.8
Wealth quintile						
Lowest	18.4	19.6	19.1	19.8	22.8	20.9
Second	19.2	15.5	16.9	21.3	27.4	23.7
Middle	19.7	16.8	18.0	20.0	23.6	21.4
Fourth	22.6	20.4	21.3	20.3	16.4	18.8
Highest	20.1	27.8	24.7	18.6	9.9	15.3
Total	100.0	100.0	100.0	100.0	100.0	100.0
Number of households	2,475	3,286	5,761	2,476	3,345	5 <i>,</i> 821

¹ Improved sources: piped into dwelling, piped into yard/plot, piped into public tap/standpipe, tube well or borehole, protected dug well, protected spring, rain water, and bottled water.

² Non-improved sources: unprotected dug well, unprotected spring, surface water, and others.

Women's Survey

Table A.1.3: Sociodemographic characteristics

Percentage distribution of currently married women ages 15–49, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III	
Background characteristics	Low	High	Total	Low	High	Total
Age of women						
15–19	11.0	9.8	10.3	10.6	10.4	10.5
20–24	19.6	18.5	18.9	18.4	17.5	18.1
25–29	18.3	20.3	19.5	19.6	19.9	19.7
30–34	17.1	18.8	18.1	18.1	16.6	17.5
35–39	12.9	12.4	12.6	14.2	13.4	13.9
40–44	12.5	11.4	11.8	11.5	11.8	11.6
45–49	8.7	9.0	8.8	7.7	10.3	8.7
Total	100.0	100.0	100.0	100.0	100.0	100.0
Number of children ever born						
0	9.0	8.6	8.8	7.8	8.6	8.1
1-2	43.8	55.2	50.6	44.6	50.8	47.0
3+	47.2	36.1	40.6	47.6	40.6	44.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
Education of women						
No education	21.8	24.7	23.5	23.7	25.6	24.4
Primary incomplete	19.1	19.6	19.4	19.1	19.1	19.1
Primary complete	16.1	11.8	13.6	13.3	12.7	13.1
Secondary incomplete	32.1	28.5	30.0	29.7	31.0	30.2
Secondary complete and higher	10.9	15.3	13.5	14.2	11.4	13.2
Total	100.0	100.0	100.0	100.0	100.0	100.0
Asset quintile						
Lowest	15.7	17.8	17.0	17.5	19.5	18.2
Second	18.5	15.1	16.5	20.3	27.1	22.8
Middle	19.6	17.8	18.5	20.4	24.9	22.1
Fourth	23.2	21.1	22.0	21.3	18.0	20.1
Highest	23.0	28.2	26.1	20.5	10.5	16.7
Total	100.0	100.0	100.0	100.0	100.0	100.0

Table A.1.3: Socio-demographic characteristics (continued)

Percentage distribution of currently married women ages 15–49, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III		
Background characteristics	Low	High	Total	Low	High	Total	
Watching television							
Don't watch	42.4	35.3	38.2	43.8	48.0	45.4	
Watch but not every day	11.2	12.3	11.9	11.5	14.0	12.4	
Watch almost every day	46.4	52.4	50.0	44.8	37.9	42.2	
Missing	0.0	0.0	0.0	0.0	0.0	0.0	
Total	100.0	100.0	100.0	100.0	100.0	100.0	
Husband's place of living							
With respondent	88.8	96.0	93.1	85.8	95.6	89.5	
Elsewhere but visited her 0–5 months ago	2.6	1.2	1.7	3.3	1.4	2.5	
Elsewhere but visited her 6–11 months ago	1.5	0.6	1.0	2.2	0.8	1.6	
Elsewhere but visited her 12 months or more ago	7.0	2.3	4.2	8.8	2.3	6.3	
Total	100.0	100.0	100.0	100.0	100.0	100.0	
Number of women	2,271	3,011	5,282	2,269	3,108	5,377	

Client-Provider Contact in the Past Six Months

Table A.1.4: Client-provider contact in family planning care in the past six months

Percentage of currently married women ages 15–49 who are not currently pregnant and not using LARCs/ PMs who had contact with FP services in the six months preceding the survey, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

	Phase I			Phase III			
FP care seeking	Low	High	Total	Low	High	Total	
Was visited at home by FP workers	20.7	33.3	28.1	26.6	32.4	28.8	
Sought FP care from government facilities	10.1	16.8	14.0	12.8	18.9	15.1	
Sought FP care from NGO/private facilities	1.3	4.3	3.1	1.8	2.8	2.2	
Sought FP care from satellite clinics	5.3	5.9	5.6	4.4	6.9	5.4	
Sought FP care from any facility	14.8	24.7	20.6	18.0	26.4	21.2	
Number of women	1,979	2,583	4,562	1,915	2,673	4,588	

Table A.1.5: Family planning services received at home

Among women ages 15–49 who are not pregnant and not using LARCs/PMs and were visited at home by any FP workers in the past six months, percentage who received selected types of FP services, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III	
FP services received at home	Low	High	Total	Low	High	Total
Counseling on female sterilization	30.3	33.2	32.3	33.2	31.4	32.4
Counseling on male sterilization	10.5	18.2	15.8	13.9	11.0	12.7
Counseling on IUDs	24.7	35.7	32.4	31.0	32.5	31.7
Counseling on implants	37.9	48.5	45.3	37.3	40.3	38.6
Counseling on injectables	23.7	22.5	22.8	26.5	26.3	26.4
Counseling on pills	29.6	19.6	22.6	23.8	20.8	22.5
Counseling on condoms	7.8	5.0	5.9	6.5	5.8	6.2
Supplied pills	24.2	29.3	27.8	36.1	28.7	32.9
Supplied condoms	2.2	3.6	3.2	3.7	5.2	4.4
Received injection	7.3	8.8	8.4	8.3	7.3	7.8
Advised to go to health center	26.7	29.1	28.4	20.4	19.0	19.8
Other services	1.0	0.3	0.5	0.6	0.2	0.4
Number of women	409	859	1,268	509	867	1,376

Table A.1.6: Family planning services received at a government health facility

Among women ages 15–49 who are not pregnant and not using LARCs/PMs and visited any government health facility in the last six months to receive FP services, percentage who received selected types of FP services, by low- and high-performance areas and Phase I and Phase III areas, the 2015 MH-II survey.

FP services received at a government		Phase I		Phase III		
health facility	Low	High	Total	Low	High	Total
Received information on female sterilization	21.6	27.4	25.7	20.4	14.3	17.5
Received information on IUDs	18.1	31.6	27.6	20.4	22.2	21.3
Received information on implants	25.1	39.4	35.2	24.9	21.4	23.2
Obtained pills	48.7	48.6	48.7	51.8	40.5	46.4
Obtained injectables	37.7	34.8	35.6	29.8	45.0	37.1
Obtained condoms	3.5	3.9	3.8	5.3	5.8	5.5
Obtained other services	2.5	4.4	3.8	3.3	1.6	2.5
Number of women	199	434	633	245	504	749

Table A.1.7: Family planning services received at a private/NGO health facility

Among women age 15–49 who are not pregnant and not using LARCs/PMs and visited any private/NGO health facility in the past six months to receive FP services, percentage who received selected types of FP services, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

FP services received at a private/NGO		Phase I		Phase III		
health facility	Low	High	Total	Low	High	Total
Received information on female sterilization	(15.4)	18.0	17.6	(17.6)	17.6	17.6
Received information on IUDs	(11.5)	24.3	22.1	(11.8)	28.4	20.0
Received information on implants	(19.2)	33.3	30.9	(23.5)	33.8	28.6
Obtained pills	(42.3)	31.5	33.4	(26.5)	23.0	24.7
Obtained injectables	(34.6)	46.8	44.7	(35.3)	58.1	46.5
Obtained condoms	(7.7)	7.2	7.3	(5.9)	2.7	4.3
Obtained other services	(7.7)	5.4	5.8	(26.5)	1.4	14.1
Number of women	26	111	137	34	74	108

Note: Numbers in parentheses are based on fewer than 50 cases (weighted).

Table A.1.8: Family planning services received at a satellite clinic

Among women age 15–49 who are not pregnant and not using LARCs/PMs and visited any satellite clinic in the past six months to receive FP services, percentage who received selected types of FP services, by low-and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

	Phase I			Phase III			
FP services received at a satellite clinic	Low	High	Total	Low	High	Total	
Received information on female sterilization	14.4	17.0	16.0	17.6	10.9	14.3	
Received information on IUDs	13.5	18.3	16.4	16.5	17.9	17.2	
Received information on implants	30.8	23.5	26.3	22.4	21.2	21.8	
Obtained pills	46.2	39.9	42.3	44.7	40.2	42.5	
Obtained injectables	46.2	43.8	44.7	47.1	51.6	49.3	
Obtained condoms	3.8	4.6	4.3	4.7	4.3	4.5	
Other services	1.9	2.0	1.9	2.4	1.6	2.0	
Number of women	104	153	257	85	184	269	

Table A.1.9: Behavior change communication materials during family planning services

Among women ages 15–49 who are not pregnant and not using LARCs/PMs, percent who were given BCC materials during FP services, by place where FP services received in the past six months, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

	Phase I			Phase III			
	Low	High	Total	Low	High	Total	
Among those who were visited at home by FP workers in the past six months:							
Given BCC materials during home visits	1.0	1.5	1.4	0.6	1.3	0.9	
Number of women	409	859	1,268	509	867	1,376	
Among those who sought FP care at any facility in the past six months:							
Given BCC materials during facility contact	1.7	2.7	2.4	1.7	2.4	2.1	
Number of women	293	637	930	344	706	1,050	

Quality of Care

Table A.1.10: Quality of family planning care

Among women ages 15–49 who are not pregnant and are using female sterilization, IUDs, or implants, percent who reported selected actions during the visit in which they received their method, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I		Phase III			
FP actions	Low	High	Total	Low	High	Total	
Were told about other methods before the delivery of the currently used method	26.8	24.1	24.9	29.3	30.8	29.8	
Were told about probable side effects of the currently used method	28.3	24.5	25.7	25.1	25.6	25.3	
Confidentiality was maintained during the delivery of the currently used method	93.7	92.2	92.7	93.7	89.9	92.4	
Given a follow-up card	78.7	76.3	77.1	76.4	66.1	72.8	
Number of women	127	245	372	191	227	418	

Knowledge of LARCs/PMs

Table A.1.11: Knowledge of LARC/PM

Percentage of women ages 15–49 who have ever heard about LARCs/PMs, and percent who have heard/ saw/read about LARCs/PMs in the six months preceding the survey, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III			
LARCs/PMs	Low	High	Total	Low	High	Total		
Have ever heard about:								
Male sterilization	71.7	74.7	73.5	72.4	73.3	72.7		
Female sterilization	94.5	95.4	95.0	93.9	93.8	93.9		
IUDs	68.1	77.9	73.9	71.0	81.2	74.9		
Implants	86.9	92.4	90.1	85.1	92.5	88.0		
Any LARC/PM	97.8	99.0	98.5	97.2	98.2	97.6		
Have heard/saw/read in the past six months about:1								
Male sterilization	11.6	13.7	12.8	13.5	11.6	12.8		
Female sterilization	19.3	21.8	20.8	21.0	20.5	20.8		
IUDs	14.8	21.9	19.0	17.5	20.8	18.7		
Implants	24.7	33.1	29.7	27.3	30.1	28.4		
Any LARC/PM	32.1	40.7	37.2	34.5	37.2	35.5		
Number of women	2,271	3,011	5,282	2,269	3,108	5,377		

¹ For each method, women who have not heard of the method in the past were classified as not having heard/ saw/read about the method in the past 6 months.

Knowledge of Postpartum Family Planning

Table A.1.12: Knowledge of postpartum family planning

Percentage of women ages 15–49 who know about postpartum IUDs and postpartum female sterilization, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I		Phase III			
PPFP methods	Low	High	Total	Low	High	Total	
Knowledge about IUDs ¹							
Know that IUD can be inserted at the time of normal delivery	13.4	12.5	12.9	13.0	14.7	13.6	
Know that IUD can be inserted at the time of Caesarean section	14.0	14.4	14.3	16.4	18.9	17.3	
Know that IUD can be inserted at the time of normal/Caesarean section delivery	16.9	18.6	17.9	19.6	23.1	20.9	
Knowledge about female sterilization ¹							
Know that female sterilization can be taken at the time of normal delivery	33.5	23.5	27.6	29.1	27.7	28.6	
Know that female sterilization can be taken at the time of Caesarean section	64.5	64.4	64.4	62.4	65.0	63.3	
Know that female sterilization can be taken at the time of normal/Caesarean section delivery	66.6	66.4	66.5	64.5	67.5	65.7	
Number of women	2,271	3,011	5,282	2,269	3,108	5,377	

¹ For each method, women who have not heard of the method in the past were classified as not knowing specific things about the method in subsequent questions.

Table A.1.13: Sources of knowledge of postpartum IUDs

Among women ages 15–49 with knowledge about postpartum IUDs, percentage who reported selected sources of that knowledge, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I		Phase III			
Source of knowledge of postpartum IUDs	Low	High	Total	Low	High	Total	
Among those who know that IUD can be inserted at the time of normal delivery:							
Husband/friend/relative/neighbor	71.8	71.2	71.5	65.0	81.4	71.7	
Health provider	55.7	52.8	54.1	55.8	46.3	51.9	
Mass media	6.9	2.9	4.6	7.8	2.9	5.8	
Community events	2.6	5.9	4.5	2.0	6.8	4.0	
Other	0.0	0.3	0.2	0.3	0.0	0.2	
Number of women	305	375	680	294	456	750	
Among those who know that IUD can be inserted at the time of Cesarean section:							
Husband/friend/relative/neighbor	76.5	75.9	76.1	72.2	83.5	76.9	
Health provider	51.1	46.9	48.6	54.4	48.9	52.1	
Mass media	6.6	6.0	6.2	4.3	3.1	3.8	
Community events	3.8	6.0	5.1	2.7	7.2	4.5	
Other	0.9	0.2	0.5	0.5	0.0	0.3	
Number of women	319	435	754	371	587	958	

Table A.1.14: Sources of knowledge of postpartum female sterilization

Among women ages 15–49 with knowledge about postpartum female sterilization, percentage who reported selected sources of that knowledge, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

Source of knowledge of postpartum		Phase I			Phase III			
female sterilization	Low	High	Total	Low	High	Total		
Among those who know that female sterilization can be taken at the time of normal delivery:								
Husband/friend/relative/neighbor	82.8	77.8	80.3	76.2	85.8	79.8		
Health provider	37.5	43.6	40.6	48.9	38.9	45.2		
Mass media	4.1	2.1	3.1	5.3	2.4	4.2		
Community events	2.0	6.6	4.3	4.1	6.4	4.9		
Other	0.5	0.3	0.4	0.6	0.7	0.6		
Number of women	761	708	1,469	661	861	1,522		
Among those who know that female sterilization can be taken at the time of Cesarean section:								
Husband/friend/relative/neighbor	88.9	85.9	87.1	81.8	88.9	84.6		
Health provider	31.5	37.7	35.2	44.2	36.5	41.2		
Mass media	3.3	2.6	2.9	3.2	1.9	2.7		
Community events	1.4	4.7	3.4	2.8	4.3	3.4		
Other	0.4	0.1	0.2	0.6	0.0	0.4		
Number of women	1,465	1,938	3,403	1,415	2,019	3,434		

Table A.1.15: Perceptions of male and female sterilizations

Percentage distribution of women ages 15–49 by their opinion on statements about male and female sterilizations, by low- and high-performance areas and Phase and Phase III areas, 2015 MH-II survey.

Statements about male and		Phase I			Phase III	
female sterilization	Low	High	Total	Low	High	Total
Women become physically weak or may have health complications after accepting female sterilization						
Agree	67.4	67.4	67.4	68.4	72.4	69.9
Disagree	16.7	16.9	16.8	15.6	13.7	14.9
Do not know	15.9	15.7	15.8	16.1	13.9	15.3
Total	100.0	100.0	100.0	100.0	100.0	100.0
Men who adopt male sterilization lose their libido						
Agree	39.3	39.0	39.1	39.6	46.0	42.0
Disagree	14.6	18.0	16.6	16.2	13.2	15.1
Do not know	46.1	43.0	44.3	44.2	40.8	42.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
Men become physically weak after accepting male sterilization						
Agree	46.1	45.6	45.8	46.5	52.0	48.6
Disagree	14.4	17.3	16.1	13.9	12.7	13.5
Do not know	39.5	37.0	38.0	39.6	35.4	38.0
Total	100.0	100.0	100.0	100.0	100.0	100.0
Contraception is women's business and a man does not have to worry about it						
Agree	4.1	4.1	4.1	8.9	4.2	7.1
Disagree	94.6	94.0	94.3	86.9	95.0	90.0
Do not know	1.4	1.9	1.7	4.3	0.7	2.9
Total	100.0	100.0	100.0	100.0	100.0	100.0
Number of women	2,271	3,011	5,282	2,269	3,108	5,377

Method Mix

Table A.1.16: Use of contraception by method

Percentage of married women ages 15–49 who currently use contraceptive methods, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III			
Use of contraceptive methods	Low	High	Total	Low	High	Total		
No use	39.4	26.6	31.8	36.4	29.4	33.7		
Female sterilization	3.8	5.0	4.6	5.4	4.7	5.1		
Male sterilization	1.1	1.7	1.4	1.3	1.1	1.2		
IUD	0.2	0.7	0.5	0.9	0.9	0.9		
Implant	1.5	2.4	2.0	2.1	1.7	1.9		
Injectables	12.2	14.9	13.8	10.3	18.6	13.4		
Pill	27.5	33.3	31.0	30.6	29.7	30.2		
Condom	4.5	7.1	6.1	4.9	5.9	5.3		
Traditional method	9.7	8.2	8.8	8.1	8.0	8.1		
Total	100.0	100.0	100.0	100.0	100.0	100.0		
Contraceptive prevalence (any method)	60.6	73.4	68.2	63.6	70.6	66.3		
Number of women	2,271	3,011	5,282	2,269	3,108	5,377		

Note: When a woman used multiple methods, only the most effective method was considered.

Source of Current Contraceptive Method

Table A.1.17: Last source of current family planning method

Percentage distribution of married women ages 15–49 who currently use FP methods by the last source of their current method, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III			
Source of the current FP method	Low	High	Total	Low	High	Total		
Last source of IUD among users of IUDs								
Government	-	-	(80.8)	-	(96.6)	95.7		
NGO	-	-	(7.5)	-	(3.4)	4.3		
Private	-	-	(11.7)	-	(0.0)	0.0		
Total	-	-	(100.0)	-	(100.0)	100.0		
Number of IUD users	5	21	26	21	29	50		
Last source of implant among users of implants								
Government	(85.7)	94.4	91.8	(93.6)	86.5	91.3		
NGO	(11.4)	4.2	6.4	(4.3)	7.7	5.4		
Private	(2.9)	1.4	1.8	(2.1)	5.8	3.3		
Total	(100.0)	100.0	100.0	(100.0)	100.0	100.0		
Number of implant users	35	72	107	47	52	99		
Last source of female sterilization among users								
of female sterilization								
Government	71.3	68.4	69.4	78.9	65.1	74.1		
NGO	5.7	5.3	5.4	0.8	0.0	0.5		
Private	23.0	26.3	25.2	19.5	34.2	24.6		
Do not know	0.0	0.0	0.0	0.8	0.7	0.8		
Total	100.0	100.0	100.0	100.0	100.0	100.0		
Number of female sterilization users	87	152	239	123	146	269		
Last source of male sterilization among users of male sterilization								
Government	-	90.0	86.7	(96.6)	(91.4)	94.8		
NGO	-	0.0	5.1	(0.0)	(0.0)	0.0		
Private	-	8.0	6.8	(3.4)	(0.0)	2.2		
Do not know	-	2.0	1.4	(0.0)	(8.6)	3.0		
Total	-	100.0	100.0	(100.0)	(100.0)	100.0		
Number of male sterilization users	24	50	74	29	35	64		
Last source of a short-acting method among users of a short-acting method								
Government	35.2	39.5	38.0	44.9	50.4	47.2		
NGO	6.0	7.9	7.2	6.3	7.9	6.9		
Private	58.9	52.5	54.7	48.8	41.6	45.8		
Do not know	0.0	0.1	0.0	0.1	0.1	0.1		
Total	100.0	100.0	100.0	100.0	100.0	100.0		
Number of short-acting method users	1,004	1,667	2,671	1,040	1,682	2,722		

Note: Numbers are suppressed if based on fewer than 25 cases (weighted). Numbers in parentheses are based on 25–49 cases (weighted).

Table A.1.18: Contraceptive use by young recently married women

Percentage distribution of women under age 25 who have been married for two years or less by type of contraceptive methods used, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

	Phase I			Phase III		
Use of contraceptive methods	Low	High	Total	Low	High	Total
No use	56.0	42.3	48.9	57.9	43.6	52.3
Female sterilization	0.0	0.0	0.0	0.0	0.0	0.0
Male sterilization	0.0	0.0	0.0	0.0	0.4	0.2
IUD	0.0	0.0	0.0	0.6	0.4	0.5
Implant	1.7	1.3	1.5	0.6	0.0	0.3
Injectables	3.9	6.2	5.1	2.2	7.7	4.4
Pill	26.3	32.6	29.6	27.0	31.3	28.7
Condom	8.6	13.2	11.0	7.9	13.5	10.1
Traditional method	3.4	4.4	3.9	3.9	3.1	3.6
Total	100.0	100.0	100.0	100.0	100.0	100.0
CPR	44.0	57.7	51.1	42.1	56.4	47.7
Number of women under age 25 who have been married for two years or less	232	227	459	178	259	437

Note: When a woman used multiple methods, only the most effective method was considered.

Postpartum Family Planning

Table A.1.19: Use of postpartum family planning among women who had given birth between January 2012 and September 2013

Percentage of women ages 15–49 who gave birth between January 2012 and September 2013, percent distribution of those who gave birth between January 2012 and September 2013 by place of delivery, and percent of those who gave birth who were offered/accepted PPFP services, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

	Phase I			Phase III			
	Low	High	Total	Low	High	Total	
Gave birth between January 2012 and September 2013	14.5	13.6	14.0	16.5	12.4	14.9	
Number of women	2,271	3,011	5,282	2,269	3,108	5,377	
Among those who gave birth between January 2012 and September 2013:							
Delivered at home	70.2	62.8	66.0	61.8	63.3	62.2	
Delivered at a facility	29.8	37.2	34.0	38.2	36.7	37.8	
Were offered IUD/female sterilization during facility delivery	4.6	5.6	5.2	7.0	4.4	6.2	
Were offered and accepted IUD/female sterilization during facility delivery	1.2	1.7	1.5	1.9	1.6	1.8	
Were not offered IUD/female sterilization during facility delivery, but accepted from own interest	0.0	0.5	0.3	0.3	0.3	0.3	
Number of women	329	409	738	374	384	758	

Table A.1.20: Use of postpartum family planning among women who had given birth sinceOctober 2013

Percentage of women ages 15–49 who had given birth since October 2013, percent distribution of those who had given birth since October 2013 by place of delivery, and percent of those who had given birth who were offered/accepted PPFP services, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

	Phase I			Phase III			
	Low	High	Total	Low	High	Total	
Given birth since October 2013	19.8	13.1	15.8	18.2	14.6	16.9	
Number of women	2,271	3,011	5,282	2,269	3,108	5,377	
Among those who had given birth since October 2013:							
Delivered at home	66.8	50.1	58.6	61.5	55.8	59.6	
Delivered at a facility	33.2	49.9	41.4	38.5	44.2	40.4	
Were offered IUD/female sterilization during facility delivery	4.2	8.6	6.4	7.5	4.4	6.5	
Were offered and accepted IUD/female sterilization during facility delivery	1.1	2.8	1.9	1.9	1.1	1.7	
Were not offered IUD/female sterilization during facility delivery, but accepted from own interest	0.2	0.3	0.2	0.2	0.2	0.2	
Number of women	449	395	844	413	455	868	

Discussion of LARCs/PMs in Past Six Months

Table A.1.21: Discussion of LARCs/PMs in the past six months

Percentage of women ages 15–49 who discussed LARCs/PMs with their husband and other people in the six months preceding the survey, by low- and high-performance areas and Phase and Phase III areas, 2015 MH-II survey.

		Phase I			Phase III	
LARC/PM discussed with husband	Low	High	Total	Low	High	Total
Discussed with husband:						
IUD	1.3	1.3	1.3	1.2	1.4	1.3
Implant	2.5	2.0	2.2	2.7	2.4	2.6
Female sterilization	2.1	1.7	1.9	2.0	2.6	2.2
Male sterilization	0.9	1.2	1.1	1.3	1.0	1.2
Any LARC/PM	4.8	3.9	4.3	4.7	4.3	4.5
Discussed with other people:						
IUD	7.9	17.0	13.2	9.2	16.2	11.8
Implant	12.5	25.4	20.0	14.3	21.8	17.2
Female sterilization	9.2	16.4	13.4	10.4	14.9	12.1
Male sterilization	4.4	9.6	7.4	5.8	8.5	6.8
Any LARC/PM	15.3	30.3	24.1	17.6	25.6	20.6
Number of women	2,120	2,716	4,836	2,049	2,846	4,895

Intention to Use LARC/PM in Next 12 Months

Table A.1.22: Intention to use LARC/PM

Among women ages 15–49 who are not pregnant, not using LARCs/PMs, and do not want any more children or are undecided about wanting more children, percentage who intend to use IUDs/implants/female sterilization within the next 12 months, by low- and high-performance areas, 2015 MH-II survey.

		Phase I			Phase III	
Intention to use:	Low	High	Total	Low	High	Total
IUD	0.3	0.4	0.3	0.4	0.3	0.4
Implant	2.4	1.3	1.8	1.4	1.3	1.4
Female sterilization	1.8	0.6	1.1	1.2	1.2	1.2
IUD, implant, or female sterilization	4.3	2.3	3.1	3.0	2.7	2.9
Number of women	1,370	1,798	3,168	1,362	1,891	3,253

Table A.1.23: Duration of current LARC/PM use

Percentage distribution of women ages 15–49 who are not pregnant and who currently use LARCs/PMs, by timing of adoption of current LARC/PM, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Phase I			Phase II	
Duration of use of current LARC/PM method	Low	High	Total	Low	High	Total
Started using LARC/PM in or after January 2014	24.5	21.4	22.4	26.4	16.4	22.9
Started using LARC/PM before 2014	75.5	78.6	77.6	73.2	83.6	76.8
Date unknown	0.0	0.0	0.0	0.5	0.0	0.3
Total	100.0	100.0	100.0	100.0	100.0	100.0
Number of women	151	295	446	220	262	482

Appendix A.2. Provider Survey Tables

Table A.2.1: Type of respondents

Percentage and number of providers by type, by Phase I and Phase III areas, 2015 MH-II survey.

	Phc	ise l	Pha	se III
Type of respondents	N	%	Ν	%
OB/GYN	118	13.1	125	13.0
RMO	83	9.2	119	12.4
MO/clinic manager	213	23.6	188	19.6
FWV/SACMO/nurse/nurse midwife/paramedic	362	40.1	394	41.0
Other ¹	127	14.1	134	14.0
Total	903	100	960	100

¹ Includes FWAs, service prompters, and community health workers.

Provider Training

Table A.2.2: Training since 2014

Percentage of providers who have received training since 2014 by type of training and training provider, by type of provider and Phase I and Phase III areas, the 2015 MH-II survey.

	Ę	FWA	F	FWV	W) OW	MO (MCH-FP)	RN	RMO	OB/GYN	SΥN
Training received	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase =
Training on LARC/PM										
Training by any training providers	1.1.1	8.1	26.2	25.7	23.5	6.5	1.2	2.5	33.1	20.8
Training provided by EH/MH	2.8	1.6	7.9	8.2	16.5	5.2	1.2	0.8	25.4	10.4
Training where EH/MH was involved	4.6	0.0	2.3	1.2	1.2	1.3	0.0	0.0	3.4	0.8
Training where any representative from EH/MH was present or participated	4.6	0.0	2.3	2.0	0.0	0.0	0.0	0.0	3.4	0.8
Training provided by EH/MH, or training where EH/MH was involved, or representative from EH/ MH was present	7.4	1.6	10.3	9.8	16.5	6.5	1.2	0.8	28.8	11.2
Training on PPFP										
Training by any training providers	7.4	6.5	15.0	13.1	11.8	5.2	0.0	0.8	15.3	8.8
Training provided by EH/MH	0.9	1.6	5.6	5.7	8.2	3.9	0.0	0.8	11.0	4.8
Training where EH/MH was involved	2.8	0.0	0.9	0.4	1.2	1.3	0.0	0.0	0.8	0.0
Training where any representative from EH/MH was present or participated	2.8	0.0	0.9	1.2	0.0	0.0	0.0	0.0	0.8	0.0
Training provided by EH/MH, or training where EH/MH was involved, or representative from EH/ MH was present	3.7	1.6	6.5	6.9	9.4	5.2	0.0	0.8	11.9	4.8
Number of providers	108	123	214	245	85	77	83	119	118	125

57

4
0
2
since
ommunication
change c
behavior c
g on be
Training
A.2.3:

Percentage of providers who have received training on BCC since 2014, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FV	FWA	F	FWV	MO (MCH-FP)	CH-FP)	RMO	0	OB/GYN	SΥN
BCC training received	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Training on BCC	5.6	2.4	7.0	8.6	5.9	7.8	4.8	3.4	1.7	1.6
Training where EH/MH was involved	4.6	0.8	3.7	3.7	2.4	2.6	0.0	0.8	0.0	1.6
Training where any representative from EH/MH was present or participated	4.6	0.8	3.3	3.7	3.5	2.6	1.2	0.0	0.8	1.6
Training provided by EH/MH, or training where EH/MH was involved, or representative from EH/ MH was present	4.6	0.8	3.7	3.7	3.5	2.6	1.2	0.8	0.8	1.6
Number of providers	108	123	214	245	85	77	83	119	118	125

Provider's Knowledge and Practice: IUDs

Table A.2.4: Pre-counseling elements for IUD clients

Percentage of providers who spontaneously reported that they provide selected elements of pre-counseling services to IUD clients, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	F	FWA	Ę	FWV	-OW	MO-MCH	RA	RMO	OB/(OB/GYN
Elements of pre-counseling for IUD clients	Phase I	Phase III	Phase I	Phase Ⅲ	Phase P I	Phase III	Phase I	Phase III	Phase Phase I III	Phase III
Providing the follow-up card	46.3	31.7	51.4	54.7	55.3	49.4	14.5	11.8	38.1	30.4
Determining that the client has understood the key points of counseling	6.5	8.9	14.5	15.1	11.8	5.2	4.8	3.4	7.6	6.4
Number of providers	108	123	214	245	85	77	83	83 119	118	125

Ð
an
pting
acce
for
Conditions
2.5:
Fable A
-

Percentage of providers who spontaneously reported conditions under which a woman can accept an IUD or can be recommended for an IUD, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

Phase 1 87.0			A A A	5	MO-MCH	RMO	0	OB/GYN	ίN
87.0	Phase	Phase	Phase Phase	Phase	Phase	Phase	Phase	Phase	Phase
87.0	≡	_	≡	_	≡	_	≡	_	≡
	91.1	91.6	92.7	90.6	97.4	73.5	64.7	90.7	89.6
bon i wani a criiia iora iorig iirrie oraon i wani 232.3 3. child at all	53.7	53.7	58.4	80.0	66.2	66.3	62.2	78.8	72.8
Cannot use a hormonal FP method (e.g., pills, 20.4 4(implants, injectables)	40.7	36.9	40.4	52.9	51.9	33.7	42.0	50.0	49.6
Regular menstruation 50.9 40	40.7	52.8	53.9	0.08	58.4	9.6	18.5	46.6	47.2
Within first 5 days of menstruation 27.8 2:	22.0	32.7	28.2	30.6	15.6	0.0	7.6	26.3	12.8
Number of providers	123	214	245	85	77	83	119	118	125

Table A.2.6: Conditions for not accepting an IUD

Percentage of providers who spontaneously reported conditions under which a woman cannot be recommended for IUD, by type of providers and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	Ā	FWV	2	-0W	MO-MCH ¹	RN	RMO		γN
	Phase	Phase	Phase	Phase	Phase	Phase	Phase	Phase Phase Phase Phase Phase Phase Phase Phase Phase	Phase	Phase
Conditions for not accepting an IUD	_	≡	_	≡	_	≡	_	≡	_	≡
Has no child	ı	I	77.6	82.0	ı	ı	I	ı	ı	ı
Has been suffering from a reproductive tract infection	I	I	82.2	88.6	ı	I	I	I	I	I
Menstruation stopped	I	I	43.9	43.7	ı	I	I	I	I	I
Pregnancy	ı	I	69.2	62.0	ı	ı	I	I	I	ı
Irregular menstruation	ı	I	56.1	58.8	ı	I	I	I	I	ı
Excessive menstrual bleeding	ı	I	53.3	62.9	ı	ı	I	I	I	ı
Chronic jaundice	ı	I	18.7	15.9	ı	ı	I	I	I	ı
Breast cancer	ı	ı	14.0	9.0	ı	I	I	I	I	I
Number of providers	108	123	214	245	85	77	83	119	118	125

¹ FWAs, MOs-MCH, RMOs, and OB/GYNs were not asked this question.

Table A.2.7: Possible side effects of IUDs

Percentage of providers who spontaneously reported possible side effects of IUDs, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FV	FWA	FΜ	FWV	MO-MCH	MCH	RN	RMO	OB/GYN	SΥN
Possible side effect of IUDs	Phase I	Phase III								
Abdominal pain	80.6	78.0	1	1	84.7	92.2	53.0	52.9	83.9	76.0
Excessive bleeding between menstrual cycles	56.5	56.1	I	I	54.1	42.9	44.6	38.7	56.8	55.2
Spotting	59.3	53.7	I	ı	69.4	71.4	33.7	42.0	74.6	68.8
Abnormal menstrual bleeding	55.6	48.8	I	I	67.1	59.7	36.1	41.2	53.4	59.2
White discharge/excessive white discharge	50.0	63.4	I	ı	48.2	61.0	21.7	22.7	41.5	43.2
The thread of the IUD comes out	43.5	37.4	I	ı	60.09	53.2	42.2	42.0	55.1	54.4
Number of providers	108	123	214	245	85	77	83	119	118	125

¹ FWVs were not asked this question.

Table A.2.8: Provision of care to IUD clients with excessive bleeding

Percentage of providers who reported that they will provide specific care to an IUD client with excessive bleeding, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	Ā	FWV	2	MO-MCH	MCH	RMO	0	OB/GYN	λN
Type of care	Phase I	Phase III	Phase I	Phase III	Phase I	Phase Ⅲ	Phase I	Phase ≡	Phase I	Phase III
Examine her to determine the reasons for excessive bleeding	I	I	66.4	72.7	87.1	85.7	68.7	73.1	85.6	85.6
Provide treatment for bleeding	ı	I	80.8	78.0	84.7	67.5	69.9	58.8	78.0	68.8
Refer to higher level of treatment	I	I	24.3	24.1	11.8	15.6	24.1	20.2	5.1	8.0
Remove IUD	I	I	60.3	60.8	56.5	54.5	26.5	42.9	55.9	55.2
Number of providers	108	123	214	245	85	77	83	119	118	125

¹ FWAs were not asked this question.

Table A.2.9: Provision of care to IUD clients with abdominal pain

Percentage of providers who reported that they will provide specific care to an IUD client with abdominal pain, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	'A'	FV	FWV	MO-MCH	MCH	RN	RMO	OB/GYN	γN
	Phase	Phase	Phase	Phase	Phase Phase Phase	Phase		Phase	Phase Phase Phase	Phase
Type of care	_	≡	_	≡	_	≡	_	≡	_	=
Examine her to determine the probable reasons for pain	I	I	73.4	82.9	88.2	92.2	73.5	70.6	89.0	96.0
Provide treatment and assure her that further services are available if needed	I	I	84.1	79.6	84.7	77.9	66.3	62.2	86.4	77.6
Refer to higher level of treatment	ı	ı	16.8	23.3	8.2	13.0	19.3	21.0	9.3	8.0
Remove IUD	·	ı	43.5	38.8	43.5	42.9	16.9	27.7	42.4	42.4
Number of providers	108	123	214	245	85	77	83	119	118	125
1 TVAVA										

¹ FWAs were not asked this question.

Provider's Knowledge and Practice: Implants

Table A.2.10: Pre-counseling elements for implant clients

Percentage of providers who spontaneously reported that they provide selected elements of pre-counseling services to implant clients, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	F	FWA	FWV	2	-OW	MO-MCH	RN	RMO		١N١
Element of pre-counseling for implant clients	Phase I	Phase =	Phase Phase Phase Phase Phase Phase I III I III I III I III I III I III	Phase =	Phase I	Phase III	Phase I	Phase Phase I III	Phase Phase	Phase III
Explaining advantages and disadvantages of implants	91.7	90.2	92.1	91.8	91.8 97.6 93.5 75.9	93.5	75.9	77.3	1	I
Ensuring that the client has made the decision after having full information	13.9	13.8	13.9 13.8 24.8 19.6 21.2	19.6	21.2	24.7	6.0	5.0	·	I
Number of providers	108	123	214	245	85	77	83	119	118 125	125

¹ OB/GYNs were not asked this question.

i implant
an
accepting
P
Conditions 1
Ë
A.2.
Table

Percentage of providers who spontaneously reported conditions under which a woman can accept an implant or can be recommended for an implant, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FΜ	FWA	FV	FWV	MO-MCH	MCH	RN	RMO		ŗΝΥ
	Phase	Phase	Phase	Phase	Phase	Phase	Phase	Phase	Phase	Phase
Conditions for accepting an implant	_		_	≡	_	≡	_			≡
Want to avoid pregnancy for a long time	77.8	78.0	72.0	82.4	96.5	92.2	75.9	75.6	I	I
Have no children	69.4	65.9	71.5	71.4	78.8	80.5	34.9	30.3	I	I
Menstruating regularly (i.e. she is not pregnant)	33.3	39.0	48.1	48.2	51.8	51.9	15.7	19.3	I	I
Number of providers	108	123	214	245	85	77	83	119	118	125

¹ OB/GYNs were not asked this question.

Table A.2.12: Possible side effects of implants

Percentage of providers who spontaneously reported possible side effects of implants, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	A	FWV	N	MO-MCH	MCH	RMO	01	OB/GYN	۶۲N
Possible side effect of implants	Phase I	Phase III	Phase I	Phase Ⅲ	Phase I	Phase Ⅲ	Phase I	Phase III	Phase I	Phase III
Menstruation stopped	77.8	80.5	80.8	77.6	88.2	88.3	49.4	49.6	ı	I
Excessive bleeding	80.6	78.0	85.5	86.5	85.9	89.6	56.6	67.2	ı	I
Spotting	73.1	72.4	72.9	73.1	84.7	80.5	44.6	40.3	ı	I
Weight gain	23.1	20.3	25.7	26.9	38.8	42.9	31.3	23.5	ı	I
Nausea/vomiting	32.4	24.4	32.7	27.8	27.1	22.1	21.7	21.8	I	I
Depression	26.9	31.7	36.9	31.8	35.3	37.7	14.5	15.1	ı	I
Pain in arm	41.7	50.4	42.5	51.8	56.5	70.1	45.8	47.9	I	I
Number of providers	108	123	214	245	85	77	83	119	118	125

¹ OB/GYNs were not asked this question.

62

Table A.2.13: Provision of care to implant clients with excessive bleeding

Percentage of providers who reported that they will provide specific care to an implant client with excessive bleeding, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	'A'	Ę	FWV	MO-MCH	MCH	RA	RMO	OB/GYN	γN
	Phase	'hase Phase Phase Phase Phase	Phase	Phase	Phase	Phase	Phase	Phase	Phase Phase Phase Phase	Phase
Type of care	_	≡	_	≡	_	≡	_	≡	_	=
Examine her to determine the reasons for excessive bleeding	I	I	57.9	73.9	81.2	90.9	65.1	69.7	I	I
Provide treatment for bleeding	I	ı	83.2	76.3	82.4	75.3	65.1	53.8	ı	1
Refer to higher level of treatment	ı	ı	40.2	34.3	7.1	13.0	25.3	18.5	ı	1
Remove implant	ı	I	32.7	36.3	52.9	49.4	18.1	36.1	I	I
Number of providers	108	123	214	245	85	77	83	119	118	125

¹ FWAs and OB/GYNs were not asked this question.

Table A.2.14: Provision of care to implant clients with amenorrhea

Percentage of providers who reported that they will provide specific care to an implant client with amenorrhea, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	Ā	FWV	2	-OM	MO-MCH	RA	RMO	OB/GYN	γN
Type of care	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	³ hase Phase	Phase III	Phase I	Phase III
Check pregnancy	I	I	77.1	78.8	78.8 85.9	87.0	62.7	69.7	I	I
If she is not pregnant, counsel and reassure her that this is normal	ı	I	81.8	80.0	81.2	83.1	63.9	48.7	I	I
Remove implant	ı	ı	16.4	18.8	24.7	28.6	16.9	27.7	ı	ı
Number of providers	108	123	214	245	85	77	83	119	118 125	125

¹ FWAs and OB/GYNs were not asked this question.

Provider's Knowledge and Practice: Female Sterilization

Table A.2.15: Pre-counseling for female sterilization

Percentage of providers who spontaneously reported that they provide specific elements of pre-counseling to clients seeking female sterilization, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	A I	F	FWV	MO-MCH	MCH	RMO	Q	OB/(OB/GYN
Elements of pre-counseling	Phase I	Phase III								
Explain advantages and disadvantages of female sterilization	85.2	85.4	89.7	89.0	95.3	90.9	84.3	79.0	93.2	92.0
Explain probable side effects, discomfort, and complications of female sterilization	61.1	61.0	59.8	73.5	82.4	76.6	50.6	64.7	78.8	79.2
Ensure that the client does not have any health conditions unfavorable to the operation	25.9	34.1	34.1	35.5	51.8	58.4	22.9	24.4	40.7	54.4
Ensure that the client understood the advantages and disadvantages of female sterilization before she made the decision	16.7	22.8	21.5	27.3	29.4	28.6	15.7	10.9	25.4	13.6
Number of providers	108	123	214	245	85	77	83	119	118	125

Table A.2.16: Post-counseling for female sterilization

Percentage of providers who spontaneously reported that they provide specific elements of post-counseling to clients who have just accepted female sterilization, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	A I	FWV	2	-OW	MO-MCH	RA	RMO	OB/	OB/GYN
Elements of post-counseling	Phase I	Phase Ⅲ	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Give her the follow-up card	53.7	37.4	48.6	52.2	60.0	46.8	21.7	19.3	39.8	30.4
Remind her about the probable side effects and discomfort, and assure her of the follow-up	48.1	48.8	48.6	61.2	57.6	68.8	41.0	39.5	59.3	52.8
Remind her of the procedure for follow-up	40.7	32.5	41.6	51.0	38.8	53.2	16.9	19.3	25.4	32.8
Encourage the client to contact a service provider if there are any side effects or complications	59.3	65.0	61.7	59.6	78.8	64.9	62.7	58.0	75.4	68.8
Remind her to take full rest for 2 days	56.5	60.2	59.8	56.7	65.9	66.2	39.8	45.4	55.1	64.0
Encourage her to avoid heavy work or avoid lifting heavy weight for 3 weeks	66.7	69.1	71.5	66.5	76.5	76.6	49.4	44.5	72.9	69.6
Remind her to take medications that have been given to her	32.4	37.4	40.2	39.6	47.1	50.6	13.3	25.2	44.9	34.4
Ensure that the client understood the main points of counseling	6.5	6.5	15.9	11.4	7.1	15.6	8.4	5.9	11.0	7.2
Number of providers	108	123	214	245	85	77	83	119	118	125

Table A.2.17: Conditions for accepting female sterilization

Percentage of providers who spontaneously reported conditions under which a woman can accept female sterilization or can be recommended for female sterilization, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	IA	FWV	2	MO-MCH	MCH	RMO	0	OB/GYN	γN
Conditions for accepting female sterilization	Phase I	hase Phase I III	Phase I	Phase Phase I III	Phase I	Phase Phase I III		Phase Phase I III	Phase Phase	Phase III
Do not want to have any more children and have at least one living child	62.0	68.3	65.9	69.0	69.4	74.0	67.5	59.7	67.8	66.4
Do not want to have any more children and the age of youngest child is at least 2 years	86.1	82.1	82.7	86.5	88.2	84.4	67.5	69.7	87.3	86.4
Have had 2 or more Caesarean sections	11.1	8.9	17.8	16.7	45.9	27.3	19.3	15.1	35.6	40.0
Husband has agreed to female sterilization	33.3	44.7	39.7	47.3	60.0	64.9	34.9	28.6	45.8	44.8
Number of providers	108	123	214	245	85	77	83	119	118	125

Table A.2.18: Follow-up with female sterilization clients

Percentage of providers who reported that they or their facility follow up with female sterilization clients, and percent reporting specified follow-up times, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	Ĩ.	FWA		FWV	Ŵ	MO-MCH	R	RMO	OB/	OB/GYN
	Phase	Phase III								
Follow up with female sterilization	81.5	97.6	82.7	86.1	100.0	94.8	65.1	72.3	87.3	96.0
Do not follow up with female sterilization	18.5	2.4	17.3	13.9	0.0	5.2	34.9	27.7	12.7	4.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Timing of follow-up ¹										
Within 3 days	23.1	16.3	3.3	1.6	10.6	2.6	1.2	4.2	5.1	4.8
Within 7 days	76.9	78.9	79.9	71.0	83.5	88.3	20.5	34.5	66.1	72.0
After 1 month	72.2	65.9	60.3	59.6	55.3	58.4	22.9	34.5	55.1	47.2
2–5 months	22.2	17.1	10.3	6.9	7.1	10.4	3.6	6.7	14.4	14.4
6–11 months	22.2	20.3	28.5	34.7	28.2	42.9	13.3	10.1	22.9	24.8
After 1 year	25.0	12.2	19.6	20.8	18.8	23.4	7.2	8.4	14.4	16.0
When problem arises	57.4	74.0	63.1	75.1	69.4	76.6	36.1	46.2	74.6	73.6
Number of providers	108	123	214	245	85	77	83	119	118	125

¹ Multiple responses allowed

clients
e sterilization
h female
۸iH
follow-up
time of
at the ti
Counseling at
2.19:0
Table A.

Percentage of providers who spontaneously reported that they provide specific elements of counseling to a female sterilization client at the time of follow-up, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	F	FWA	F	FWV	-OW	MO-MCH	R	RMO	OB/	OB/GYN
Elements of counseling	Phase I	Phase III Phase I Phase II Phase I Phase III Phase I Phase II Phase I Phase	Phase I	Phase III	Phase	Phase III	Phase I	Phase III	Phase	Phase III
Provide counseling and treatment immediately if client complains of side	70.4	71.5	75.7	77.1	94.1	83.1	62.7	68.9	86.4	81.6
effects, complications, and discomfort Refer to appropriate place if client										
complains of side effects, complications,	36.1	43.9	37.9	38.8	29.4	29.9	19.3	20.2	28.0	18.4
or discomfort Provide assurance that other services										
are available if she has no side effects,	28.7	34.1	32.7	41.2	50.6	51.9	25.3	21.8	43.2	44.8
complications, or discomfort										
Number of providers	108	123	214	245	85	77	83	119	118	125
	ī									

Provider Knowledge of Postpartum Family Planning Policies

Table A.2.20: Awareness of government policies regarding postpartum IUDs and female sterilization

Percentage of providers who are aware of government policies regarding postpartum IUDs and female sterilization, by type of provider and Phase I and Phase III areas, 2015 MH-II survey.

	FWA	IA I	FWV	2	-OM	MO-MCH	RA	RMO	OB/GYN	GΥN
Awareness of government policy that:	Phase I	Phase III	Phase I	Phase Phase I III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
IUD may be offered to those women who deliver at facilities, immediately after delivery	77.8	65.9	95.8	95.1	97.6	94.8	66.3	44.5	94.9	81.6
Female sterilization may be offered to those women who deliver at facilities, right at delivery	84.3	72.4	92.5	89.0	97.6	97.4	79.5	60.5	94.1	87.2
An IUD may be offered during a Caesarean section delivery	64.8	61.0	86.0	85.3	92.9	90.9	60.2	58.0	91.5	76.8
Female sterilization may be offered during a Caesarean section delivery	97.2	94.3	98.6	9.66	100.0	100.0	90.4	89.1	9.6.6	96.8
Number of providers	108	123	214	245	85	77	83	119	118	125

Appendix A.3. Facility Readiness Survey Tables

Table A.3.1: Types of facilities

Number and percentage of facilities by type, by low- and high-performance areas and Phase I and Phase III areas, 2015 MH-II survey.

		Pha	se l			Phas	e III	
	L	ow	Hi	igh	Lo	w	Hi	igh
Type of facilities	N	%	Ν	%	Ν	%	Ν	%
DH/MCHo	9	4.8	12	6.3	14	7.1	10	5.1
UHC/MCWC	60	32.3	61	32.1	72	36.5	69	35.2
FWC	47	25.3	56	29.5	51	25.9	68	34.7
Private/NGO	69	37.1	57	30.0	56	28.4	46	23.5
Rural dispensary	1	0.5	4	2.1	4	2.0	3	1.5
Total	186	100.0	190	100.0	197	100.0	196	100.0

Services Available at Facilities

Table A.3.2: Availability of LARC/PM services

Percentage of facilities where LARC/PM services are available, by facility type and Phase I and Phase III areas, 2015 MH-II survey.

	DH/Publ	іс МСНо	UHC/I	исис	FV	vc	Private	e/NGO
Available LARC/ PM services	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Female sterilization	100.0	87.5	93.4	95.7	0.0	0.8	51.6	54.9
Male sterilization	4.8	4.2	92.6	95.7	0.0	0.8	13.5	6.9
Implant	9.5	4.2	94.2	96.5	1.0	2.5	27.8	14.7
IUD	61.9	37.5	100.0	100.0	97.1	99.2	69.0	55.9
Number of facilities	21	24	121	141	103	119	126	102

Ş
y service
delivery
, of
Availability
A.3.3: /
Table

rve)
ll su
₩
15 /
2015
sas,
l are
hase III areas
Pha
٦
e a
has
nd Pl
e al
ity type and
acility
ole, by fa
ivai
vices are availak
ses c
<u>ervi</u>
ry se
eliveı
ere de
her
es 🗸
ciliti
of fa
ge c
snta(
erce
۵

	DH/Publi	DH/Public MCHo	UHC//	UHC/MCWC	F	FWC	Private	Private/NGO
Available delivery services	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Does not provide delivery care	4.8	0.0	5.8	0.7	35.9	29.4	47.6	37.3
Provides delivery care excluding Cesarean section	0.0	4.2	46.3	61.0	61.2	69.7	3.2	7.8
Provides delivery care including Cesarean section	95.2	95.8	47.9	38.3	0.0	0.0	48.4	53.9
Missing	0.0	0.0	0.0	0.0	2.9	0.8	0.8	1.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Number of facilities	21	24	121	141	103	119	126	102

Table A.3.4: Availability of postpartum family planning services

Percentage of facilities where PPFP services are available by availability of delivery services, by facility type and Phase I and Phase III areas, 2015 MH-II survey.

	DH/Public MCHo	c MCHo	UHC/I	UHC/MCWC	F	FWC	Private	Private/NGO
Available PPFP services	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Among all facilities								
Postpartum IUD	52.4	20.8	29.8	25.5	6.8	3.4	9.5	11.8
Postpartum female sterilization	95.2	91.7	47.1	42.6	0.0	0.0	47.6	53.9
Number of facilities	21	24	121	141	103	119	126	102
Among facilities that provide delivery care								
Postpartum IUD	55.0	20.8	31.6	25.7	10.6	4.8	18.2	18.8
Postpartum female sterilization	100.0	91.7	50.0	42.9	0.0	0.0	90.9	85.9
Number of facilities	20	24	114	140	66	84	99	64

Quality of Care Assessment and Feedback Mechanisms

Table A.3.5: Routine assessment of quality of services

Percentage of facilities where routine quality-of-care assessment and feedback mechanisms are in place, by facility type and Phase I and Phase III areas, 2015 MH-II survey.

Availability of routine	DH/P MC	ublic Ho	UH MC	C/ WC	FV	VC		ate/ GO
assessment and feedback of quality of care	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Routine assessment of quality of services is in place	85.7	95.8	100.0	99.3	96.1	99.2	95.2	96.1
Number of facilities	21.0	24.0	121.0	141.0	103.0	119.0	126.0	102.0
Among facilities that have routine assessment of quality of services								
Assessed by DGFP officer/FP clinical supervision team	27.8	39.1	62.0	65.0	51.5	48.3	37.5	28.6
Assessed internally	33.3	30.4	14.0	8.6	16.2	7.6	53.3	48.0
Assessed by other external quality control team	55.6	52.2	61.2	52.1	58.6	61.0	60.0	55.1
Written feedback from supervisor is available	38.9	34.8	65.3	71.4	74.7	76.3	68.3	48.0
Informal feedback from supervisor is available	50.0	43.5	27.3	15.7	22.2	14.4	26.7	33.7
No feedback mechanism is available	11.1	21.7	7.4	12.9	3.0	9.3	5.0	18.4
Any filled-in checklist on quality assessment is available	44.4	52.2	85.1	80.0	82.8	83.1	71.7	55.1
Number of facilities	18	23	121	140	99	118	120	98

Facility Infrastructure

Table A.3.6: Facility infrastructure

Percentage of facilities with enabling infrastructure, by type of facility and Phase I and Phase III areas, 2015 MH-II survey.

	DH/P MC			IC/ WC	FV	VC		ate/ 30
Infrastructure	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Toilet								
No functional toilet	0.0	0.0	1.7	2.1	10.7	8.4	0.0	0.0
Functional and clean toilet: water and soap	52.4	45.8	45.5	61.7	42.7	42.0	96.0	81.4
Functional and clean toilet: no water but soap	0.0	0.0	0.0	0.0	1.0	0.8	0.0	0.0
Functional and clean toilet: water but no soap	9.5	8.3	21.5	24.1	15.5	23.5	2.4	17.6
Functional and clean toilet: no water and no soap	0.0	0.0	2.5	0.7	2.9	4.2	0.0	0.0
Functional but unclean toilet: water and soap	9.5	12.5	4.1	1.4	2.9	6.7	0.8	0.0
Functional but unclean toilet: no water but soap	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0
Functional but unclean toilet: water but no soap	28.6	33.3	24.8	9.9	4.9	7.6	0.0	0.0
Functional but unclean toilet: no water and no soap	0.0	0.0	0.0	0.0	15.5	5.9	0.0	0.0
Missing	0.0	0.0	0.0	0.0	2.9	0.8	0.8	1.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Audio and visual privacy								
Audio and visual privacy	81.0	70.8	81.0	82.3	76.7	80.7	92.1	90.2
Audio but not visual privacy	0.0	0.0	1.7	0.0	1.0	0.0	0.0	1.0
Visual but not audio privacy	0.0	4.2	1.7	2.1	1.9	2.5	1.6	0.0
No space with privacy	9.5	20.8	13.2	14.9	16.5	16.0	4.8	7.8
Missing	9.5	4.2	2.5	0.7	3.9	0.8	1.6	1.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Number of facilities	21	24	121	141	103	119	126	102

Behavior Change Communication Materials Available in Facilities

Table A.3.7: Availability of behavior change communication materials

Percentage of facilities with selected types of BCC materials available, by type of facility and Phase I and Phase III areas, 2015 MH-II survey.

		ublic CHo		IC/ WC	FV	VC		ate/ 30
Available BCC materials	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Billboard/banner/poster	52.4	45.8	97.5	93.6	90.3	91.6	62.7	61.8
Easily identifiable leaflet/ booklet kept for clients	19.0	20.8	41.3	42.6	35.0	38.7	52.4	50.0
Sufficient number of leaflets/booklets kept for clients	14.3	12.5	37.2	39.0	28.2	31.9	49.2	49.0
Job aids and/or flip charts available for service provider	28.6	37.5	86.0	63.8	78.6	58.0	61.9	49.0
Number of facilities	21	24	121	141	103	119	126	102

Availability of Equipment and Supplies

Table A.3.8: Availability of basic equipment

Percentage of facilities with basic equipment for physical examination available, by type of facility and Phase II and Phase III areas, 2015 MH-II survey.

		ublic CHo		IC/ WC	FV	VC		ate/ 30
Available basic equipment	Phase	Phase III	Phase	Phase III	Phase	Phase III	Phase	Phase III
Available basic equipment							I	
Blood pressure instruments	100.0	100.0	99.2	97.9	93.2	89.9	99.2	97.1
Stethoscope	100.0	100.0	99.2	100.0	93.2	95.0	99.2	99.0
Thermometer	100.0	100.0	91.7	95.7	76.7	74.8	96.8	98.0
Height and weight scale	76.2	66.7	57.9	56.7	42.7	39.5	46.8	45.1
Gloves for provider	100.0	95.8	95.0	95.0	84.5	90.8	97.6	94.1
Number of facilities	21	24	121	141	103	119	126	102

Table A.3.9: Availability and functionality of operation theater

Percentage distribution of facilities by availability of operation theater (OT), and among facilities with an OT, percent that meet selected requirements for functionality of the OT, by type of facility and Phase I and Phase III areas, 2015 MH-II survey.

		Public CHo		IC/ WC	FV	vc		ate/ 30
Availability and functionality	Phase	Phase	Phase	Phase	Phase	Phase	Phase	Phase
of OT	I	III	I	III	I	III	I	
Availability of OT								
Separate OT is available	100.0	100.0	99.2	98.6	71.8	66.4	92.9	88.2
No OT	0.0	0.0	0.8	1.4	25.2	32.8	6.3	10.8
Missing	0.0	0.0	0.0	0.0	2.9	0.8	0.8	1.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Number of facilities	21	24	121	141	103	119	126	102
Functionality of OT among facilities v	with OT							
Instrument processing room close to/space in OT	85.7	100.0	70.8	74.1	16.2	29.1	72.6	77.8
Toilet adjacent to OT	28.6	50.0	34.2	37.4	48.6	58.2	35.9	35.6
Functional standard OT table	95.2	100.0	91.7	95.0	68.9	57.0	88.9	90.0
Functional OT light	100.0	100.0	64.2	69.1	9.5	3.8	63.2	75.6
Post-operative recovery area	90.5	75.0	58.3	67.6	27.0	39.2	66.7	74.4
Number of facilities	21	24	120	139	74	79	117	90
Functionality of post-operative recovery area among facilities with OT and post-operative								
recovery area								
Functional beds in post-operative recovery area	100.0	100.0	91.4	92.6	95.0	96.8	97.4	100.0
Functional seating arrangement in post-operative recovery area	78.9	72.2	58.6	79.8	45.0	80.6	84.6	86.6
Number of facilities	19	18	70	94	20	31	78	67

Table A.3.10: Availability of equipment and supplies for providing LARCs/PMs

Percentage of facilities where minimally required equipment and supplies for providing LARCs/PMs were available on the day of survey, by type of facility and Phase I and Phase III areas, 2015 MH-II survey.

		DH/Public MCHo		UHC/ MCWC		vc		ate/ GO
LARC/PM	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III	Phase I	Phase III
Female sterilization ¹	42.9	37.5	36.4	42.6	1.9	1.7	30.2	34.3
Male sterilization ²	14.3	8.3	34.7	35.5	0.0	0.8	12.7	12.7
Implant ³	9.5	12.5	14.0	19.1	0.0	0.8	23.0	16.7
IUD⁴	4.8	8.3	16.5	23.4	1.9	7.6	15.1	14.7
Any of the LARCs/PMs	47.6	41.7	49.6	52.5	2.9	8.4	42.1	46.1
Number of facilities	21	24	121	141	103	119	126	102

¹ Minimally required equipment and supplies for providing female sterilization are 4 small curved Mosquito Artery forceps, 2 long straight Medium Artery forceps, 1 Blood Pressure handle, 1 plain detecting forceps, 1 needle holder, 1 surgical scissors straight, 1 surgical scissors curved, 2 Alley's tissue forceps, 1 Babcock tissue forceps, 1 retractor, 1 sponge holding straight forceps, 1 tooth dissecting forceps, 2 large scissors for cutting gauge, 2 large scissors for cutting thread, 2 Blood Pressure machines, 2 stethoscopes, 1 weight machine, 5 gully pots, 5 kidney trays, and 5 lifters.

² Minimally required equipment and supplies for providing male sterilization are 1 ring forceps, 1 vas dissecting forceps, 1 small surgical scissors, 2 large scissors for cutting gauge, 2 large scissors for cutting thread, 2 Blood Pressure machine, 2 stethoscopes, 1 weight machine, 5 gully pots, 5 kidney trays, and 5 lifters.

³ Minimally required equipment and supplies for providing implants are 1 table to examine client, 1 rest/side table (same height as the examining table) to keep hand of the client, 1 soap for hand washing, 1 marker pen, 2 surgical drape, 1 povidon-iodine solution, 1 galipot to keep antiseptic mixture, 3 cotton balls, 1 surgical blade, 1 disposable antiseptic syringe with needle for one time use, 1 medicine for local anesthesia (1% lidocaine, without adrenalin), 1 sterile gauze, and 1 normal bandage/butterfly bandage/Band-Aid/elastomeric dressing.

⁴ Minimally required equipment and supplies for providing IUDs are 1 speculum (medium), 1 tenaculum, 1 uterine sound, 1 straight Artery forceps, 1 long placenta/kali forceps, 1 sponge holding forceps, 1 straight cutting scissors, 8 sponge cotton balls (6 wet with povidon-iodine and 2 dry), 2 povidon-iodine mixture, 1 Macintosh, 1 mask, 1 torch light, 1 draping sheet, one 0.5% chlorine mixture and red bucket with cover, 1 blue bucket for waste disposal, 1 IUD table with plastic sheet, 1 high tool for sitting, and 1 table for keeping instruments.

APPENDIX B. BALANCE TEST TABLES

		Phase I			Phase III		
Household characteristics	Ν	Mean	SE	Ν	Mean	SE	p value
% of households that own land	5,761	93.5	0.76	5,821	96.1	0.75	0.016*
% of households headed by a male member	5,761	87.0	0.62	5,821	88.0	0.68	0.266
% of households with "tin" as the main roof material	5,761	81.5	1.60	5,821	89.0	1.03	0.000***
% of households with "tin" as the main wall material	5,761	38.3	2.25	5,821	50.2	2.63	0.001***
% of households with "earth/sand" as the main flooring material	5,761	57.9	2.56	5,821	72.7	2.05	0.000***
% of households with improved access to improved toilet facility	5,761	99.4	0.27	5,821	99.5	0.27	0.891
% of household with electricity	5,761	79.4	1.66	5,821	78.0	1.63	0.534
% of households with a television	5,761	47.8	2.01	5,821	39.8	2.03	0.005**
% of households with a mobile phone	5,761	92.7	0.56	5,821	92.8	0.52	0.884
Number of household members	5,761	4.4	0.04	5,821	4.5	0.05	0.198

Table B.1: Balance test results for household characteristics

		Phase I		F	hase III		
Women's background characteristics	Ν	Mean	SE	Ν	Mean	SE	p value
Age (years)	5,282	30.8	0.15	5,377	30.8	0.13	0.754
Total number of children ever born	5,282	2.5	0.03	5,377	2.6	0.04	0.019*
Educational attainment	5,282			5,377			0.903
% of women with no education	1,239	23.5	0.94	1,334	24.4	1.01	
% of women with incomplete primary education	1,024	19.4	0.63	1,028	19.1	0.65	
% of women with complete primary education	721	13.6	0.57	697	13.1	0.60	
% of women with incomplete secondary education	1,588	30.0	0.85	1,640	30.2	0.90	
% of women with secondary or higher education	710	13.5	0.89	678	13.2	0.94	
Wealth quintiles	5,282			5,377			0.000***
% of women in the 1st quintile (poorest)	893	17.0	1.51	1,002	18.2	1.48	
% of women in the 2nd quintile	874	16.5	1.08	1,301	22.8	1.19	
% of women in the 3rd quintile	980	18.5	0.94	1,238	22.1	0.97	
% of women in the 4th quintile	1,163	22.0	1.16	1,044	20.1	1.00	
% of women in the 5th quintile (wealthiest)	1,372	26.1	1.98	792	16.7	1.52	
% of women who are Muslim	5,282	89.0	1.57	5,377	91.0	1.78	0.403
% of women who watch TV	5,282	61.8	2.01	5,377	54.6	2.42	0.022*
% of women who live with their husband	5,282	93.1	0.64	5,377	89.5	0.87	0.001***
% of women who are currently pregnant	5,282	5.1	0.34	5,377	5.8	0.37	0.214

Table B.3: Balance test results for women's knowledge and practice of reproductive health services

		Phase I		P	hase III		
Women's reproductive knowledge and practices	Ν	Mean	SE	Ν	Mean	SE	p value
% of women who were visited by a fieldworker who talked about FP or gave an FP method in the past 6 months	4,562	28.1	1.67	4,588	28.8	1.45	0.734
% of women who were visited by any government health facility for FP services in the past 6 months	4,562	14.0	1.12	4,588	15.1	0.94	0.456
% of women who visited any private/ NGO health facility for FP services	4,562	3.1	0.55	4,588	2.2	0.36	0.168
% of women who have heard about female sterilization	5,282	73.5	0.98	5,377	72.7	1.12	0.602
% of women who have heard about male sterilization	5,282	95.0	0.36	5,377	93.9	0.54	0.080
% of women who have heard about IUDs	5,282	73.9	1.00	5,377	74.9	1.26	0.543
% of women who have heard about implants	5,282	90.1	0.65	5,377	88.0	0.85	0.041*
Contraceptive method mix	5,282			5,377			0.364
% of women who use PMs	313	6.0	0.47	333	6.4	0.49	
% of women who use LARCs	133	2.5	0.28	149	2.8	0.31	
% of women who use short-acting methods	2,671	50.8	0.99	2,722	49.0	0.94	
% of women who use traditional methods	468	8.8	0.45	433	8.1	0.51	
% of women not using contraceptive	1,697	31.8	0.88	1,740	33.7	0.99	

Table B.4: Balance test results for health providers' characteristics and exposure to the program

		Phase I			Phase III		
Health provider's characteristics	Ν	Mean	SE	Ν	Mean	SE	p value
% of providers who received training on LARCs/PMs since 2014	903	18.1	1.36	960	13.9	1.26	0.025*
% of providers who received training since the 2014 LARC/PM training that an EH/MH provided or was involved in, or that an EH/MH representative was present for	903	10.9	1.25	960	6.3	1.02	0.005**
% of providers who received training on PPFP since 2014	903	10.0	1.14	960	6.9	0.95	0.038*
% of providers who received training since the 2014 PPFP training that EH/MH provided or was involved in, or that an EH/MH representative was present for	903	5.9	1.00	960	3.8	0.82	0.101
% of providers who received training on BCC since 2014	903	4.9	0.73	960	4.7	0.80	0.864
% of providers who received since 2014 BCC training which EH/MH provided or was involved in, or an EH/MH representative was present	903	2.3	0.57	960	1.7	0.54	0.402

Note: * p<0.05; ** p<0.01; *** p<0.001

Table B.5: Balance test results for health facilities' characteristics

		Phase I			Phase II	l	
Health facility characteristics	N	Mean	SE	Ν	Mean	SE	p value
% of facilities where female sterilization is available	371	53.6	2.34	386	55.2	2.16	0.628
% of facilities where male sterilization is available	371	35.0	1.72	386	37.3	1.72	0.353
% of facilities where implants are available	371	41.0	1.82	386	40.2	1.77	0.748
% of facilities where IUDs are available	371	86.5	1.79	386	84.2	1.60	0.333
% of facilities where delivery services are available	367	71.4	2.29	384	80.7	1.90	0.002**
% of facilities where postpartum IUDs are available	367	18.0	2.31	384	14.8	2.13	0.318
% of facilities where postpartum female sterilization is available	367	37.3	2.79	384	35.7	2.63	0.667
% of facilities with routine quality-of- service assessment	367	97.5	0.87	383	99.0	0.52	0.166

APPENDIX C. MAYER HASHI II QUESTIONNAIRES

Appendix C.1. Household and Women's Questionnaire

Mayer Hashi II (II) Baseline Survey 2015

Household and Women's Questionnaire (English)

Mitra and Associates

(Centre for Research and Consultancy) 2/17 Iqbal Road, Mohammadpur Dhaka-1207, Tel: 8118065, 9115503, Fax:9126806

and

MEASURE Evaluation

Carolina Population Center University of North Carolina at Chapel Hill USA

HOUSEHOLD QUESTIONNAIRE Face Sheet

IDENTIFICATION									
DIVISION:									
DISTRICT:									
UPAZILA:									
UNION:									
MOUZA:									
VILLAGE/MOHALLA	4:								
SEGMENT NUMBER									
TYPE OF CLUSTER:	RURAL 1	URBAN 2							
CLUSTER NUMBER									
HOUSEHOLD NUMB	ER								
NAME OF THE HOU	SEHOLD HEAD								
NAME OF THE RESP	PONDENT								
		INTERVIEWE	RVISITS						
	1	2	3	FINAL VISIT					
DATE				DAY					
INTERVIEWER'S									
NAME				YEAR 2 0 1 5					
RESULT*									
NEXT VISIT:DATE				TOTAL NO.					
TIME									

INTERVIEWER VISITS								
*RESULT CODES:								
 COMPLETED NO HOUSEHOLD MEMBER AT RESPONDENT AT HOME AT ENTIRE HOUSEHOLD ABSENT TIME POSTPONED REFUSED DWELLING VACANT OR ADDR DWELLING DESTROYED BWELLING NOT FOUND OTHER 	FOR EXTENDED PERIOD OF	TOTAL PERSO IN HOUSEHOL TOTAL ELIGIBI WOMEN LINE NO. OF R TO HOUSEHOI SCHEDULE	D					
(SPECIF)	()							
SUPERVISOR	FIELD EDITOR	OFFICE EDITOR	KEYED BY					
NAME	NAME							
DATE	DATE							

Form 1

INFORMED CONSENT FOR HOUSEHOLD QUESTIONNAIRE

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement:

My name is . I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development programs in the country, we conduct different types of surveys. We are now conducting a survey, which aims to assess the knowledge, attitude, and practices of couples about family planning and maternal health issues. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey. Why the study being done?

The study will help understand the state and determinants about family planning and maternal health issues in Bangladesh.

What is involved in the study?

You have been selected as a respondent in this study. The study will collect information from the household. I would like to ask you about your household.

What will you have to do if you agree to participate?

Since, you have been selected as a respondent in this study. I shall be thankful if you provide your valuable response on certain issues. If some questions cause you embarrassment or make you feel uncomfortable, you can refuse to answer them. The survey usually takes between 20 and 30 minutes to complete.

What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies plan and develop health programs.

Confidentiality:

Whatever information you provide will be kept strictly confidential. It will be used for research purposes only and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit; however, the Government particularly the Ministry of Health and Family Planning (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since your views are important.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can reach an IRB person through collect call if necessary, at 001-919-966-3012. You may also call the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730-376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065,02-9115503). At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes 1 No 2 END					
Participant's Name:	Signature (or thumb print): _	Date:				
Name of witness:	Signature:	Date:				
Name of person obtaining consent:	Signature:	Date:				
(Must be study investigator or individual who has been designated to obtain consent)						

	Hour
RECORD THE TIME STARTED.	Minute

LIST OF ALL HOUSEHOLD MEMBERS

Now we would like some information about the members who usually live in your household.

LINE	USUAL RESIDENTS	SEX	AGE	MARITAL STATUS	ELIGIBILITY
NO.				(If age 10 years or older)	[Currently married
					women of age 13-
					49 years]
	Please give me the names of the	Is (NAME) male or	How old is (NAME)?	What is the current marital status of	Circle if Q3=1 &
	members who	female?	(IF LESS THAN 1 YEAR	(NAME)?	Q4=Age 13-49 & Q5=1
	usually live in your	Torrialo :	WRITE 00)	(
	household, starting				
	with the head of the household				
(1)	(2)	(3)	(4)	(5)	(6)
1		Female 1-		Currently married 1	(-)
-		Male2		Separated/Deserted/	1
		↓	years	Widowed/Divorced 2	
0		, Famala d		Never married 3	
2		Female 1-		Separated/Deserted/	
		Male2	years	Widowed/Divorced 2	2
		•		Never married 3	
		Female 1-	► In	Currently married 1	
3		Male2	years	Separated/Deserted/ Widowed/Divorced 2	3
		•		Never married 3	
		Female 1-	► In	Currently married 1 -	
4		Male2	years	Separated/Deserted/	4
		↓		Widowed/Divorced 2 Never married 3	
		Female 1-	▶ In	Currently married 1	
5				Separated/Deserted/	5
5		Male2 ↓	years	Widowed/Divorced 2	5
		, Famala d		Never married 3	
		Female 1–		Currently married 1 - Separated/Deserted/	
6		Male2	years	Widowed/Divorced 2	6
		•		Never married 3	
		Female 1-	► In	Currently married 1	
7		Male2	years	Separated/Deserted/	7
		•		Never married 3	
8		Female 1-	In	Currently married 1 -	
		Male2	years	Separated/Deserted/	8
		↓		Widowed/Divorced 2 Never married 3	
9		Female 1–	In	Currently married 1	•
		Male2		Separated/Deserted/	9
		₩ 4	years	Widowed/Divorced 2	Ŭ
10		Fomolo 1		Never married 3	
10		Female 1–		Separated/Deserted/	10
		Male2	years	Widowed/Divorced 2	10
		•		Never married 3	
11		Female 1-	►In	Currently married 1 -	
		Male2	years	Separated/Deserted/	11
		▼		Never married 3	

No.	QUESTIONS AND FILTERS	CODING CATEGORIES	SKIP
08.	What is the main source of drinking water for	PIPED WATER	
	members of your household?	Piped into dwelling 11	
		Piped to yard plot 12	
		Public tap stand pipe 13	
		Tube well or borehole 21	
		DUG WELL	
		Protected well	
		Unprotected well	
		Protected sprint	
		Unprotected spring	
		Rain water	
		Surface water (River/dam/lake/	
		pond/stream/canal irrigation	
		channel) 81	
		Bottled water 91	
		Other 96 (Specify)	
		(Specify)	
09.	What kind of toilet facility do members of your	Flush latrine 11	
	household usually use?	Pit latrine with slab21	
		Pit latrine without slab/open pit 22	
		Bucket latrine	
		Hanging toilet latrine	
		No facility/bush/field61	▶10
		Other 96	
		(Specify)	
09a	Is this toilet shared by person(s) from other	Yes1	
oou	household(s)	No	
10	Does your household (or any member of your	1102	
10	household) have:		
	Read outElectricity1 2	Yes No	
	Solar electricity1 2	Electricity 1 2	
	Radio1 2	Solar electricity 1 2	
	Television1 2	Radio 1 2	
	Mobile phone1 2	Television 1 2	
	Non-Mobile phone	Mobile phone	
	1	-	
	Refrigerator/Freezer1 2	Non-Mobile phone 1 2	
	Almirah/Wardrobe 1 2	Refrigerator/Freezer 1 2	
	Electric Fan1 2	Almirah/Wardrobe 1 2	
	DVD/VCD Player1 2	Electric Fan 1 2	
	Water pump	DVD/VCD Player 1 2	
	IPS generator1 2	Water pump 1 2	
	Air conditioner1 2	IPS generator 1 2	
	Computer/Laptop1 2	Air conditioner 1 2	
		Computer/Laptop	
11.	MAIN MATERIAL OF THE FLOOR.	NATURAL FLOOR	
		Earth/stand11	
		RUDIMENTARY FLOOR	
	RECORD OBSERVATION.	Wood planks21	
		Palm/Bamboo22	
		FINISHED FLOOR	
		Parquet or polished wood31	

Ceramic Tiles	
Cement	
Other 96	1
(Specify)	

No.	QUESTIONS AND FILTERS	CODING CATEGORIES	SKIP
11a.	MAIN MATERIAL OF THE ROOF.	NATURAL ROOFING	
		No roof 11	
		Thatch/Palm Leaf 12	
	RECORD OBSERVATION.	Polythine 13	
		RUDIMENTARY ROOFING	
		Bamboo21	
		Wood planks22	
		Cardboard 23	
		FINISHED ROOFING	
		Tin 31	
		Wood	
		Ceramic Tiles 33	
		Cement	
		Roofing Shingles (Tali or slat) 35	
		Other 96	
		(Specify)	
11b.	MAIN MATERIAL OF THE EXTERIOR WALLS	NATURAL WALLS	
		No walls 11	
		Cane/Palm leaf/Trunks12	
	RECORD OBSERVATION.	Dirt 13	
		RUDIMENTARY WALLS	
		Bamboo with mud21	
		Stone with mud 22	
		Plywood23	
		Cardboard 24	
		FINISHED WALLS	
		Tin 31	
		Cement	
		Stone with lime/Cement	
		Bricks 34	
		Wood planks/shingles	
		Other 96	
		(Specify)	
12.	Does this household own any livestock, herds,	Yes1	
	other farm animals, or poultry?	No2	13
12a	How many of the following animals does this	Cows/bulls/buffalos	┍╸
	household own?	Goats/Sheep	
	IF NONE, ENTER '00'		
	IF MORE THAN 95, ENETR '95'	Chickens/Ducks	
	IF UNKNOWN, ENTER '98'		

13.	Does your household own any homestead?	Yes1
	IF 'NO', PROBE:	No 2
	Does your household own homestead any other	
	places?	
13a.	Does your household own any land (other than the	Yes1
	homestead land)?	No2
14.	INTERVIEWER: INTERVIEW ALL WOMEN RECOR	DED IN Q6 USING THE WOMEN'S
	QUESTIONNAIRE.	

Article I.

RECORD THE TIME ENDED FOR HOUSEHOLD PART	Hour	
	Minute	

Women's Questionnaire

Face Sheet

IDENTIFICATION	
CLUSTER NUMBER	
HOUSEHOLD NUMBER	
NAME AND LINE NUMBER OF ELIGIBLE RESPONDENT	

INTERVIEWER VISITS					
	1	2	3	FINAL VISIT	
				DAY	
DATE				MONTH	
INTERVIEWER'S				YEAR 2 0 1 5	
NAME					
RESULT*				RESULT	
NEXT VISIT:DATE				TOTAL NO.	
				OF VISITS	
TIME					
*RESULT CODES:					
1 COMPLETED					
2 NOT AT HOME					
3 POSTPONED					
4 REFUSED					
5 PRTLY COMPLE	TED				
6 RESPONDENT I	VCAPACITATED				
7 OTHER					
	(SPECIFY)				
SUPERVISOR	F	FIELD EDITOR		OFFICE EDITOR KEYED BY	
NAME	1	NAME			
DATE	[DATE			

INFORMED CONSENT FOR WOMEN'S QUESTIONNAIRE

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015 (Age 18-49 years)

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement:

My name is . I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development programs in the country, we conduct different types of surveys. We are now conducting a survey, which aims to assess the knowledge, attitude, and practices of couples about family planning and maternal health issues. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey.

Why the study being done?

The study will help understand the state and determinants about family planning and maternal health issues in Bangladesh.

What is involved in the study?

You have been selected as a respondent in this study. I would like to ask you some questions about yourself, including about your health.

What will you have to do if you agree to participate?

Since, you have been selected as a respondent in this study. I shall be thankful if you provide your valuable response on certain issues. If some questions cause you embarrassment or make you feel uncomfortable, you can refuse to answer them. The survey usually takes between 30 and 45 minutes to complete.

What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies and develop health programs.

Confidentiality:

88

Whatever information you provide will be kept strictly confidential. It will be used for research purposes and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit; however, the Government particularly the Ministry of Health and Family Planning (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since your views are important.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can reach an IRB person through collect call, if necessary, at 001-919-966-3012. You may also call the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730-376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates2/17, Igbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065, 02-9115053). At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes 1 No 2 → ENE)
Participant's Name:	Signature (or thumb print):	Date:
Name of witness:	Signature:	Date:
Name of person obtaining consent: _	Signature:	Date:

INFORMED CONSENT OF HUSBAND/IN-LAWS/LEGAL GUARDIAN FOR INTERVIEW OF WOMAN AGE 13-17 YEARS FOR WOMEN'S QUESTIONNAIRE

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement: My name is ______. I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development programs in the country, we conduct different types of surveys. We are now conducting a survey, which aims to assess the knowledge, attitude, and practices of couples about family planning and maternal health issues. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your wife's/daughter-in-law's/daughter's participation in this survey.

Why the study being done?

The study will help understand the state and determinants about family planning and maternal health issues in Bangladesh.

What is involved in the study?

Your wife/daughter-in-law/daughter has been selected as respondents in this study. I would like to ask her some questions about herself, including about her health.

What will you have to do if you agree to let her participate?

Since, your wife/daughter-in-law/daughter has been selected as respondents in this study. I shall be thankful if she provide her valuable response on certain issues. If some questions cause her embarrassment or make her feel uncomfortable, she can refuse to answer them. The survey usually takes between 30 and 45 minutes to complete. What are the risks and benefits of this study?

By providing information you and your wife/daughter-in-law/daughter will not have any risk what so ever, rather this will help the government and policy planners to formulate policies plan and develophealth programs.

Confidentiality:

Whatever information your wife/daughter-in-law/daughter provide will be kept strictly confidential. It will be used for research purposes and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your wife's/daughter-in-law's/daughter's participation in the study is voluntary and promises no financial benefit; however, the Government particularly Ministry of Health and Family Planning (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and your wife/daughter-in-law/daughter can choose not to answer any individual question or all of the questions. However, we hope that your wife/daughter-in-law/daughter will participate in this survey since her views are important.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can reach an IRB person through collect call if necessary, at 001-919-966-3012. You may also call the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730-376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065, 02-9115053). At this time, do you want to ask me anything about the survey?

May I begin the interview now? Yes 1	No 2 → END
Husband's/In-law's/Legal Guardian's Name:	Signature (or thumb print): Date:
Name of witness:	Signature: Date:

Name of person obtaining consent:	Signature:	Date:
(Must be study investigator or individu	al who has been designated to obtain consent)	

ASSENT FORM FOR WOMAN AGE 13-17 YEARS FOR WOMEN'S QUESTIONNAIRE

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement:

. I have come from Mitra and Associates, a private research organization, located in My name is Dhaka. To assist in the implementation of socio-development programs in the country, we conduct different types of surveys. We are now conducting a survey, which aims to assess the knowledge, attitude, and practices of couples about family planning and maternal health issues. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey.

Why the study being done?

The study will help understand the state and determinants about family planning and maternal health issues in Bangladesh.

What is involved in the study?

You have been selected as a respondent in this study. I would like to ask you some questions about yourself, including about your health.

We have discussed this research with your Husband/In-laws/Legal Guardian and they know that we are also asking you for your agreement. If you are going to participate in the research, your Husband/In-laws/Legal Guardian also have to agree. But if you do not wish to take part in the research, you do not have to, even if your Husband/Inlaws/Legal Guardian have agreed.

You may discuss anything in this form with your Husband/In-laws/Legal Guardian or friends or anyone else you feel comfortable talking to. You can decide whether to participate or not after you have talked it over. You do not have to decide immediately.

What will you have to do if you agree to participate?

Since, you have been selected as a respondent in this study. I shall be thankful if you provide your valuable response on certain issues. If some questions cause you embarrassment or make you feel uncomfortable, you can refuse to answer them. The survey usually takes between 30 and 45 minutes to complete.

What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies plan and develophealth programs.

Confidentiality:

Whatever information you provide will be kept strictly confidential. It will be used for research purposes and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since your views are important.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can reach an IRB person through collect call if necessary, at 001-919-966-3012. You may also call the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730-376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065, 02-9115053). At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes	1	No	2 → END	
Participant's Name:		_ Si	gnature (or thu	mb print):	_ Date:

Form 4

Name of witness:	Signature:	Date:		
Name of person obtaining consent:	Signature:	Date:		
(Must be study investigator or individual who has been designated to obtain consent)				

Section 1:	Respondent's Socio-Demographic Background
------------	---

No.	QUESTIONS AND FILTERS	CODING CATEGORIES	SKIP
101	RECORD THE START TIME OF TAKING	Hour	
	INTERVIEW.	Minutes	
	(according to 24 hours clock)		
102	Are you currently married?	Yes1	Termi-
		No2-	nate
			interview
103	How old are you at present?	Age (completed year)	
104	What is your religion?	Islam1	
		Hinduism2	
		Buddhism3	
		Christianity4	
		Others6	
		(Specify)	
105	Have you ever attended school/madrasha? IF	Yes, school1	
	YES, where?	Yes, madrasha2	
		Yes, both3	
400		No4	▶ 108
106	What is the highest class you completed at		
	that level? (IF NO CLASS PASSED WRITE 00; OTHERWISE WRITE THE HIGHEST	Class	
	CLASS COMPLETED)		
107	Interviewer: Check Q.106 and circle in	Primary (00-04)1	
107	appropriate code	Secondary and above	
		(05 or above)	▶ 109
108	Can you read newspaper or magazine?	Yes1	
		No2-	▶ 111
109	Do you read newspaper or magazine?	Yes1	
		No2-	▶ 111
110	Do you read newspaper or magazine almost	Almost every day1	
	every day, at least once a week, or less than	At least once a week2	
	once a week?	Less than once a week3	
111	Do you listen to the radio?	Yes1	
		No2–	▶ 113
112	Do you listen to the radio almost every day, at	Almost every day1	
	least once a week, or less than once a week?	At least once a week	
113	Do you watch television?	Less than once a week3 Yes1	
113	Do you watch television?	Yes1 No2–	▶ 115
114	Do you watch television almost every day, at	Almost every day1	► 113
	least once a week, or less than once a week?	At least once a week	
		Less than once a week	
115	Is your husband staying with you at present or	Staying in the household	▶ 118
-	is he staying elsewhere?	Staying elsewhere	
116	How long has your husband been staying	Below one month00	1
	away from you?	Months	
117	How often did he come home in the past 12		
117	months?	Number of times	
		Didn't come in last 12 months96	

118	Check 103: If age is less than 25	If age is 25 or h	igher	— ₽ Sec.2
119			Age (completed year)	

Section 2: Reproduction

201	Now I would like to ask about all the births you	Yes1	
	have had during your life.	No2–	> 206
		110	P 200
	Have you ever given birth?		
202	Do you have any sons or daughters to whom you	Yes1	
	have given birth who are now living with you?	No2-	▶ 204
203	How many sons live with you?	SONS AT HOME	
	And how many daughters live with you?		
	IF NONE, RECORD '00'.	DAUGHTERS AT HOME	
204	Do you have any sons or daughters to whom you	Yes1	
	have given birth who	No2-	▶ 206
	are alive but do not live with you?		
205	How many sons are alive but do not live with	SONS ELSEWHERE	
	you?		
	And how many daughters are alive but do not live		
	with you?		
	IF NONE, RECORD '00'.		
206	Have you ever given birth to a boy or girl who	Yes1	
	was born alive but later	No2–	▶ 208
	died?		
	IF NO, PROBE: Any baby who cried or showed		
	signs of life but did		
	not survive?		
207	How many boys have died?	SONS DEAD	
	And how many girls have died?		
	IF NONE, RECORD '00'.		
208	SUM ANSWERS TO 203, 205, AND 207, AND	TOTAL BIRTHS	
	ENTER TOTAL.		
	IF NONE, RECORD '00'.		
209	CHECK 208:		
	Just to make sure that I have this right: you have		
	had in TOTALbirths during your life. Is that		
	correct?	NO	
	YES	↓	
		PROBE AND CORRECT 201-208 AS	
	▼	NECESSARY	
210	CHECK 208:		
	One or more live birth	No live birth	➡ 300a
	↓ ↓		
210a			
2100	May I know the name of your youngest child?		
2100			
2100	May I know the name of your youngest child? Name:	Month1	
2100	Name:		
2100		Month1	

Section 3A

Knowledge about Long-acting and Reversible Contraceptives (LARC) and Permanent Methods (PM)

	Now I would like to talk about some of the family planning methods that a couple can use to delay or avoid a			
pregnancy. Interviewers: After completing the column A and then ask B,C,and D Column A Column B Column C Column D				
(ask column wise)	(ask column wise)	(ask column wise)	(ask column wise)	
300A. Women can have	300B. Man can have an	300C. Woman can have	300D. Woman can have	
an operation, called	operation, called male	an IUD inserted in her	an implant, small tube	
female sterilization, to	sterilization, to stop or	uterus to avoid having	like substance beneath	
stop or avoid having any	avoid having any more	children for some years	her skin of an arm to	
more children	children.	of time?	avoid having children for some years?	
Have you ever heard about female sterilization?	Have you ever heard about male sterilization?	Have you ever heard about IUD?	Have you ever heard about implants?	
Yes1 No2 (Skip to col. B) ◀	Yes1 No2 (Skip to col. C) ◀	Yes1 No2 (Skip to col. D) ◀	Yes1 No2 (Skip to 300e) ◀	
300a1. Could you tell me the places/persons from where a person can obtain the method? Anywhere else?	300b1. Could you tell me the places/persons from where a person can obtain the method? Anywhere else?	300c1. Could you tell me the places/persons from where a person can obtain the method? Anywhere else?	300d1. Could you tell me the places/persons from where a person can obtain the method? Anywhere else?	
PROBE TO IDENTIFY	PROBE TO IDENTIFY	PROBE TO IDENTIFY	PROBE TO IDENTIFY	
EACH TYPE OF	EACH TYPE OF	EACH TYPE OF	EACH TYPE OF	
SOURCE AND CIRCLE	SOURCE AND CIRCLE	SOURCE AND CIRCLE	SOURCE AND CIRCLE	
THE APPROPRIATE CODE(S).	THE APPROPRIATE CODE(S).	THE APPROPRIATE CODE(S).	THE APPROPRIATE CODE(S).	
IF UNABLE TO	IF UNABLE TO	IF UNABLE TO	IF UNABLE TO	
DETERMINE IF	DETERMINE IF	DETERMINE IF	DETERMINE IF	
HOSPITAL, HEALTH	HOSPITAL, HEALTH	HOSPITAL, HEALTH	HOSPITAL, HEALTH	
CENTER OR CLINIC IS				
PUBLIC OR PRIVATE	PUBLIC OR PRIVATE	PUBLIC OR PRIVATE	PUBLIC OR PRIVATE	
MEDICAL, WRITE THE	MEDICAL, WRITE THE	MEDICAL, WRITE THE	MEDICAL, WRITE THE	
NAME OF THE PLACE.				
NAME OF THE PLACE				
Public Sector/Service	Public Sector/Service	Public Sector/Service Provider	Public Sector/Service	
Provider	Provider	District Hospital/Medical	Provider	
District Hospital/Medical College HospitalA	District Hospital/Medical	College HospitalA Maternal & Child	District Hospital/Medical	
Maternal & Child	College Hospital A Maternal & Child	Welfare	College Hospital A Maternal & Child	
Welfare	Welfare	Centre (MCWC)B	Welfare	
Centre (MCWC)B	Centre (MCWC)B	Upazila Health	Centre (MCWC)B	
Upazila Health	Upazila Health	ComplexC	Upazila Health	
ComplexC	Complex C	Family Welfare Centre .D	Complex C	
Family Welfare Centre .D	Family Welfare Centre . D	CampE	Family Welfare Centre . D	
CampE	Camp E		Camp E	

NGO Sector /NGO	NGO Sector /NGO	NGO Sector /NGO	NGO Sector /NGO
Worker	Worker	Worker	Worker
NGO Static Clinic	NGO Static ClinicI	NGO Static Clinic	NGO Static ClinicI
Private Medical	Private Medical	Private Medical	Private Medical
Sector/Provider	Sector/Provider	Sector/Provider	Sector/Provider
Private hospital/clinicN	Private hospital/clinic N	Private hospital/clinicN	Private hospital/clinic N
Doctor (Qualified)O	Doctor (Qualified) O	Doctor (Qualified) O	Doctor (Qualified)O
Private Medical	Private Medical	Private Medical	Private Medical
College HospitalR	College HospitalR	College HospitalR	College HospitalR
OtherX	OtherX	Other X	OtherX
(Specify)	(Specify)	(Specify)	(Specify)
Don't knowY	Don't knowY	Don't knowY	Don't knowY
300a2. In the last six	300b2. In the last six	300c2. In the last six	300d2. In the last six
months, did you hear,	months, did you hear,	months, did you hear,	months, did you hear,
see, watch, or read about	see, watch, or read about	see, watch, or read about	see, watch, or read about
the Female sterilization?	the Male sterilization?	the IUD?	the Implant?
Yes 1	Yes1	Yes 1	Yes1
No2	No2	No2	No2
(Skip to col. B)	(Skip to col. C)	(Skip to col. D)	(Skip to 300e)
300a3. Where did you	300b3. Where did you	300c3. Where did you	300d3. Where did you
hear, see, watch, or read	hear, see, watch, or read	hear, see, watch, or read	hear, see, watch, or read
about the Female	about the Male	about the IUD?	about the implant?
sterilization?	sterilization?	(Probe every answer)	(Probe every answer)
(Probe every answer)	(Probe every answer)		
People	People	People	People
•	•	-	-
I HUSDADO A	Huspand A	Husband A	Huspand A
HusbandA	Husband A Friend/relatives/	HusbandA Friend/relatives/	HusbandA Friend/relatives/
Friend/relatives/	Friend/relatives/	Friend/relatives/	Friend/relatives/
Friend/relatives/ neighborB	Friend/relatives/ neighborB	Friend/relatives/ neighborB	Friend/relatives/ neighborB
Friend/relatives/ neighborB Health provider	Friend/relatives/ neighborB Health provider	Friend/relatives/ neighborB Health provider	Friend/relatives/ neighborB Health provider
Friend/relatives/ neighborB Health provider FP worker (field worker)C	Friend/relatives/ neighborB Health provider FP worker (field)C	Friend/relatives/ neighborB Health provider FP worker (field worker)C	Friend/relatives/ neighborB Health provider FP worker (field worker)C
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker	Friend/relatives/ neighborB Health provider FP worker (field)C Health/FP worker	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D	Friend/relatives/ neighborB Health provider FP worker (field)C Health/FP worker (Health or FP center) D	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center) D
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media	Friend/relatives/ neighbor B Health provider FP worker (field) C Health/FP worker (Health or FP center) D Mass Media	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center) D Mass Media
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioE	Friend/relatives/ neighbor B Health provider FP worker (field) C Health/FP worker (Health or FP center) D Mass Media Radio E	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE	Friend/relatives/ neighbor B Health provider FP worker (field worker)C Health/FP worker (Health or FP center) D Mass Media Radio E
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioE TelevisionF	Friend/relatives/ neighbor B Health provider FP worker (field) C Health/FP worker (Health or FP center) D Mass Media Radio E Television F	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE TelevisionF	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media Radio	Friend/relatives/ neighbor B Health provider FP worker (field) C Health/FP worker (Health or FP center) D Mass Media Radio E Television F Newspaper/ magazine . G	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media Radio	Friend/relatives/ neighbor B Health provider FP worker (field worker)C Health/FP worker (Health or FP center) D Mass Media Radio E Television F Newspaper/ magazine . G
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioE TelevisionF Newspaper/ magazine .G PosterH	Friend/relatives/ neighbor	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE TelevisionF Newspaper/ magazine G PosterH	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media Radio	Friend/relatives/ neighbor	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE TelevisionF Newspaper/ magazine G PosterH BillboardI	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioE TelevisionF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ	Friend/relatives/ neighbor	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE TelevisionF Newspaper/ magazine G PosterH BillboardI Leaflet/ brochureJ	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media Radio	Friend/relatives/ neighbor	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE TelevisionF Newspaper/ magazine G PosterH BillboardI	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioE TelevisionF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ	Friend/relatives/ neighbor	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE TelevisionF Newspaper/ magazine G PosterH BillboardI Leaflet/ brochureJ	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media Radio E Television F Newspaper/ magazine .G Poster H Billboard I Leaflet/ brochureJ Filpchart	Friend/relatives/ neighbor	Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health and FP center).D Mass Media RadioE TelevisionF Newspaper/ magazine G PosterH BillboardI Leaflet/ brochureJ FilpchartK	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ FilpchartK Community Events	Friend/relatives/ neighbor	Friend/relatives/ neighbor	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ FilpchartK Community Events Street drama/folk song . L	Friend/relatives/ neighbor	Friend/relatives/ neighbor	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioD Mass Media RadioD Mass Media Radio	Friend/relatives/ neighbor	Friend/relatives/ neighbor	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media Radio E TelevisionF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ FilpchartK Community Events Street drama/folk song . L Uthan Baithak (Courtyard meeting) M	Friend/relatives/ neighbor	Friend/relatives/ neighbor	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ FilpchartK Community Events Street drama/folk song . L Uthan Baithak (Courtyard meeting) M One to one discssionN Film showO	Friend/relatives/ neighbor	Friend/relatives/ neighbor	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ FilpchartK Community Events Street drama/folk song . L Uthan Baithak (Courtyard meeting) M One to one discssionN Film showO	Friend/relatives/ neighbor	Friend/relatives/ neighbor	Friend/relatives/ neighbor
Friend/relatives/ neighborB Health provider FP worker (field worker)C Health/FP worker (Health or FP center)D Mass Media RadioF Newspaper/ magazine .G PosterH BillboardI Leaflet/ brochureJ FilpchartK Community Events Street drama/folk song . L Uthan Baithak (Courtyard meeting) M One to one discssionN Film showO	Friend/relatives/ neighbor	Friend/relatives/ neighbor	Friend/relatives/ neighbor

300e Check 300a: Not circled 1 in 300a	Circled 2 in 300a	► 303j
---	-------------------	--------

	(FOR THOSE WHO HEARD ABOUT TUBECTOMY)		
300f	Now I would like to talk about family planning methods that are available at facilities where deliveries are conducted.	Yes1	
	Can a woman get female sterilization immediately after normal delivery at a facility?	No2-	► 300h
300g	Where did you hear, see/watch, or read	People	
	about postpartum female sterilization	HusbandA	
	services?	Friend/relatives/neighbor B	
	(Probe every answer)	Health provider	
		FP worker (field worker) C	
		Health/FP worker (Health or FP	
		center)D	
		Mass Media	
		RadioE	
		TelevisionF	
		Newspaper or magazineG	
		Poster H	
		BillboardI	
		Leaflet/ brochureJ	
		FlipchartK	
		Community Events	
		Street drama/folk songL	
		Uthan Baithak (Courtyard meeting) M One-to-one discussionN	
		Film showO	
		OtherX (Specify)	
300h	Are you aware that female sterilization can be done during C-section at a facility?	Yes1 No2-	► 300i
300i	Where did you hear, see/watch, or read	People	000
0001	this information?	HusbandA	
	(Probe every answer)	Friend/relatives/neighborB	
		Health provider	
		FP worker (field worker) C	
		Health/FP worker (Health or FP	
		center)D	
		Mass Media	
		RadioE	
		TelevisionF	
		Newspaper or magazineG	
		PosterH	
		BillboardI	
		Leaflet/ brochureJ	
		FlipchartK	
		Community Events	
		Street drama/folk songL	
		Olicel ulama/loik songL	

		One-to-one discussionN	
		Film showO	
		OtherX	
		(Specify)	
300j	Check 300c:		
-	Circled 2 in 300c		3 01
	Circled 1 in 300c	_	
	(FOR THOSE WHO HEARD ABOUT IUD)		
		↓	
300k	Are you aware that an IUD can be inserted	Yes1	
	during or immediately after delivery at a	No2-	► 300m
	facility?		
3001	Where did you hear, see/watch, or read	People	
	this information?	HusbandA	
	(Probe every answer)	Friend/relatives/neighborB	
		Health provider	
		FP worker (field worker) C	
		Health/FP worker (Health or FP	
		center)D Mass Media	
		Radio E	
		TelevisionF	
		Newspaper or magazineG	
		Poster	
		Billboard	
		Leaflet/ brochureJ	
		FlipchartK	
		Community Events	
		Street drama/folk songL	
		Uthan Baithak (Courtyard meeting) M	
		One-to-one discussionN	
		Film showO	
		OtherX	
		(Specify)	
300m	Are you aware that an IUD can be inserted	Yes1	
	during or immediately after caesarian	No2-	▶ 301
	delivery at a facility?		
300n	Where did you hear, see/watch, or read	People	
	this information?	HusbandA	
	(Probe every answer)	Friend/relatives/neighborB	
		Health provider	
		FP worker (field worker) C	
		Health/FP worker (Health or FP	
		center)D	
		Mass Media	
		RadioE	
		TelevisionF	
		Newspaper or magazineG	
		Poster H	
		BillboardI	
		Leaflet/ brochureJ	

FlipchartK
Community Events
Street drama/folk songL
Uthan Baithak (Courtyard meeting) M
One-to-one discussionN
Film showO
OtherX
(Specify)

Section 3B:

Contraceptive Use

No.	QUESTIONS AND FILTERS	CODING CATEGORIES	S	KIP
301	Are you pregnant now?	Yes1	1	
		No2=	1.	
<u></u>		Don't know/Not sure8	┣	302
301a	How many months pregnant are you?	Month		307a
	I would like to talk about the various ways or me	ethods that a couple can use to delay or		
	avoid a pregnancy.			
302	Are you or your partner currently doing	Yes1		
	something or using any method to delay or	No2-		307a
	avoid getting pregnant?			
303	Which method are you using at present?	Female sterilizationĀ		205
		Male sterilizationB		305
	CIRCLE ALL MENTIONED.	IUDC		
		ImplantsD		
		InjectablesE		
		PillF		
		CondomG		
		Safe period/Periodic abstinenceH	1	
		WithdrawalI		
		Other X	_	306
		(Specify)	J	
	If more than one method mentioned in Q303,	Public Sector/Service Provider		
	ask the highest method in list of Q.303.	Medical College Hospital		
		Specialized Govt. Hospital		
304	Where did you obtain (Current	District Hospital		
	method) the last time?	Maternal & Child Welfare		
	Whore did the starilization take place?	Centre (MCWC)14		
305	Where did the sterilization take place? PROBE: Any other place?	Upazila Health Complex15		
	PROBE TO IDENTIFY EACH TYPE OF	Health & Family Welfare Centre16		
		Satellite Clinic/EPI outreach17		
	SOURCE AND CIRCLE THE APPROPRIATE	Community Clinic		
		Family Welfare Assistant (FWA)19		
	IF UNABLE TO DETERMINE IF HOSPITAL,	Other20		
	HEALTH CENTER OR CLINIC IS PUBLIC	(Specify)		
	OR PRIVATE MEDICAL, WRITE THE NAME	NGO Sector /NGO Worker		
	OF THE PLACE.	NGO Static Clinic		
		NGO Satellite Clinic		
		NGO depot holder		
	NAME OF THE PLACE	NGO fieldworker24 Other 26		
		(Specify)		
		Private Medical Sector/Provider		
		Private hospital/clinic		
		Doctor (Qualified)		
		Private Medical College Hospital33		
		Quack/Traditional healer		
		Pharmacy		
		Shop		
		Relative		
		Neighbours/friend		
		Other96		
		(Specify)		
		Don't know	1	

306	Since what month and year have you been using the (Current method) without stopping? (If you don't know for sure, you can give me	Month	
207	your best estimate) Check 303:		
307	if A/B/C/D is circled (TUBECTOMY, NSV, IUD, OR IMPLANT USE	ER)	▶ 308
	if A/B/C/D is not circled ↓		
307a	Have you ever used IUD or implant since January 2011?	Yes, IUD1 Yes, Implant2 No3-	► 323
307b	Which month and year did you accept the method?	Month	
307c	Which month and year did you drop the method?	Month	
307d	Why did you stop using the method?	Method-related reasons General health concerns A Side effects Difficulty in having sex Interfered physiological normal processes Dothaving sex E Infrequent sex Sub-fecund/in-fecund H Opposition to Use Did not like the method Husband opposed J Others opposed K Social stigma L Religious prohibition M Other X	→ ³²³
308	CHECK 303: If none of A/C/D is circled TUBECTOMY, IUD, OR IMPLANT NON USE If A/C/D is circled Vow I would like to ask some questions about	R)	323
310	received the method () you are Before providing the method you are using,		
510	did the health provider (HP) tell you about other possible methods that can be used?	No2	

-	-		
311	Did the HP tell that you might have some side effects/ complications after the procedure?	Yes1 No2	
312	Did he/she maintain privacy/confidentially	Yes1	
512	during providing service?	No2	
313	Did you receive any medicine from the HP	Yes1	
	(FWV/MO-MCH)?	No2	
313a	CHECK 303:		
	if C/D is circled		316
	If A is circled (TUBECTORMY USER)		
	\downarrow		
314	Where did you stay at the facility after the	On a bed1	
	operation until discharge (i.e., in post-	On the floor of a room2	
	operative care)?	On the floor of a corridor	
		Other6	
		(Specify)	
316	Did the HP ask you for follow-up visit?	Yes1	
		No2	
317	Did the service provider give you follow-up	Yes1	
	card?	No2	
318	Do you think you understood everything that	Yes1	
	the provider told?	No2	
319	Did you go for a follow-up visit?	Yes1	
		No2	
320	Did you experience any side effects?	Yes1	
		No2-	▶ 323
321	What type of complication/side-effect did you	Stopped menstruationA	
	face?	Abnormal menstrual bleeding B	
		Abdominal painC	
		Pain during intercourseD	
		Infection or abnormal vaginal	
		dischargeE	
		Feeling discomfort with fever and feel	
		coldF	
		Thread lose or be long or shortG	
		Other X	
		(Specify)	
322	What did you do for the side	Saw FWA/other NGO workers A	
	effects/complications?	Saw FWV/paramedics B	
		Saw MOMCH C	
		Saw NGO medical officerD	
		Saw a private qualified doctor E	
		Saw an unqualified doctorF	
		Went to pharmacyG	
		Discussed with friends/relatives	
		OthersX	
		Did nothingZ	
323	Check 301:		
	1 is circled (CURRENTLY PREGNANT)]	3 56a
	2 or 3 is circled		

323a	Check 303:		
	if A/B/C/D is circled		
	(TUBECTOMY, NSV, IUD, OR IMPLANT USEF	R)	►356b
			0000
	if A/B/C/D is not circled		
	or not asked		
	★		
337	In last six months, have you visited any	Yes1	
	government health facility (Medical College	No	→ 343
	Hospital/Specialized Govt. Hospital/District		040
	Hospital/MCWC/UHC/HDWC/CC) for family		
	, , ,		
	planning services?		
338	What were the services you received?	Received information on female	
		sterilization	
	(IF THE RESPONDENT MENTIONS ANY	Received information on IUDB Received information on implantsC	
	FAMILY PLANNING METHOD HERE THEN	Obtained pillD	
	CHECK WHETHER MENTIONED THE SAME	Obtained injectablesE	
	IN 303)	Obtained condomF	
	(IF THE RESPONDENT DOES NOT	OtherX (Specify)	
	MENTION FAMILY PLANNING METHOD	(opcony)	
	HERE THEN PROBE WHETHER SHE HAD		
	RECEIVED FAMILY PLANNING SERVICE		
	WITH ANY OTHER SERVICES)		
	WITH ANT OTHER SERVICES)		
	MULTIPLE ANSWERS POSSIBLE.		
000			
339	CHECK: 338		0.40
	A or B or C is circled		342
	Not circled A or B or C (PILL,		
	INJECTABLE, OR CONDOM ACCEPTOR)↓	1	
340	Did the provider tell you about any methods	Yes1	
	other than you accepted (mentioned in 338)?	No2-	→ 342
341	Which method did the provider tell about?	Female sterilizationA	
		Male sterilizationB	
		IUDC	
		ImplantD	
	MULTIPLE ANSWERS POSSIBLE	InjectablesE	
		PillF	
		CondomG	
		Other X	
342	Did they give you any BCC materials (picture/	(Specify) Yes1	
342			50.40
	leaflet/booklet) for taking home?	No 2-	▶343
342a	Was the poster/picture/leaflet/booklet from the	Yes1	
0.20	Mayer Hashi project?	No	
		Don't know	
343	In last six months have you visited any	Yes1	
545	private/NGO health facility for family planning	No	→ 348
	services?	110	F 340
244		Dessived information on family	
344	What were the services you received?	Received information on female sterilizationA	
		Received information on IUDB	
	(IF THE RESPONDENT MENTIONS ANY	Received information on IODB Received information on implantsC	
1	FAMILY PLANNING METHOD HERE THEN	received information on implantsC	

	CHECK WHETHER MENTIONED THE SAME	Obtained pillD	
	IN 304A)	Obtained injectablesE Obtained condomF	
	(IF THE RESPONDENT DOES NOT	OtherX (Specify)	
	MENTION FAMILY PLANNING METHOD	(opcony)	
	HERE THEN PROBE WHETHER SHE HAD		
	RECEIVED FAMILY PLANNING SERVICE		
	WITH ANY OTHER SERVICES)		
	MULTIPLE ANSWERS POSSIBLE.		
345	CHECK: 344		347a
	A or B or C is circled		547 a
	Not circled A or B or C		
	(PILL, INJECTABLE, OR CONDOM ACCEPTO		
	(,	▼ ,	
346	Did the provider tell you about any methods	Yes1	
	other than you accepted (mentioned in 344)?	No2-	➡ 347a
347	Which method did they told about?	Female sterilizationA	
		Male sterilizationB	
		IUDC	
		ImplantD	
	MULTIPLE ANSWERS POSSIBLE	InjectionE PillF	
		CondomG	
		OtherX	
		(Specify)	
347a	Did they give you any BCC materials (picture/	Yes1	
	leaflet/booklet) for taking home?	No2_	▶ 348
347b	Was the poster/picture/leaflet/booklet from the	Yes1	
3470		No	
	Mayer Hashi project?		
240	In some places there is a slipic set on far a	Don't know	
348	In some places, there is a clinic set up for a	Yes1 No2	
	day or part of a day in someone's house or in	Don't know	▶ 351
	a school. During the past six months, was		
0.40	there any such clinic in this village or Mohalla?		
349	Did you visit such temporary health/family	Yes1 No2-	054
	planning clinic in the past six months for family	Z	- 351
040-	planning services?	Descined information on family	
349a	What were the services you received?	Received information on female sterilizationA	
		Received information on IUDB	
	(IF THE RESPONDENT MENTIONS ANY	Received information on implants C	
	FAMILY PLANNING METHOD HERE THEN	Obtained pill D	
	CHECK WHETHER MENTIONED THE SAME	Obtained injectablesE	
	IN 304A)	Obtained condomF	
		OtherX (Specify)	
	(IF THE RESPONDENT DOES NOT	(Specify)	
	MENTION FAMILY PLANNING METHOD		
	HERE THEN PROBE WHETHER SHE HAD		
	RECEIVED FAMILY PLANNING SERVICE		
	WITH ANY OTHER SERVICES)		
	MULTIPLE ANSWERS POSSIBLE.		
	WOLTFLE ANOWERS FUSSIBLE.		

349B	CHECK: 349a		
	A or B or C is circled		349e
	Not circled A or B or C		
	(PILL, INJECTABLE, OR CONDOM ACCEPT	OR)	
		\downarrow	
349c	Did the provider tell you about any methods	Yes1	
	other than you accepted (mentioned in 349a)?	No2-	► 349e
349d	Which method did they told about?	Female sterilizationA	
		Male sterilizationB	
		IUDC	
		ImplantD	
	MULTIPLE ANSWERS POSSIBLE	InjectionE PillF	
		CondomG	
		OtherX	
		(Specify)	
349e	Did they give you any BCC materials (picture/	Yes1	
0100	leaflet/booklet) for taking home?	No2 —	▶351
349f	Was the poster/picture/leaflet/booklet from the	Yes1	
	Mayer Hashi project?	No2	
		Don't know8	
351	In the last 6 months, were you visited by a	Yes1	
	fieldworker who talked to you about family	No2–	► 356b
	planning or gave you a family planning		
	method?		
352	Which field worker visited you?	Family Welfare Assistant (FWA)A	
		Health Assistant (HA)B	
	Name:	NGO worker C	
	PROBE: Anyone else?	OtherX	
	Name:	(Specify)	
353	What services were provided?	Counseling on female sterilizationA	
		Counseling on male sterilizationB	
		Counseling on IUD C	
		Counseling on implantD	
		Counseling on injectionE	
		Counseling on pillF	
		Counseling on condomG	
		Supplied pillH	
		Supplied condomI	
		Pushed injectionJ	
		Advised to go to health center for FP methodK	
		OtherX (Specify)	
353a	Check 353:		
0004	If A/B/C/D is not circled		355
	if A/B/C/D is circled		
	· · · · · · · · · · · · · · · · · · ·		
354	Did the service provider use any	Yes, for female sterilizationA	
	picture/poster/ flipchart/leaflet/booklet to make	Yes, for male sterilizationB	
	you understand about the method	Yes, for IUDC	
		Yes, for implant D	

	MULTIPLE ANSWERS POSSIBLE	NoE
355	Did the provider give you any materials (picture/leaflet/booklet)?	Yes1 No2 Can't remember
355a	Was the poster/picture/leaflet/booklet from the Mayer Hashi project?	Yes1 No2 Don't know8

Fertility preference

1 358b 2 358a 3 358a 3 362 1 358b 2 3 358b 2 3 362 sure
3 362 362 1 358b 2 3 362
362 1→ 358b 2 3 362
1→ 358b 2 3 → 362
1→ 358b 2 3 → 362
1→ 358b 2 3 → 362
2 3 362
2 3 362
3
→ 362
→ 362
sure
8
▶ 359
8
8
9993
9994
9996
9998
→ 362
362
ç

	C or D is not circled (FOR THOSE WHO ARE NOT USING IUD OR IMPLANT)	
358e	In the next one year, do you have any plan to adopt (Name of method)?	Yes No Unsure
	IUD?	IUD1 2 8 362 ←
	Implant? Female sterilization? If circled any 'YES' then skip to 362	Implant128Female sterilization128
359	What are the reasons for not accepting female sterilization/IUD/implant?	Method-related reasons General health concernsA Fear of surgeryB Fear of post-surgery infectionC Fear of side effectsD
	MULTIPLE ANSWER	Perceived side effects
		Fertility related issues Not having sexL Infrequent sexM Menopausal/hysterectomyN Sub-fecund/in-fecundO Fatalistic/no controlP
		Opposition to Use Respondent does not wantQ Husband oppose Others oppose Social stigmaT Religious prohibition U Lack of Knowledge Does not know source of sterilizationV Other X
362	I will now read some statements about contraception. Please let me know if you agree or disagree with each one:	(Specify)] Yes1

"Women become physically weak or may	Disagree2
have health complications after accepting	Don't know3
female sterilization"are you agree with this	
statement?	
	Yes1
"Men who adopt male sterilization lose their	Disagree2
libido "are you agree with this statement?	Don't know3
	Yes1
"Men become physically weak after accepting	Disagree2
male sterilization"are you agree with this	Don't know3
statement?	
	Yes1
Contraception is women's business and a	Disagree2
man does not have to worry about itare you	Don't know3
agree with this statement?	

Section 4

Discussion on female or male sterilization, IUD, and implant

Now, I would like to ask some questions on your discussion about female or male sterilization, IUD, and implant.

No.	QUESTIONS AND FILTERS	CODING CATEGORIES	SKIP
410	Check 303:		
	If A or B or C or D is circled		501
	If A or B or C or D is not circled or not asked		
		T	
411	In the past six months, did you discuss about	Yes1	
	female sterilization, male sterilization, IUD, or	No2-	▶ 413
	implant with your husband?		
412	In the past six months, which method did you		
	discuss about with your husband? (Probe every		
	answer)		
	Female sterilization	Female sterilizationA	
	Male sterilization	Male sterilizationB	
	IUD	IUDC	
	Implant	ImplantD	
413	In the past six months, did you discuss with	Yes1	
	anybody about female sterilization, male	No2—	▶ 501
	sterilization, IUD, or implant?		
414	In the past six months, which method did you		
	discuss about? (Probe every answer)		
	Female sterilization	Female sterilizationA	
	Male sterilization	Male sterilizationB	
	IUD	IUDC	
	Implant	ImplantD	
415	In the past six months, who did you discuss	Health/FP field workerA	
	with? (Probe every answer)	Health provider at facilityB	
		Friend/relative/neighborC	
		OtherX	

Section 5 Information on postpartum female sterilization and IUD available from facilities where deliveries are conducted

501	Check 210a If 2 is circled and year of birth is 2012 or later (IF THE CHILD WAS BORN IN 2012 OR LATER)	If year of birth is 2011 or before	→ 506
501a	Where was your youngest child (Name) born?	HOME Home (own, parents, other)01— PUBLIC SECTOR Hospital/Medical college hospital02 Upazilla Health Complex03 Maternal and Child Welfare Centre (MCWC)04 Other10 (Specify) NGO SECTOR NGO Static Clinic	▶ 506
		Other16 (Specify) PRIVATE MEDICAL SECTOR Private hospital/clinic22 Other96 (Specify)	*
501b	Was the child (Name) delivered through C-section?	Yes1 No2	503
502	In the facility were you told that IUD or female sterilization can be adopted during delivery?	IUDA Female SterilizatoinB NoX	► 504
503	In the facility were you told that female sterilization can be adopted during caesarian delivery?	IUDA Female SterilizatoinB NoX	
504	In the facility, did you accept IUD or female sterilization?	Yes1 No2-	▶ 506
505	Which method did you accept?	IUD1 Female sterilization2	
506	Record the time	Hour	
SAY TH	ANK YOU AND END THE INTERVIEW		

Appendix C.2. Questionnaire for FWA, Service Promoter, and Community Health Worker

Mayer Hashi II (MH II) Baseline Survey 2015

Questionnaire for FWA, Service Promoter, and Community Health Worker

(English)

Mitra and Associates

(Centre for Research and Consultancy) 2/17 Iqbal Road, Mohammadpur Dhaka-1207, Tel: 8118065, 9115503, Fax: 9126806

and

MEASURE Evaluation

Carolina Population Center University of North Carolina at Chapel Hill

Mayer Hashi II Baseline Survey 2015 Questionnaire for FWA, Service Promoter, and Community Health Worker Face Sheet

IDENTIFICATION						
DIVISION						
DISTRICT						
UPAZILA/THANA						
UNION/WARD						
CLUSTER						
TYPE OF SERVICE 09=FWA, 10=Service	e promoter, 1	11=Co	-			
NAME OF THE RES	PONDENT_				-	
INTERVIEWER VISI	TS					
	1	2	2	3	FINAL VISIT	
DATE					- DAY	
INTERVIEWER'S NAME					YEAR 2	
RESULT**					RESULT	
NEXT VISIT: DATE		-			TOTAL NO	
TIME		-			OF VISITS	
**RESULT CODES: 1 COMPLETED 4 REFUSED 2 NOT AVAILABLE 5 PARTLY COMPLETED 3 POSTPONED 6 OTHER						
					KEYED BY	
NAME		NAM	E			
DATE		DATE	E			

Mayer Hashi II Baseline Survey 2015

Informed Consent for Family Planning Service Provider (FWA, Service Promoter, and

Community Health Worker) Questionnaire

(Verbal)

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement:

My name is ______. I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development and health programs in the country, we conduct different types of surveys. We are now conducting a survey, a part of which aims to assess the knowledge, attitude, and practices of providers about IUD, implants, and female and male sterilization. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey.

Why the study being done?

This part of the study will help understand the state and determinants of provider knowledge and skills of long acting and reversible contraceptives (LARC) and permanent method (PM) of family planning in Bangladesh. What is involved in the study?

What is involved in the study?

You have been selected randomly for the survey. If you agree to participate, we will ask you some questions related to long acting and reversible contraceptives (LARC) and permanent method (PM) of family planning. If some questions cause you embarrassment or make you feel uncomfortable, you can refuse to answer them. Your opinion is very important to us as it will help the government to take policy decisions to reach goals related to enabling couples to achieve their reproductive intentions. The survey usually takes between 25 and 30 minutes to complete.

What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies and future plans leading to program improvements.

Confidentiality:

Whatever information you provide will be kept strictly confidential. It will be used for research purposes only and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit; however, the Government particularly the Ministry of Health and Family Welfare (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since the information you provide will help future program planning.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can speak to an IRB person through "collect call" if necessary, at the phone 001-919-966-3012. You can also speak to the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates 2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065, 02-9115053). At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes 1	No 2 END	
Name of person obtaining consent:	•	_ Signature:	Date:

(Must be study investigator or individual who has been designated to obtain consent)

Article II. Section 1: Background

First, I would like to ask you some background-related questions like your education and job.

	QUESTION	RESPONSE	SKIP
<i>(i)</i>	Starting time of interview:	Hour	
		Minute	
(ii) 101		Name:	
(ii) 101	Would you please tell your name?	Name	
(iii) 102	How old are you?	Year (in completed Years)	
103	What is your educational qualification?	SSS 1	
		HSC	
		BA/B.COM /BSC 3	
		MA/M.COM/MSC 3	
		Other 8	
		Other 8 (Specify)	
103a	What is your job title?	FWA1	
		Service Promoter (SP) 2	
		Community Health Worker (CHA) 3	
		Other 8	
		(Specify)	
104	How long have you been a FWA/SP/CHA?	Year (in completed Years)	
	Section 2.02 (If less than 1 year		
	write 00)		
105	How long have you been associated with this	Year (in completed Years)	
	facility?		
	Section 2.03 (If less than 1 year		
	write 00)		
	,		1

Section 2a: In-service Training on Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I would like to ask you some questions on the in-service training, orientation, or refresher training you might have received, provided by the Government of Bangladesh and/or other organizations. In-service training, orientation, or refresher training on LARC/PM since 2014

		IUD	Implant	Tubectomy	NSV	PPFP
		а	b	C	D	f
A201	Since 2014, have you received any in-service training, orientation, or refresher training on?	Yes1 No2 Don't know8 (skip to A201b)	Yes1 No2 Don't know8 (skip to A201c) ←	Yes1 No2 Don't know8 (skip to A201d)	Yes1 No2 Don't know8 (skip to A201e)	Yes1 No2 Don't know8 (skip to sec 2b)
A202	In what month and year did you receive this training, orientation, or refresher training last time?	Month	Month	Month	Month	Month
A203	For how many days was the training the last time you received this training, orientation, or	(0 for less than 1 day)	(0 for less than 1 day)	(0 for less than 1 day)	(0 for less than 1 day)	(0 for less than 1 day)

	refresher training?					
		IUD	Implant	Tubectomy	NSV	PPFP
A204	Who provided	GoB1	GoB1	GoB1	GoB1	GoB1
	the training, orientation, or	EH/MH2	EH/MH2	EH/MH2	EH/MH2	EH/MH2
	refresher training	(skip to A201b)	(skip to A201c)	(skip to A201d)	(skip to A201e)	(Sec.2b)
	the last time you received?	Other3 (specify)	Other3 (specify)	Other3 (specify)	Other3 (specify)	Other3 (specify)
		Don't know8 (skip to A201b)	Don't know8- (skip to A201c) ▼	Don't know8 (skip to A201d) ▼	Don't know8 (skip to A201e) ▼	Don't know8- (skip to Sec2b) ▼
A205	Was Engender Health/ Mayer Hashi involved in the training	Yes1 No2 Don't know8	Yes 1 No 2 Don't know 8	Yes1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know8
A206	Did any person from Engender Health/ Mayer Hashi participate in or observe the training?	Yes1 No2 Don't know8	Yes 1 No 2 Don't know 8	Yes 1 No 2 Don't know 8	Yes1 No2 Don't know8	Yes 1 No 2 Don't know 8

Section 2b: BCC and Interpersonal Communication Now I would like to ask you some questions on the in-service training, orientation, or refresher training you might have received on BCC and interpersonal communication, provided by the Government of Bangladesh and/or other organizations.

In-service training, orientation, or refresher training on BCC and interpersonal communication since 2014.

	QUESTION	RESPONSE	SKIP
B201	Since 2014, have you ever received any training on BCC?	Yes 1 No	B205
B202	On what topics/areas of BCC you have received training?	Personal CounselingA Group sessionB Community mobilizationC Other X (Specify)	
B203	In which month and year you received training on BCC?	Month	
B204	Was Mayer Hashi or <i>EngenderHealth</i> involved in the training?	Yes 1 No	
B204a	Was any trainer/facilitator from Mayer Hashi or <i>EngenderHealth</i> present in the training?	Yes	
B205	Since 2014, have you received any training, orientation, or refresher training on BCC?	Yes1 No	→Sec 3
B206	On what topic/areas of BCC you have received training? Multiple response	Personal CounselingA Group sessionB Community mobilizationC OtherX (Specify)	
B207	In which month and year have you received training, orientation, or refresher training on BCC?	Month	
B208	Was Mayer Hashi or <i>EngenderHealth</i> involved in the training?	Yes	
B208a	Was any trainer/facilitator from Mayer Hashi or <i>EngenderHealth</i> present in the training?	Yes	

Section 3: Respondent's Involvement on the Provision of Long-acting and Reversible Contraceptives (LARC) and Permanent Methods (PM)

	QUESTION	RESPONSE	SKIP
301	In the community where you work, do you help couples choose or select LARC/PM as methods of contraception?	Yes1 No2—	▶ 305
302	Which methods of LARC/PM do you provide?	IUDA ImplantsB	
	Multiple response	TubectomyC NSVD	
303	When was the last time you have help a client to adopt LARC/PM?	Month Year Can't remember when 888888	
304	Do you follow up those clients who received LARC/PM services through your help?	Yes1 No2	
305	Do you provide counseling to those clients of LARC/PM who experience discomfort, side effects, or complications?	Yes1 No2	
306	Do you help those clients of LARC/PM who experience discomfort, side effects, or complications to get services from the provider who provided the services?	Yes1 No2	

[I would like to know about your involvement in the provision of LARC/PM.]

Section 4: Skills and Practices on Long Acting Reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I want to discuss with you some issues that are considered by service providers of IUD, IMPLANT, Tubectomy and NSV. The issues are client selection, screening, pre- and post-counseling, method side effects, and others.

[INTERVIEWER: DON'T READ OUT THE ANSWERS, CIRCLE THE CODES RELATED TO THE SPONTANEOUS ANSWERS PROVIDED BY THE RESPONDENT. PROBE THOSE ANSWERS THAT ARE NOT CIRCLED IN THE SPONTANEOUS ANSWER COLUMN.]

QUESTION	RESPONSE				SKI
		Sponta -neous	Promp -ted	No/ DK	
What are the conditions under	Women who have at least 1 living child.	1	2	3	
which a woman can accept IUD	Women who don't want child for long				
or can be recommended for	time or don't want child	1	2	3	
having an IUD?	Women who can not use hormonal				
	FP method	1	2	3	
	Regular menstruation	1	2	3	
	Within first 5 days of menstruation	1	2	3	
	Other	1	2	3	
	(Specify)	•	2	5	
What are the conditions	(Specify) Women who have no child	Δ			
	Women who have been suffering				
under which a woman	from RTI	B			
cannot be recommended	Menstruation stopped				
for IUD?	Pergnancy				
	Irregular menstruation				
Multiple response	Excessive menstrual bleeding				
manapiereoponoe	Cronic jaundice				
	Breast cancer				
	Other	X			
	(Specify)		1		
		Sponta	Promp	No/	
	Abdominal pain	-neous	-ted	DK	
What are the probable	Excessive bleeding in between	1	2	3	
side effects of IUD?	the two menstrual cycle				
	Spotting	11	2	33	
	Abnormal menstrual bleeding	1	2	3	
	White discharge/excessive white		2		
	discharge	1		3	
	The thread of IUD come out	1	2	3	
	Other		2	_	
	(Specify)				

Section 4a: Skills and Practices on IUD

		Sponta -neous	Promp -ted	No/ DK	
(Pre-counseling) A woman comes to you	Explain advantages and disadvantages of IUD Explain probable side effects,	1	2	3	
for accepting IUD, what advice/counseling should you provide to	discomfort and complications of IUD Assist the provider to know that the client does not have	1	2	3	
her?	RTI or infection in reproductive organ Ensure that the client understood the advantages and disadvantages	1	2	3	
	of IUD before she made the decision Assist the provider to find that the client is still under	1	2	3	
	regular menstrution, and not pregnant Other (Specify)	1 1	2 2	3 3	

		Sponta- neous	Promp -ted	No/ DK	
(Post-counseling) What important	Give her the follow-up card Remind her about the probable side effects and discomfort and	1	2	3	
advice/counseling should you provide to a	assure her of the follow-up Remind her the procedure of	1	2	3	
woman who just accepted IUD?	follow-up Encourage the client to contact with service provider if there is any	1	2	3	
	side effects or complications Encourage the client to check the	1	2	3	
	thread Advise the client to avoid	1	2	3	
	sexual intercourse for 2-3 days Ensure that the client understood	1	2	3	
	the main points of counseling Other (Specify)	1 1	2 2	3 3	
Do you or your facility do follow up of IUD clients?	Yes No				
When is the timing of follow up?	Within 3 days Within 7 days After 1 month 2-5 months	B C			
Multiple response	6-11 months After 1 year When problem arises Other(Specify)	E F G			

		Sponta- neous	Promp -ted	No/ DK	
What advice/counseling should you provide to a IUD user at the time of	Counsel the client to go to the facility for routine check up Provide counseling and treatment immediately if client complains of side	1	2	3	
follow-up?	effects, complications and discomfort Refer to appropriate place if client	1	2	3	
	complains of side effects, complications, discomfort Assure for any other service if she	1	2	3	
	has no side-effects, complication or discomfort Other(Specify)	1 1	2 2	3 3	

Section 4b: Skills and Practices on IMPLANT

			Sponta- neous	Promp -ted	No/ DK	
)	What are the conditions under which a woman can accept IMPLANT or can be recommended for adopting IMPLANT?	Women who want to avoid pregnancy for a long time Women who have no child Ensure that she is still under regular menstrution, i.e., she is not pregnant Other	1 1 1 1	2 2 2 2 2	3 3 3 3	
)	What are the probable side effects of IMPLANT?	(Specity) Menstruation stopped Excessive bleeding Spotting Weight gain Motion of vomiting Depression Pain in arm Other	Sponta- neous 1 1 1 1 1 1 1 1 1 1	Promp -ted 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	No/ DK 3 3 3 3 3 3 3 3 3 3 3 3 3 3	
		(Specify)	Sponta-		No/	
))	(Pre-counseling) A woman comes to you for accepting IMPLANT, what advice/counseling should you provide her?	Explain advantages and disadvantages of IMPLANT Explain probable side effects, discomfort and complications of IMPLANT Ensure that the client understood the	neous 1 1	<u>-ted</u> 2 2	<u>DК</u> 3 3	
		advantages and disadvantages of IMPLANT before she made the decision Other (Specify)	1 1	2 2	3 3	

		Sponta- neous	Promp -ted	No/ DK	
(Post-counseling) What important	Give her the follow-up card Remind her about the probable side effects and discomfort and assure	1	2	3	
advice/counseling would you provide to a woman	her of the follow-up Remind her the procedure of	1	2	3	
who just accepted Implant?	follow-up Encourage the client to contact with service provider if there is	1	2	3	
	any side effects or complications Remind her that there may be	1	2	3	
	little pain on the arm Advise the client to avoid sexual	1	2	3	
	intercourse for 2-3 days Ensure that the client understood the main	1	2	3	
	points of counseling Other (Specify)	1 1	2 2	3 3	
Do you or your facility follow-up IMPLANT clients?	Yes No		<u> </u>		
When is the timing of follow up?	Within 3 days Within 7 days After 1 month 2-5 months	B C			
Multiple response	6-11 months After 1 year When problem arises Other	E F G			
	(Specify) DK				
		Sponta- neous	Promp -ted	No/ DK	
What advice/counseling would you provide to IMPLANT client at the time of follow up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort	1	2	3	
time of follow-up?	Refer to appropriate place if client complains of side effects, complications, discomfort Assure for any other service if she	1	2	3	
	has no side-effects, complication or discomfort Other	1 1	2 2	3 3	

Section 4c: Skills and Practices on Tubectomy

		QUESTION	RESPONSE				SKIP
				Sponta- neous	Promp- ted	No/ DK	
)	403a	What are the conditions under which a woman can accept tubectomy or can be recommended for adopting tubectomy?	Women who do not want to have any more children and have at least 1 living child Women who do not want to have any more children and the age of	1	2	3	
			the youngest child is at least 2 years.	1	2	3	
			Women who have 2 nd time CS	1	2	3	
			Husband agreed for tubectomy	1	2	3	
			Other	1	2	3	
			(Specify)	Sponta-	Promp-	No/	
				neous	ted	DK	
))	403g	(Pre-counseling) A woman comes to you for accepting	Explain advantages and disadvantages of tubectomy Explain probable side effects,	1	2	3	
		tubectomy, what advice/counseling	discomfort and complications of Tubectomy Ensure that the client receives the enpreprinte check to determine that	1	2	3	
		should be provided to her?	appropriate check to determine that she does not have any health conditions unfavorable to the operation Ensure that the client understood the advantages and disadvantages of tubectomy before she made the	1	2	3	
			decision	1	2	3	
			Other	1	2	3	
			(Specify)	Sponta-	Promp-	No/	
				neous	ted	DK	
))	403h	(Post-counseling) What important advice/counseling would you provide to a	Give her the follow-up card Remind her about the probable side effects and discomfort and assure her of the follow-up Remind her the procedure of	1	2	3	
		woman who has just accepted tubectomy?	follow-up Encourage the client to contact with service provider if there is	1	2	3	
			any side effects or complications Remind her to take full rest for	1	2	3	
			2 days Encourage her to avoid heavy work or avoid lifting heavy weight	1	2	3	
			for 3 weeks Reminf her to take medications	1	2	3	
			that have been given to her Ensure that the client understood	1	2	3	
			the main points of counseling	1	2	3	
			Other	1	2	3	
			(Specify)				

) 403j	Do you or your facility follow up tubectomy clients?	Yes No				
) 403k	When is the timing of follow up? Multiple response	Within 3 days Within 7 days After 1 month 2-5 months 6-11 months After 1 year When problem arises Other (Specify) DK	B D E F G X			
			Sponta- neous	Promp- ted	No/ DK	
) 4031	What advice/counseling would you provide to tubectomy acceptor at the time of follow up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications, discomfort Assure for any other service if she has no side-effects, complication or discomfort Other(Specify)	1	2 2 2 2 2	3 3 3 3 3	

Section 4d: Skills and Practices on NSV

			Sponta- neous	Promp- ted	No/ DK
) 404a	What are the conditions under which a man can accept NSV or can be recommended for having?	Man (and his wife) who do not want to have any more children and have at least 1 living child Man (and his wife) who do not want to have any more children and the age of the youngest child is at least 2 years Wife agreeable to husband having NSV Other	1 1 1 1	2 2 2 2	3 3 3 3
		(Specity)	Sponta-	Promp-	No/
			neous	ted	DK
)) 404g	(Pre-counseling) What advice/counseling should be provided to a	Explain advantages and disadvantages of NSV Explain probable side-effects,	1	2	3
	man comes to you for accepting NSV?	discomfort, and complications of NSV Assist the provider to determine that the	1	2	3
		client does not have any health conditions unfavorable to the operation Ensure that the client understood the advantages and disadvantages	1	2	3
		of tubectomy before she made the decision Other (Specify)	1 1	2 2	3 3

		Sponta-	Promp-	No/	
1		neous	ted	DK	
(Post-counseling)	Give him the follow-up card	1	2	3	
What important	Remind him about the probable discomforts				
	and assure him of the				
advice/counseling	follow-up	1	2	3	
should be provided to	Remind him the procedure of				
a man who has just	follow-up	1	2	3	
accepted NSV?	Encourage the client to contact with service				
	provider if there is any complications	1	2	3	
	Encourage him to avoid heavy work				
	or avoid lifting heavy weight for 1				
	day	1	2	3	
	Remind him to use condom during				
	sex for a period of 3 months	1	2	3	
	Ensure that the client understood				
	the main points of counseling				
	including the follow-up procedures	1	2	3	
	Other	1	2	3	
	(Specify)		-	Ũ	
 Do you or your facility	Yes	1			
Do you or your facility	No				
do follow-up for NSV					
clients?					
When is the timing of	Within 3 days	А			
•	Within 7 days				
follow-up?	After 1 month	С			
	2-5 months				
Multiple response	6-11 months				
	After 1 year				
	When problem arises	G			
	Other				
	(Specify)				
	DK	Z			
		Sponta-	Promp-	No/	
		neous	ted	DK	
What	Provide counseling and treatment				
	immediately if client complains of side				
advice/counseling	effects, complications				
should you provide to	and discomfort	1	2	3	
NSV acceptor at the	Refer to appropriate place if client		<u> </u>		
time of follow up?	complains of side effects, complications,				
	discomfort				
	Assure for any other service if she	1	2	3	
			2	J	
	has no side-effects, complication or	1	2	2	
	discomfort	1	2	3	
	Other(Specify)	1	2	3	
	(эреспу)				

Section 5: Postpartum IUD and Tubectomy [Now, I would like to know on new policies or changed policies regarding family planning from you]

	QUESTION	RESPONSE	SKIP
501	Are you aware of the government policy which encourages that IUD may be offered to those women who deliver at facilities, immediately after delivery?	Yes 1 No 2	
502	Are you aware of the government policy which encourages that tubectomy may be offered to those women who deliver at facilities, right at delivery?	Yes 1 No 2	
503	Are you aware of the government policy which encourages that IUD may be offered during C- section delivery?	Yes 1 No 2	
504	Are you aware of the government policy which encourages that tubectomy may be offered during C-section delivery?	Yes 1 No 2	
505	Do you disseminate about the availability of postpartum IUD and postpartum tubectomy in you work area?	Yes 1 No 2	
506	Has any women from your work area adopted postpartum IUD from a facility in last 12 months?	Yes 1 No 2	
506a	How many?	Number of postpartum	
507	Has any women from your work area adopted postpartum tubectomy from a facility in last 12 months?	Yes 1 No 2	
507a	How many?	Number of postpartum tubectomy	
508	Ending time of Interview:	Hour	

Now, I am ending the interview here, if have you any question then you can ask me. Thank you for providing the information.

Appendix C.3. Questionnaire for FWV, SACMO, Nurse, Nurse Midwife, and Paramedic

Mayer Hashi II (MH II) Baseline Survey 2015

Questionnaire for FWV, SACMO, Nurse, Nurse Midwife, and Paramedic

(English)

Mitra and Associates

(Centre for Research and Consultancy) 2/17 Iqbal Road, Mohammadpur Dhaka-1207, Tel: 8118065, 9115503, Fax: 9126806

and

MEASURE Evaluation

Carolina Population Center University of North Carolina at Chapel Hill

Mayer Hashi II Baseline Survey 2015 Questionnaire for FWV, SACMO, Nurse, Nurse Midwife, and Paramedic Face Sheet

			IDENTIFICA	TION			
DIVISION							
DISTRICT							
UPAZILA/THANA							
UNION/WARD							
CLUSTER							
TYPE OF SERVICE 04=FWV, 05=SACM			=Nurse Midwife	08=Paramedi	с		
NAME OF THE RES	PONDENT						
	TS 1		2	3	FINAL VISIT		
			2	3	DAY		
DATE					- MONTH		
					YEAR 2		
INTERVIEWER'S					INTV. CODE		
NAME					RESULT		
RESULT**					RESULT		
NEXT VISIT: DATE					TOTAL NO		
TIME					OF VISITS		
**RESULT CODES: 1 COMPLETED 4 REFUSED 2 NOT AVAILABLE 5 PARTLY COMPLETED 3 POSTPONED 6 OTHER (SPECIFY)							
SUPERVISOR		FIF	ELD EDITOR		OFFICE	KEYED BY	
					EDITOR		
NAME		NA	ME				
DATE		DA	TE				

Mayer Hashi II Baseline Survey 2015

Informed Consent for Family Planning Service Provider (FWV, SACMO, Nurse, Nurse Midwife, and Paramedic) Questionnaire

(Verbal)

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement:

My name is . I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development and health programs in the country, we conduct different types of surveys. We are now conducting a survey, a part of which aims to assess the knowledge, attitude, and practices of providers about IUD, implants, and female and male sterilization. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey.

Why the study being done?

This part of the study will help understand the state and determinants of provider knowledge and skills of long acting and reversible contraceptives (LARC) and permanent method (PM) of family planning in Bangladesh.

What is involved in the study?

You have been selected randomly for the survey. If you agree to participate, we will ask you some questions related to long acting and reversible contraceptives (LARC) and permanent method (PM) of family planning. If some questions cause you embarrassment or make you feel uncomfortable, you can refuse to answer them. Your opinion is very important to us as it will help the government to take policy decisions to reach goals related to enabling couples to achieve their reproductive intentions. The survey usually takes between 25 and 30 minutes to complete.

What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies and future plans leading to program improvements.

Confidentiality:

Whatever information you provide will be kept strictly confidential. It will be used for research purposes only and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit; however, the Government particularly the Ministry of Health and Family Welfare (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since the information you provide will help future program planning.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can speak to an IRB person through "collect call" if necessary, at the phone 001-919-966-3012. You can also speak to the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065, 02-9115053). At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes	1	No 2-	→ END	
Name of person obtaining consent:		*	Signature: _	Date:	_

(Must be study investigator or individual who has been designated to obtain consent)

Article III. Section 1: Background

First, I would like to ask you some background-related questions like your education and job.

	QUESTION	RESPONSE	SKIP
(i)	Starting time of interview:	Hour	
		Minute	
(ii) 101	Would you please tell your name?	Name:	
(iii) 102	How old are you?	Year (in completed Years)	
103	What is your professional qualification?	SSS 1 HSC 2 BA/B.COM/BSC 3 MA/M.COM/MSC 4 Other 8 (Specify) 8	
103a	What is your job title?	FWV	
104	How long have you been a FWV/SACMO/Nurse/ Nurse Midwife or Paramedic? Section 3.02 (If less than 1 year write 00)	Year (in completed Years)	
105	How long have you been in this facility? Section 3.03 (If less than 1 year write 00)	Year (in completed Years)	

Section 2a: In-service Training on Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I would like to ask you some questions on the in-service training, orientation, or refresher training you might have received, provided by the Government of Bangladesh and/or other organizations. In-service training, orientation, or refresher training on LARC/PM since 2014

		IUD	Implant	Tubectomy	NSV	PPFP
		а	b	С	d	f
A201	Since 2010, have you received any in-service training, orientation, or refresher training on? In what month	Yes1 No2 Don't know8 (skip to A201b)	Yes1 No2 Don't know8 (skip to A201c)	Yes1 No2 Don't know8 (skip to A201d)	Yes1 No2 Don't know8 (skip to A201e)	Yes 1 No 2 Don't know 8 (skip to sec 2b)
	and year did you receive this training, orientation, or refresher training last time?	Year	Year	Year	Year	Year
A203	For how many days was the training the last time you received this training, orientation, or refresher training?	(0 for less than 1 day)	(0 for less than 1 day)			
A204	Who provided the training, orientation, or refresher training the last time you received?	GoB1 EH/MH2 (skip to A201b) Other3 (specify) Don't know8 (skip to A201b)	GoB1 EH/MH2 (skip to A201c) Other3 (specify) Don't know8 (skip to A201c)	GoB1 EH/MH2 (skip to A201d) Other3 (specify) Don't know8 (skip to A201d)	GoB1 EH/MH2 (skip to A201e) Other3 (specify) Don't know8 (skip to A201e)	GoB1 EH/MH2 (Sec.2b) Other3 (specify) Don't know8 (skip to Sec2b)
A205	Was Engender Health/ Mayer Hashi involved in the training	Yes1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know8
A206	Did any person from Engender Health/ Mayer Hashi participate in or observe the training?	Yes1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know8

Section 2b: BCC and Interpersonal Communication

Now I would like to ask you some questions on the in-service training, orientation, or refresher training you might have received on BCC and interpersonal communication, provided by the Government of Bangladesh and/or other organizations.

In-service training, orientation, or refresher training on BCC and interpersonal communication since 2014.

	QUESTION	RESPONSE	SKIP
B201	Since 2014 have you received any training on	Yes1	
	BCC?	No2 –	▶B205
B202	On what topics/areas of BCC you have received	Personal CounselingA	
	training?	Group session B	
		Community mobilizationC	
		OtherX	
		(Specify)	
B203	In which month and year you received training on	Month	
	BCC?	Year	
B204	Was Mayer Hashi or <i>EngenderHealth</i> involved in	Yes1	
	the training?	No2	
B204a	Was any trainer/facilitator from Mayer Hashi or	Yes1	
	EngenderHealth present in the training?	No2	
		Can't remember8	
B205	Since 2014 have you received any training,	Yes1	
	orientation, or refresher training on BCC?	No2	
		Can't remember8	▶Sec 3
B206	On what topic/areas of BCC you have received	Personal CounselingA	
	training?	Group sessionB	
	Multiple response	Community mobilizationC	
		OtherX	
		OtherX	
B207	In which month and year have you received	Month	
	training, orientation, or refresher training on BCC?	Year	
B208	Was Mayer Hashi or EngenderHealth involved in	Yes1	
	the training?	No2	
	, , , , , , , , , , , , , , , , , , ,	Can't remember8	
B208a	Was any trainer/facilitator from Mayer Hashi or	Yes1	
	EngenderHealth present in the training?	No2	
		Can't remember8	

Section 3: Respondent's Involvement on the Provision of Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM)

	QUESTION	RESPONSE	SKIP
301	Do you provide any services on LARC/PM?	Yes1 No2—	▶ 304
302	Which methods of LARC/PM do you provide? Multiple response	IUDA ImplantsB TubectomyC NSVD	
303	When was the last time you have done a procedure of LARC/PM?	Month	
304	Do you provide counseling or treatment to those clients of LARC/PM who experience discomfort, side effects, or complications?	Yes1 No2	

[I would like to know about your involvement in the provision of LARC/PM.]

Section 4: Skills and Practices on Long Acting Reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I want to discuss with you some issues that are considered by service providers of IUD, IMPLANT, Tubectomy and NSV. The issues are client selection, screening, pre- and post-counseling, method side effects, and others.

[INTERVIEWER: DON'T READ OUT THE ANSWERS, CIRCLE THE CODES RELATED TO THE SPONTANEOUS ANSWERS PROVIDED BY THE RESPONDENT. PROBE THOSE ANSWERS THAT ARE NOT CIRCLED IN THE SPONTANEOUS ANSWER COLUMN.]

	QUESTION	RESPONSE				SKIP
			Sponta- neous	Promp- ted	NO/ DK	
)	under which a woman can accept IUD or can be recommended for having an	Women who have at least 1 living child Women who don't want child for long	1	2	3	
		time or don't want child Women who can not use hormonal	1	2	3	
		FP method	1	2	3	
		Regular menstruation	1	2	3	
		Within first 5 days of menstruation	1	2	3	
		Other(Specify)	1	2	3	
	·		Sponta- neous	Promp- ted	NO/ DK	

Section 4a: Skills and Practices on IUD

QUESTION	RESPONSE				SKIP
		Sponta- neous	Promp- ted	NO/ DK	
What are the conditions under which a woman cannot be recommended for IUD?	Women who have no child A Women who have been suffering from RTI from RTI B Menstruation stopped C Pergnancy D Irregular menstruation E Excessive menstrual bleeding F Cronic jaundice G Breast cancer H Other X	1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 2 2 2 2 2	3 3 3 3 3 3 3 3 3 3 3	
What are the probable side effects of IUD? Multiple response	(Specify) Abdominal painA Excessive bleeding in between the two menstrual cycleB SpottingC Abnormal menstrual bleedingD White discharge/excessive white dischargeE The thread of IUD come outF OtherX (Specify)				

)	An IUD client comes to you with excessive bleeding, what will you do? Multiple response	Examine her to know the reasons for excessive bleeding Provide treatment for bleeding Refer to higher level for treatment Remove IUD Other	B C D			
)	An IUD client comes to you with abdominal pain, what will you do?	Examine her to know the probable reasons for pain Provide treatment and assure her for further service Refer her to higher level for	В			
	Multiple response	treatment Remove IUD Other	D X	Γ		
			Sponta -neous	Promp -ted	NO/ DK	
))	(Pre-counseling) A woman comes to you	Explain advantages and disadvantages of IUD Explain probable side effects,	1	2	3	
	for accepting IUD, what advice/counseling	discomfort and complications of IUD Ensure that the client does not have RTI or infection in reproductive	1	2	3	
	should you provide to her?	organ Ensure that the client understood the advantages and disadvantages of IUD before she made the	1	2	3	
		decision Ensure that she is still under regular menstrution, and not	1	2	3	
		Other(Specify)	1 1	2 2	3 3	

		Sponta -neous	Promp -ted	NO/ DK	
(Post-counseling) What important	Give her the follow-up card Remind her about the probable side effects and discomfort and	1	2	3	
advice/counseling should you provide to a	assure her of the follow-up Remind her the procedure of	1	2	3	
woman who just accepted IUD?	follow-up Encourage the client to contact with service provider if there is any	1	2	3	
	side effects or complications Encourage the client to check the	1	2	3	
	thread Advise the client to avoid	1	2	3	
	sexual intercourse for 2-3 days Ensure that the client understood	1	2	3	
	the main points of counseling Other (Specify)	1	2 2	3 3	
Do you or your facility do follow up of IUD clients?	YesNo				
When is the timing of follow up? Multiple response	Within 3 days Within 7 days After 1 month 2-5 months 6-11 months	B C D E			
	After 1 year When problem arises Other (Specify)	G X			
	DK	Z Sponta -neous	Promp -ted	NO/ DK	
What advice/counseling should you provide to a IUD user at the time of follow-up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client	1	2	3	
	complains of side effects, complications, discomfort Assure for any other service if she	1	2	3	
	has no side-effects, complication or discomfort	1	2	3	

Section 4b: Skills and Practices on IMPLANT

			Sponto	Dromp		
			Sponta -neous	Promp -ted	NO/ DK	
)	What are the conditions under	Women who want to avoid	Incous	-icu	DIX	
	which a woman can accept	pregnancy for a long time	1	2	3	
	IMPLANT or can be	Women who have no child	1	2	3	
	recommended for adopting	Ensure that she is still under regular				
	IMPLANT?	menstrution, i.e., she is not pregnant	1	2	3	
		Other	1	2	3	
		(Specify)				
			Sponta	Promp	NO/	
			-neous	-ted	DK	
)	What are the probable	Menstruation stopped	1	2	3	
	side effects of	Excessive bleeding	1	2	3	
	IMPLANT?	Spotting	1	2 2	3	
		Weight gain Motion of vomiting	1	2	3 3	
		Depression	1	2	3	
		Pain in arm	1	2	3	
		Other	1	2	3	
		(Specify)		_	Ŭ	
)	An IMPLANT client	Examine her to know the reasons for				
		excessive				
	comes to you with	bleeding	A			
	excessive bleeding,	Provide treatment for bleedingB				
	what would you do?	Refer her to higher level for treatmentC				
	Multiple response	Remove IMPLANT				
		Other	X			
		(Specify)				
)	An IMPLANT client	Check pregnancy				
	comes to you with	If she is not pregnant, counsel and assure				
	menopause, what	it is not a problem Remove IMPLANT	В С			
	would you do?	Other				
	Multiple response	(Specify)	X			
	multiple response		Onente	Duran		
			Sponta -neous	Promp -ted	NO/ DK	
)	(Pre-counseling)	Explain advantages and	-110003	-100		
		disadvantages of IMPLANT	1	2	3	
/	A woman comes to you	Explain probable side effects,		-		
	for accepting IMPLANT,	discomfort and complications of				
	what advice/counseling	IMPLANT	1	2	3	
	should you provide her?	Ensure that the client understood the				
		advantages and disadvantages of				
		IMPLANT before she made the				
		decision	1	2	3	
		Other	1	2	3	
		(Specify)				

		Sponta -neous	Promp -ted	NO/ DK	
(Post-counseling) What important	Give her the follow-up card Remind her about the probable	1	2	3	
advice/counseling would you provide to a woman	side effects and discomfort and assure her of the follow-up Remind her the procedure of	1	2	3	
	follow-up Encourage the client to contact	1	2	3	
	with service provider if there is any side effects or complications Remind her that there may be	1	2	3	
	little pain on the arm Advise the client to avoid sexual	1	2	3	
	intercourse for 2-3 days Ensure that the client understood	1	2	3	
	the main points of counseling Other (Specify)	1 1	2 2	3 3	
Do you or your facility follow-up IMPLANT clients?	Yes No		I		
	Within 3 days Within 7 days After 1 month	В С			
Multiple response	2-5 months 6-11 months After 1 year When problem arises Other	E F G			
	(Specify) DK				
		Sponta -neous	Promp -ted	NO/ DK	
What advice/counseling would you provide to IMPLANT client at the time of follow-up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications,	1	2	3	
	discomfort Assure for any other service if she has no side-effects, complication or	1	2	3	
	discomfort Other(Specify)	1 1	2 2	3 3	

Section 4c: Skills and Practices on Tubectomy

	QUESTION	RESPONSE				SKIP
			Sponta -neous	Promp -ted	NO/ DK	
)	What are the conditions under which a woman can accept tubectomy or can be recommended for adopting tubectomy?	Women who do not want to have any more children and have at least 1 living child Women who do not want to have any more children and the age of	1	2	3	
		the youngest child is at least 2 years Women who have 2 nd time CS Husband agreed for tubectomy Other	1 1 1 1	2 2 2 2	3 3 3 3	
		(Specify)	Sponta -neous	Promp -ted	NO/ DK	
))	(Pre-counseling) A woman comes to you for accepting	Explain advantages and disadvantages of tubectomy Explain probable side effects, discomfact and complications of	1	2	3	
	tubectomy, what advice/counseling should be provided to	discomfort and complications of Tubectomy Ensure that the client does not have any health conditions unfavorable	1	2	3	
	her?	to the operation Ensure that the client understood the advantages and disadvantages of tubectomy before she made the	1	2	3	
		decision Other (Specify)	1 1	2 2	3 3	
			Sponta -neous	Promp -ted	NO/ DK	
))	(Post-counseling) What important advice/counseling	Give her the follow-up card Remind her about the probable side effects and discomfort and	1	2	3	
	would you provide to a woman who has just accepted tubectomy?	assure her of the follow-up Remind her the procedure of follow-up Encourage the client to contact	1	2	3	
		with service provider if there is any side effects or complications Remind her to take full rest for	1	2	3	
		2 days Encourage her to avoid heavy work or avoid lifting heavy weight	1	2	3	
		for 3 weeks Remind her to take medications that have been given to her	1	2 2	3 3	
		Ensure that the client understood the main points of counseling Other(Specify)	1 1	2 2	3 3	

Do you or your facil follow up tubectomy clients?					
When is the timing of follow up? Multiple response	f Within 3 days A Within 7 days E After 1 month C 2-5 months E 6-11 months E After 1 year F When problem arises C Other X (Specify) DK	3) = ; ; ;			
		Sponta -neous	Promp -ted	NO/ DK	
What advice/counseling would you provide t tubectomy acceptor the time of follow up	at Refer to appropriate place if client complains	1	2	3	
	Assure for any other service if she has no side-effects, complication or	1	2	3	
	discomfort	1	2	3 3	
	Other (Specify)	I	2	3	

Section 4d: Skills and Practices on NSV

			Sponta- neous	Promp- ted	NO/ DK	
) 404a	What are the conditions under which a man can accept NSV or can be recommended for having?	Men who do not want to have any more children and have at least 1 living child Men who do not want to have any	1	2	3	
		more children and the age of the youngest child is at least 2 years Wife agreeable to husband having	1	2	3	
		NSV	1	2	3	
		Other(Specify)	1	2	3	
			Sponta- neous	Promp- ted	NO/ DK	

			Sponta- neous	Promp- ted	NO/ DK
)) 404g	(Pre-counseling) What advice/counseling should be provided to a	Explain advantages and disadvantages of NSV Explain probable side-effects,	1	2	3
	man comes to you for accepting NSV?	discomfort, and complications of NSV Ensure that the client does not have	1	2	3
		any health conditions unfavorable to the operation Ensure that the client understood	1	2	3
		the advantages and disadvantages of tubectomy before she made the decision Other	1 1	2 2	3 3
			Sponta- neous	Promp- ted	NO/ DK
)) 404h	(Post-counseling) What important	Give her the follow-up card Remind him about the probable discomforts and assure him of the	1	2	3
	advice/counseling should be provided	follow-up Remind him the procedure of	1	2	3
	to a man who has just accepted NSV?	follow-up Encourage the client to contact with service	1	2	3
		provider if there is any complications Encourage her to avoid heavy work or avoid lifting heavy weight for 1	1	2	3
		day Remind him to use condom during	1	2	3
		sex for a period of 3 months Ensure that the client understood the main points of counseling	1	2	3
		Other(Specify)	1 1	2 2	3 3

)	Do you or your facility do follow-up for NSV clients?	Yes No				
)	When is the timing of follow up? Multiple response	Within 3 days A Within 7 days B After 1 month C 2-5 months D 6-11 months E After 1 year F When problem arises C Other X (Specify) DK				
			Sponta- neous	Promp -ted	NO/ DK	
)	What advice/counseling should you provide to NSV acceptor at the time of follow up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications, discomfort	1	2	3 3	
		Assure for any other service if she has no side-effects, complication or discomfort Other(Specify)	1 1	2 2	3 3	

Section 5: Postpartum IUD and Tubectomy [Now, I would like to know on new policies or changed policies regarding family planning from you]

	QUESTION	RESPONSE	SKIP
501	Are you aware of the government policy which encourages that IUD may be offered to those women who deliver at facilities, immediately after delivery?	Yes 1 No 2	
502	Are you aware of the government policy which encourages that tubectomy may be offered to those women who deliver at facilities, right at delivery?	Yes 1 No 2	
503	Are you aware of the government policy which encourages that IUD may be offered during C- section delivery?	Yes 1 No 2	
504	Are you aware of the government policy which encourages that tubectomy may be offered during C-section delivery?	Yes 1 No	
505	Do community-level providers such as FWAs (Family Welfare Assistants), service promoters, or other community workers disseminate the postpartum IUD and postpartum tubectomy information to their catchment populations?	Yes 1 No 2	
506	Do you conduct delivery at any public-sector or private-sector facility(s) in the last 6 months?	Yes 1 No	
507	Do you offer the postpartum IUD to your delivery clients?	Yes 1 No 2	
508	Have you performed postpartum IUD in the last 6 month?	Yes1 No2	

Section 6: Policy changes or new policies

[Now, I would like to discuss with you about some policies regarding family planning services from you.]

SI. #			601a-609a. Is it being implemented?
601	DGHS staff nurses after being trained are permitted to provide IUD services?	Yes1 No2	Yes1 No2
602	Nurses at private hospitals after being trained are permitted to provide IUD services?	Yes1 No2	Yes1 No2
603	Women who have not yet given any birth of a child are allowed to accept IMPLANT?	Yes1 No2	Yes1 No2
604	Post-partum family planning services has been added in the maternal health services and such services are available in the DGHS hospitals?	Yes1 No2	Yes1 No2
605	Postpartum family planning services have been added in private-sector facilities?	Yes1 No2	Yes1 No2
606	The DGHS facilities do not require separate registration from DGFP to receive family planning commodities and funds if they want to provide family planning services?	Yes1 No2	Yes1 No2
607	The GOB-registered private or NGO facilities do not require separate registration from DGFP to receive family planning commodities and funds if they want to provide family planning services?	Yes1 No2	Yes1 No2
609	DGFP approved the use of Tab Ibuprofen after IUD insertion which will help prevent pain and bleeding among new users?	Yes1 No2	Yes1 No2
610	Ending time of Interview:	Hour Minute	

Now, I am ending the interview here, if have you any question then you can ask me. Thank you for providing the information.

Appendix C.4. Questionnaire for MO (MCH-FP), Medical Officer, RMO, and Clinic Manager

Mayer Hashi II (MH II) Baseline Survey 2015

Questionnaire for MO (MCH-FP), Medical Officer, RMO, and Clinic Manager

(English)

Mitra and Associates

(Centre for Research and Consultancy) 2/17 Iqbal Road, Mohammadpur Dhaka-1207, Tel: 8118065, 9115503, Fax: 9126806

and

MEASURE Evaluation

Carolina Population Center

University of North Carolina at Chapel Hill

Mayer Hashi II Baseline Survey 2015

Questionnaire for MO (MCH-FP), Medical Officer, and Clinic Manager

Face Sheet

		IDENTIFIC	ATION			
DIVISION	DIVISION					
DISTRICT						
UPAZILA/THANA						
UNION/WARD						
CLUSTER						
TYPE OF SERVICE PROVIDERS 01=MO (MCH-FP), 02=Medical Officer, 03=Clinic Manager, 12=RMO						
NAME OF THE RES	PONDENT					
INTERVIEWER VISI	TS					
	1	2	3	FINAL VISIT		
DATE				DAY MONTH		
INTERVIEWER'S NAME				RESULT		
RESULT**						
NEXT VISIT: DATE						
TIME				OF VISITS		
**RESULT CODES: 1 COMPLETED 4 REFUSED 2 NOT AVAILABLE 5 PARTLY COMPLETED 3 POSTPONED 6 OTHER						
SUPERVISOR	OFFICE KEYED BY					
		FIELD EDITOR		EDITOR		
NAME		NAME				
DATE		DATE				

Mayer Hashi II Baseline Survey 2015 Informed Consent for Family Planning Service Provider (MO_MCH-FP, Medical Officer, and Clinic Manager) Questionnaire (Verbal)

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015 Principal Investigator: S. N. Mitra Participating Institute: Mitra and Associates Introductory statement:

My name is ______. I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development and health programs in the country, we conduct different types of surveys. We are now conducting a survey, a part of which aims to assess the knowledge and skills of providers on the provision of IUD, implants, and female and male sterilization. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey.

Why the study being done?

This part of the study will help understand the state and determinants of provider knowledge and skills of provision of long acting and reversible contraceptives (LARC) and permanent method (PM) of family planning in Bangladesh. **What is involved in the study?**

You have been selected randomly for the survey. If you agree to participate, we will ask you some questions related to long acting and reversible contraceptives (LARC) and permanent method (PM) of family planning. If some questions cause you embarrassment or make you feel uncomfortable, you can refuse to answer them. Your opinion is very important to us as it will help the government to take policy decisions to reach goals related to enabling couples to achieve their reproductive intentions. The survey usually takes between 25 and 30 minutes to complete. What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies and future plans leading to program improvements.

Confidentiality:

Whatever information you provide will be kept strictly confidential. It will be used for research purposes only and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit; however, the Government particularly the Ministry of Health and Family Welfare (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since the information you provide will help future program planning.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can speak to an IRB person through "collect call" if necessary, at the phone 001-919-966-3012. You can also speak to the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730-376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065, 02-9115053).At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes	1	No 2 END	
Name of person obtaining consent:		*	_ Signature:	_Date:

(Must be study investigator or individual who has been designated to obtain consent)

Article IV. Section 1: Background

First, I would like to ask you some question on your background like your education and the job.

	QUESTION	RESPONSE	SKIP
(i)	Starting time of interview:	Hour	
		Minute	
(ii) 101	Would you please tell your name?	Name:	
<i>(iii)</i> 102	How old are you?	Year (in completed Years).	1
103	What is your professional qualification?	MBBS1 MBBS with OB/GYN training2 MBBS with higher level training3 Other8 (Specify)	
103a	What is your current job title?	MO-MCH	
104	How long have you been a medical officer (MCH or FW or CC)/ medical officer/clinic manager? Section 4.02 (If less than 1 year write 00)	Year (in completed Years).	
105	How long have you been in this facility? Section 4.03 (If less than 1 year write 00)	Year (in completed Years)	

Section 2a. In-service Training on Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I would like to ask you some questions on the in-service training, orientation, or refresher training on IUD, implant, tubectomy, and NSV you might have received, provided by the Government of Bangladesh and/or other organizations.

In-service training, orientation, or refresher training since 2014

			IUD	Implant	Tubectomy	NSV	PPFP
			а	b	С	d	E
A	201	Since 2014, have you received any in- service training, orientation, or refresher training on?	Yes1 No2 Don't know8 (skip to A201b)	Yes1 No2 Don't know8 (skip to A201c)	Yes1 No2 Don't know8 (skip to A201d)	Yes1 No2 Don't know8 (skip to A201c)	Yes1 No2 Don't know8 (skip to sec 2b)
A	202	In what month and year did you receive this training,	Month Year 	Month Year	Month Year 	Month Year	Month Year

· · · · · ·		1				1
	orientation, or					
	refresher training					
	last time?					
A203	For how mony					
A203	For how many	Days	Days	Days	Days	Days
	days was the	(0 for less	(0 for less	(0 for less	(0 for less	(0 for loss
	training the last	``	•	•	•	(0 for less
	time you	than 1 day)	than 1 day)	than 1 day)	than 1 day)	than 1 day)
	received this					
	training, orientation, or					
	refresher					
	training?					
	u anning :					
A204	Who provided	GoB1	GoB1	GoB1	GoB1	GoB1
	the training,	EH/MH2]	EH/MH2]	EH/MH2]	EH/MH2]	EH/MH2]
	orientation, or	(skip to A201b)	(skip to A201c)	(skip to A201d)	(skip to A201e)	(Sec.2b)
	refresher training the last time you	Other3	Other3	Other3	Other3	Other3
	received?	(specify)	(specify)	(specify)	(specify)	(specify)
		Don't know8	Don't know8 (skip to A201c)	Don't know8 (skip to A201d)	Don't know8- (skip to A201e) ▼	Don't know8 (skip to Sec2b)
		(skip to A201b) ♥	(skip to A2010) V	(skip to A2010) ¥	(skip to A201e) V	(Skip to Seczb) V
A205	Was	Yes1	Yes1	Yes1	Yes1	Yes1
	EngenderHealth/	No2	No2	No2	No2	No2
	Mayer Hashi	Don't know8	Don't know8	Don't know8	Don't know8	Don't know8
	involved in the					
	training					
A206	Did any person	Yes1	Yes1	Yes1	Yes1	Yes1
	from Engender	No2	No2	No2	No2	No2
	Health/ Mayer	Don't know8	Don't know8	Don't know8	Don't know8	Don't know8
	Hashi participate					
	in or observe the					
	training?					

Section 2b: BCC and Interpersonal Communication

Now I would like to ask you some questions on the in-service training, orientation, or refresher training you might have received on BCC and interpersonal communication, provided by the Government of Bangladesh and/or other organizations.

In-service training, orientation, or refresher training on BCC and interpersonal communication since 2014

	QUESTION	RESPONSE	SKIP
B201	Since 2010 have you received any TOT (Training of Trainers) on BCC?	Yes	►B205
B202	On what topic/areas of BCC you have received TOT? Multiple responses	Personal CounselingA Group sessionB Community mobilizationC OtherX (Specify)	

	QUESTION	RESPONSE	SKIP
B203	In which month and year you received TOT on BCC?	Month	
B204	Was Mayer Hashi or <i>EngenderHealth</i> involved in the TOT?	Yes	
B204a	Was any trainer/facilitator from Mayer Hashi or <i>EngenderHealth</i> present in the TOT?	Yes	
B205	Since 2014 have you received any training, orientation, or refresher training on BCC?	Yes	► Sec 3
B206	On what topic/areas of BCC you have received training, orientation, or refresher training? Multiple responses	Personal CounselingA Group sessionB Community mobilizationC OtherX (Specify)	
B207	In which month and year have you received training, orientation, or refresher training on BCC?	Month	
B208	Was Mayer Hashi or <i>EngenderHealth</i> involved in the training, orientation, or refresher training?	Yes	
B208a	Was any trainer/facilitator from Mayer Hashi or <i>EngenderHealth</i> present in the training, orientation, or refresher training?	Yes	

Section 3: Respondent's Involvement on the Provision of Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM)

[I would like to know about your involvement in the provision of LARC/PM.]

	QUESTION	RESPONSE	SKIP
301	Do you provide any services on LARC/PM?	Yes1	
		No2-	→ 304
302	Which methods of LARC/PM do you provide?	IUDA	
	Multiple response	ImplantsB	
		TubectomyC	
		NSVD	
303	When was the last time you have done a procedure of LARC/PM?	Month	
		Year	
		Can't remember when888888	
204		V	
304	Do you provide counseling or treatment to those clients of LARC/PM who experience discomfort,	Yes1	
	side effects, or complications?	No2	
305	Do you supervise any provider who provides	Yes1	
	IUD?	No2-	→307

	QUESTION	RESPONSE	SKIP
306	Which provider?	Nurse or nurse midwifeA	
	Multiple response	FWVB	
		SACMOC	
		ParamedicD	
		OtherX	
		(Specify)	
307	Do you provide training on LARC to providers?	Yes1	
		No2	

Section 4: Skills and Practices on Long Acting Reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I want to discuss with you some issues that are considered by service providers of IUD, IMPLANT, Tubectomy and NSV. The issues are client selection, screening, pre- and post-counseling, method side effects, and others.

[INTERVIEWER: DON'T READ OUT THE ANSWERS, CIRCLE THE CODES RELATED TO THE SPONTANEOUS ANSWERS PROVIDED BY THE RESPONDENT. PROBE THOSE ANSWERS THAT ARE NOT CIRCLED IN THE SPONTANEOUS ANSWER COLUMN.]

QUESTION	RESPONSE				SKIF
		Sponta -neous	Promp -ted	No/ DK	
What are the conditions under which a woman can accept IUD	Women who have at least 1 living child . Women who don't want child for long	1	2	3	
or can be recommended for having an IUD?	time or don't want child Women who can not use hormonal	1	2	3	
	FP method (Pill,Implant,Injection)	1	2	3	
	Regular menstruation	1	2	3	
	Within first 5 days of menstruation	1	2	3	
	Other	1	2	3	
	(Specify)				
What are the conditions under which a woman	Women who have no child Women who have been suffering	A			
	from RTI	B			
cannot be recommended	Menstruation stopped	C			
for IUD?	Pergnancy	D			
	Irregular menstruation				
	Excessive menstrual bleeding				
Multiple response	Cronic jaundice				
	Breast cancer				
	Other	X			
	(Specify)	-			
		Sponta -neous	Promp -ted	No/ DK	

Section 4a: Skills and Practices on IUD

QUESTION	RESPONSE				SKIP
		Sponta -neous	Promp -ted	No/ DK	
What are the probable side effects of IUD?	Abdominal pain Excessive bleeding in between the two menstrual cycle Spotting Abnormal menstrual bleeding White discharge/excessive white discharge The thread of IUD come out Other(Specify)	1 1 1	2 2 2 2 2 2 2 2 2	3 3 3 3 3 3 3	
An IUD client comes to you with excessive bleeding, what will you do? Multiple response	Examine her to know the reasons for excessive bleeding Provide treatment for bleeding Refer to higher level for treatment Remove IUD Other	B C D			
An IUD client comes to you with abdominal pain, what will you do? Multiple response	Examine her to know the probable reasons for painA Provide treatment and assure her for further serviceB Refer her to higher level for treatmentC Remove IUDD OtherX				
	(Specify)	Sponta -neous	Promp -ted	No/ DK	
(Pre-counseling) A woman comes to you for accepting IUD, what	Explain advantages and disadvantages of IUD Explain probable side effects, discomfort and complications of IUD	1	2	3	
advice/counseling should you be provide to her?	Ensure that the client does not have RTI or infection in reproductive organ Ensure that the client understood the advantages and disadvantages of IUD	1	2	3	
	before she made the decision Ensure that she is still under regular menstrution, and not pregnant Other(Specify)	1 1 1	2 2 2	3 3 3	
		Sponta -neous	Promp -ted	No/ DK	

	QUESTION	RESPONSE	RESPONSE			
			Sponta -neous	Promp -ted	No/ DK	
))	(Post-counseling) What important	Give her the follow-up card Remind her about the probable side effects and discomfort and assure	1	2	3	
	advice/counseling should you provide to a woman who just	her of the follow-up Remind her the procedure of follow-up Encourage the client to contact with	1 1	2 2	3 3	
	accepted IUD?	service provider if there is any side effects or complications Encourage the client to check the	1	2	3	
		thread Advise the client to avoid sexual intercourse for 2-3 days	1	2	3	
		Ensure that the client understood the main points of counseling Other(Specify)	1 1	2 2	3 3	
)	Do you or your facility do follow up of IUD clients?	YesNo				
)	When is the timing of follow up?	Within 3 days Within 7 days After 1 month 2-5 months	В С			
	Multiple response	6-11 months After 1 year When problem arises Other	E F G			
		(Specify) DK	Z	_		
			Sponta -neous	Promp -ted	No/ DK	
)	What advice/counseling should you provide to a IUD user at the time of follow-up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications,	1	2	3	
		discomfort Assure for any other service if she has no side-effects, complication or	1	2	3	
		discomfort Other (Specify)	1 1	2 2	3 3	

Section 4b: Skills and Practices on IMPLANT

QUESTION	RESPONSE				SKIP
		Sponta -neous	Promp -ted	No/ DK	
What are the conditions under which a woman can accept IMPLANT or can be recommended for adopting IMPLANT?	Women who want to avoid pregnancy for a long time Women who have no child Ensure that she is still under regular menstrution, i.e., she is not pregnant Other(Specify)	1 1 1 1	2 2 2 2 2	3 3 3 3	
		Sponta -neous	Promp -ted	No/ DK	
What are the probable side effects of IMPLANT?	Menstruation stopped Excessive bleeding Spotting Weight gain Motion of vomiting Depression Pain in arm Other(Specify)	1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 2 2 2 2	3 3 3 3 3 3 3 3 3 3 3	
An IMPLANT client comes to you with excessive bleeding, what would you do? Multiple response	Examine her to know the reasons for excessive bleeding Provide treatment for bleeding Refer her to higher level for treatment Remove IMPLANT Other(Specify)	B C D			
An IMPLANT client comes to you with menopause, what would you do? Multiple response	Check pregnancy If she is not pregnant, counsel and assure that it is not a problem Remove IMPLANT Other(Specify)	В С			
		Sponta -neous	Promp -ted	No/ DK	
 (Pre-counseling) A woman comes to you for accepting IMPLANT, what advice/counseling	Explain advantages and dis- advantages of IMPLANT Explain probable side effects, discomfort and complications of IMPLANT Ensure that the client understood the		2	3 3	
should you be provides her?	advantages and disadvantages of IMPLANT before she made the decision Other	1 1	2 2	3 3	

		Spont a- neous	Promp -ted	No/ DK	
	Give her the follow-up card Remind her about the probable side	1	2	3	
advice/counseling would vou provide to a woman	effects and discomfort and assure her of the follow-up Remind her the procedure of follow-up Encourage the client to contact with	1 1	2 2	3 3	
Implant?	service provider if there is any side effects or complications Remind her that there may be little pain	1	2	3	
	on the arm Advise the client to avoid sexual intercourse for 2-3 days	1	2 2	3 3	
	Ensure that the client understood the main points of counseling Other(Specify)	1 1	2 2	3 3	
Do you or your facility	Yes1 No2				
follow-up of implant clients?	Within 3 days Within 7 days After 1 month 2-5 months 6-11 months	B C D			
wuitipie response	After 1 year When problem arises Other (Specify) DK	G X			
		Sponta -neous	Promp -ted	No/ DK	
would you provide to IMPLANT client at the time of follow-up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications,	1	2	3	
	discomfort Assure for any other service if she has no side-effects, complication or	1	2	3	
	discomfort Other(Specify)	1 1	2 2	3 3	

Section 4c: Skills and Practices on Tubectomy

		Sponta -neous	Promp -ted	No/ DK	
What are the conditions under which a woman can accept tubectomy or can be recommended for adopting tubectomy?	Women who do not want to have any more children and have at least 1 living child Women who do not want to have any more children and the age of the youngest child is at least 2 years	1	2	3	
	Women who have 2 nd time CS Husband agreed for tubectomy Other(Specify)	1	2 2 1	3 3	
		Sponta -neous	Promp -ted	No/ DK	
 (Per-counseling) A woman comes to you 	Explain advantages and disadvantages of tubectomy Explain probable side effects,	1	2	3	
for accepting tubectomy, what advice/counseling should be provided to	discomfort and complications of Tubectomy Ensure that the client does not have	1	2	3	
her?	any health conditions unfavorable to the operation Ensure that the client understood the advantages and disadvantages of	1	2	3	
	tubectomy before she made the decision Other(Specify)	1 1	2 2	3 3	
	•	Sponta -neous	Promp -ted	No/ DK	

	Cive her the follow up card	1	2	3	
(Post-counseling)	Give her the follow-up card Remind her about the probable side	I	2	3	
What important	effects and discomfort and assure				
advice/counseling would	her of the follow-up	1	2	3	
-	Remind her the procedure of follow-up	1	2	3	
you provide to a woman	Encourage the client to contact with	I	2	3	
who has just accepted	service provider if there is any side				
tubectomy?	effects or complications	1	2	3	
	Remind her to take full rest for 2 days	1	2	3	
	Encourage her to avoid heavy work or		2	Ŭ	
	avoid lifting heavy weight for 3 weeks	1	2	3	
	Reminf her to take medications that	•	-	Ŭ	
	have been given to her	1	2	3	
	Ensure that the client understood		_	Ū	
	the main points of counseling	1	2	3	
	Other	1	2	3	
	Other(Specify)				
Do you or your facility	Yes	1			
follow up tubectomy	No	2			
clients?					
unento.					
When is the timing of	Within 3 days	A			
•	Within 7 days				
follow up?	After 1 month	C			
Multiple responses	2-5 months				
	6-11 months	E			
	After 1 year	F			
	When problem arises	G			
	Other	X			
	(Specify)				
	DK	Z			

		Sponta -neous	Promp -ted	No/ DK	
What advice/counseling would you provide to tubectomy acceptor at the time of follow up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications, discomfort Assure for any other service if she has no side-effects, complication or discomfort Other	1 1 1 1	2 2 2 2 2	3 3 3 3 3	

Section 4d: Skills and Practices on NSV

QUESTION	RESPONSE				SKIP
		Sponta -neous	Promp -ted	No/ DK	
What are the conditions under which a man can accept NSV or can be recommended for having?	Men who do not want to have any more children and have at least 1 living child Men who do not want to have any more children and the age of the	1	2	3	
	youngest child is at least 2 years Wife agreeable to husband having		2	3	
	NSV Other(Specify)		2 2	3 3	
		Sponta -neous	Promp -ted	No/ DK	
 (Pre-counseling) What advice/counseling 	Explain advantages and disadvantages of NSV Explain probable side-effects,	1	2	3	
should be provided to a man comes to you for	discomfort, and complications of NSV Ensure that the client does not have	1	2	3	
accepting NSV,?	any health conditions unfavorable to the operation Ensure that the client understood the advantages and disadvantages of	1	2	3	
	tubectomy before she made the decision Other(Specify)	1 1	2 2	3 3	

		Sponta -neous	Promp -ted	No/ DK	
(Post-counseling)	Give her the follow-up card Remind him about the probable	1	2	3	
•	discomforts and assure him of the follow-up	1	2	3	
be provided to a man who has just accepted NSV?	Remind him the procedure of follow-up Encourage the client to contact with	1	2	3	
	service provider if there is any complications Encourage her to avoid heavy work	1	2	3	
	or avoid lifting heavy weight for 1 day Remind him to use condom during sex for a period of 3 months	1	2	3	
	Ensure that the client understood the main points of counseling	1	2	3	
	including the follow up procedures Other	1 1	2 2	3 3	
Do you or your facility do follow-up for NSV clients?	Yes No				
	Within 3 days Within 7 days After 1 month 2-5 months	В С			
Multiple responses	6-11 months After 1 year When problem arises Other (Specify)	F G			
	<u>DK</u>	Sponta -neous	Promp -ted	No/ DK	
should you provide to NSV acceptor at the time of follow up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications,	1	2	3	
	discomfort Assure for any other service if she has no side-effects, complication or	1	2	3	
	discomfort Other (Specify)	1 1	2 2	3 3	

Section 5: Postpartum IUD and Tubectomy [Now, I would like to know on new policies or changed policies regarding family planning from you]

501	Are you aware of the government policy which encourages that IUD may be offered to those women who deliver at facilities, immediately <i>after</i> <i>delivery</i> ?	Yes1 No2
502	Are you aware of the government policy which encourages that tubectomy may be offered to those women who deliver at facilities, right <i>at delivery</i> ?	Yes1 No2
503	Are you aware of the government policy which encourages that IUD may be offered during <i>C</i> -section delivery?	Yes
504	Are you aware of the government policy which encourages that tubectomy may be offered during <i>C-section</i> delivery?	Yes1 No2
505	Do community-level providers such as FWAs (Family Welfare Assistants), FWVs, or others disseminate the postpartum IUD and postpartum tubectomy information to their catchment populations?	Yes1 No2
506	Have you conducted delivery at any public-sector or private-sector facility(s) in the last 6 months?	Yes1 No2
507	Do you offer the postpartum IUD to your delivery clients?	Yes1 No2
508	Do you offer the postpartum tubectomy to your delivery clients?	Yes1 No2

Section 6: Policy changes or new policies

SI. #			601a-609a. Is it being implemented?
601	DGHS staff nurses after being trained are permitted to provide IUD services	Yes1 No2	Yes1 No2
602	Nurses at private hospitals after being trained are permitted to provide IUD services	Yes1 No2	Yes1 No2
603	Women who have not yet given any birth of a child are allowed to accept IMPLANT	Yes1 No2	Yes1 No2
604	Post-partum family planning services has been added in the maternal health services and such services are available in the DGHS hospitals	Yes1 No2	Yes1 No2
605	Postpartum family planning services have been added in private-sector facilities	Yes1 No2	Yes1 No2
606	The DGHS facilities have not required separate registration from DGFP to receive family planning commodities and funds if they want to provide family planning services	Yes1 No2	Yes1 No2
607	The GOB-registered private or NGO facilities have not required separate registration from the DGFP to receive family planning commodities and funds if they want to provide family planning services	Yes1 No2	Yes1 No2
608	Fascial interposition in NSV is now mandatory to ensure greater effectiveness of the procedure	Yes1 No2	Yes1 No2
609	DGFP approved the use of Tab Ibuprofen after IUD insertion which will help prevent pain and bleeding among new users	Yes1 No2	Yes1 No2
610	Ending time of Interview:	Hour Minute	

Now, I am ending the interview here, if have you any question then you can ask me. Thank you for providing the information.

Appendix C.5. Questionnaire for Obstetrician/Gynecologist (OB/GYN)

Mayer Hashi II (MH II) Baseline Survey 2015

Questionnaire for Obstetrician/Gynecologist (OB/GYN)

(English)

Mitra and Associates

(Centre for Research and Consultancy) 2/17 Iqbal Road, Mohammadpur Dhaka-1207, Tel: 8118065, 9115503, Fax: 9126806

and

MEASURE Evaluation

Carolina Population Center University of North Carolina at Chapel Hill USA

Mayer Hashi II Baseline Survey 2015

Questionnaire for Obstetrician/Gynecologist (OB/GYN)

Face Sheet

IDENTIFICATION	
DIVISION	
DISTRICT	
UPAZILA/THANA	
UNION/WARD	
CLUSTER	
TYPE OF SERVICE PROVIDER	12
NAME OF THE RESPONDENT	

INTERVIEWER VISITS									
	1	2	3	FINAL	VISIT				
DATE				DAY MONTH YEAR2					
INTERVIEWER'S NAME RESULT**				- INTV. CODE RESULT					
NEXT VISIT: DATE TIME				TOTAL NO OF VISITS					
**RESULT CODES: 1 COMPLETED 4 REFUSED 2 NOT AVAILABLE 5 PARTLY COMPLETED 3 POSTPONED 6 OTHER									
SUPERVISO		FIELD EDI			KEYED BY				
DATE	D/	ATE							

Mayer Hashi II Baseline Survey 2015 Informed Consent for Family Planning Service Provider (OB/GYN) Questionnaire (Verbal)

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement:

My name is ______. I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development and health programs in the country, we conduct different types of surveys. We are now conducting a survey, a part of which aims to assess the knowledge and skills of providers about IUD, implants, and female and male sterilization. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey.

Why the study being done?

This part of the study will help understand the state and determinants of provider knowledge and skills of providing long acting and reversible contraceptives (LARC) and permanent methods (PM) of family planning in Bangladesh.

What is involved in the study?

You have been selected randomly for the survey. If you agree to participate, we will ask you some questions related to LARCs and permanent methods (PM) of family planning. If some questions cause you embarrassment or make you feel uncomfortable, you can refuse to answer them. Your opinion is very important to us as it will help the government to take policy decisions to reach goals related to enabling couples to achieve their reproductive intentions. The survey usually takes between 25 and 30 minutes to complete.

What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies and future plans leading to program improvements.

Confidentiality:

Whatever information you provide will be kept strictly confidential. It will be used for research purposes only and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit; however, the Government particularly the Ministry of Health and Family Welfare (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since the information you provide will help future program planning.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, CB # 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can speak to an IRB person through "collect call" if necessary, at the phone 001-919-966-3012. You can also speak to the Dhaka-based UNC MEASURE Evaluation Advisor (Phone: 01730376458). If you have further questions regarding the nature of this study you may also contact Mitra Associates2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone02-8118065, 02-9115053).At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes	1	No 2 END	
Name of person obtaining consent:		*	Signature:	Date:

(Must be study investigator or individual who has been designated to obtain consent)

Article V. Section 1: Background

	QUESTION	RESPONSE	SKIP
)	Starting time of interview:	Hour minute	
) 101	Would you please tell your name?	Name:	
) 102	How old are you?	Year (in completed Years).	
103	What is your professional qualification?	MBBS	
103a	What is your current job title?	OB/GYN1 Other8 (Specify)	
104	How long have you been a Obstetrician/ Gynecologist (OB/GYN)? (If less than 1 year write 00)	Year (in completed Years)	
105	How long have you been in this facility? Section 5.02 (If less than 1 year write 00)	Year (in completed Years)	

First, I would like to ask you some question on your background like your education and job.

Section 2a. In-service Training on Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I would like to ask you some questions on the in-service training, orientation, or refresher training you might have received, provided by the Government of Bangladesh and/or other organizations.

In-service training, orientation, or refresher training on LARC/PM since 2014

		IUD	Implant	Tubectomy	NSV	PPFP
		а	b	C	d	f
h ru ir tı o ru	Since 2010, nave you received any n-service raining, prientation, or efresher raining on?	Yes1 No2 Don't know8 (skip to 201b)	Yes1 No2 Don't know8 (skip to 201c)	Yes1 No2 Don't know 8 (skip to 201d)	Don't know.8	Yes

A202	In what month and year did you receive this training, orientation, or refresher training last time?	Month □□	Month	Month	Month .	Month
A203	For how many days was the training the last time you received this training, orientation, or refresher training?	0 for less (0 for less than 1 day)	0 for less than 1 day)	days (0 for less than 1 day)	0 for less (0 for less than 1 day)	0 for less than 1 day)
A204	Who provided the training, orientation, or refresher training the last time you received?	GoB1 EH/MH2 (skip to A201b) Other3 (specify) Don't know8 (skip to A201b)	GoB1 EH/MH2 (skip to A201c) Other3 (specify) Don't know8 (skip to A201c)	GoB1 EH/MH2 (skip to A201d) Other3 (specify) Don't know8 (skip to A201d)	GoB2 EH/MH2 (skip to A201e) Other3 (specify) Don't know8 (skip to A201e)	GoB1 EH/MH2 (Sec.2b) Other3 (specify) Don't know8 (skip to Sec2b)
A205	Was Engender Health/ Mayer Hashi involved in the training	Yes1 No2 Don't know8	Yes 1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know . 8	Yes1 No2 Don't know8
A206	Did any person from Engender Health/Mayer Hashi participate in or observe the training?	Yes1 No2 Don't know8	Yes 1 No2 Don't know8	Yes1 No2 Don't know8	Yes1 No2 Don't know . 8	Yes 1 No 2 Don't know 8

Section 2b: BCC and Interpersonal Communication

Now I would like to ask you some questions on the in-service training, orientation, or refresher training you might have received on BCC and interpersonal communication, provided by the Government of Bangladesh and/or other organizations.

In-service training, orientation, or refresher training on BCC and interpersonal communication since 2014.

B201	Since 2014 have you received any TOT (Training	Yes 1	
	of Trainers) on BCC?	No	▶B205
B202	On what topic/areas of BCC you have received	Personal CounselingA	
	TOT?	Group sessionB	
	Multiple responses	Community mobilizationC	
		OtherX	
		(Specify)	
B203	In which month and year you received TOT on	Month	
	BCC?	Year	
B204	Was Mayer Hashi or <i>EngenderHealth</i> involved in	Yes 1	
	the TOT?	No2	
		Don't know 8	
B204a	Was any trainer/facilitator from Mayer Hashi or	Yes 1	
	EngenderHealth present in the TOT?	No2	
		Don't know 8	
B205	Since 2014 have you received any training,	Yes 1	
	orientation, or refresher training on BCC?	No2	_Sec 3
		Can't remember 8	
B206	On what topic/areas of BCC you have received	Personal CounselingA	
	training, orientation, or refresher training?	Group sessionB	
	Multiple response	Community mobilizationC	
		OtherX	
		(Specify)	
B207	In which month and year have you received	Month	
	training, orientation, or refresher training on BCC?	Year	
B208	Was Mayer Hashi or Engender Health involved in	Yes 1	
	the training, orientation, or refresher training?	No2	
		Don't know 8	
B208a	Was any trainer/facilitator from Mayer Hashi or	Yes 1	
	EngenderHealth present in the training,	No 2	
	orientation, or refresher training?	Don't know 8	

Section 3: Respondent's Involvement on the Provision of Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM)

	QUESTION	RESPONSE	SKIP
301	Do you provide any services on LARC/PM?	Yes1	
		No2—	304
302	Which methods of LARC/PM do you provide?	IUD A	
		ImplantsB	
	Multiple response	TubectomyC	
		NSV D	
303	When was the last time you have done a procedure of LARC/PM?	Month	
		Year	
		Can't remember when	
304	Do you provide counseling or treatment to those	Yes1	
	clients of LARC/PM who experience discomfort, side effects, or complications?	No2	

[I would like to know about your involvement in the provision of LARC/PM.]

Section 4: Skills and Practices on Long Acting Reversible Contraceptives (LARC) and Permanent Methods (PM)

Now I want to discuss with you some issues that are considered by service providers of IUD, IMPLANT, Tubectomy and NSV. The issues are client selection, screening, pre- and post-counseling, method side effects, and others.

[INTERVIEWER: DON'T READ OUT THE ANSWERS, CIRCLE THE CODES RELATED TO THE SPONTANEOUS ANSWERS PROVIDED BY THE RESPONDENT. PROBE THOSE ANSWERS THAT ARE NOT CIRCLED IN THE SPONTANEOUS ANSWER COLUMN.]

	QUESTION	RESPONSE				SKIP
			Sponta- neous	Promp- ted	No/ DK	
	What are the conditions under which a woman can accept IUD or can be	Women who have at least 1 living child Women who don't want child for long	1	2	3	
	recommended for having an IUD?	time or don't want child Women who can not use hormonal	1	2	3	
		FP method	1	2	3	
		Regular menstruation	1	2	3	
		Within first 5 days of menstruation	1	2	3	
		Other(Specify)	1	2	3	
	What are the conditions under which a woman cannot be recommended for IUD? Multiple response	Women who have no childA Women who have been suffering from RTIB Menstruation stopped C Pergnancy D Irregular menstruation E Excessive menstrual bleeding F Cronic jaundice G Breast cancer H Other(Specify) X				
			Sponta- neous	Promp -ted	No/ DK	
	What are the probable side effects of IUD?	Abdominal pain Excessive bleeding in between the two	1	2	3	
		menstrual cycle		2	3	
		Spotting		2	3	
		Abnormal menstrual bleeding White discharge/excessive white		2	3	
		discharge		2	3	
		The thread of IUD come out		2	3	
		Other(Specify)	1	2	3	

Section 4a: Skills and Practices on IUD

401d 401f.	An IOD Unche Comeo to you	Examine her to know the reasons for e bleeding Provide treatment for bleeding Refer to higher level for treatment Remove IUD Other (Specify) Examine her to know the probable rea Provide treatment and assure her for f	sons for	A B C C D X pain . A	
	with abdominal pain, what will you do? Multiple response	Refer her to higher level for treatment Remove IUD Other(Specify)		C	
			Sponta- neous	Promp- ted	No/ DK
401g	(Pre-counseling) A woman comes to you for	Explain advantages and disadvantages of IUD	1	2	3
	accepting IUD, what advice/counseling should you be provide to her?	Explain probable side effects, discomfort and complications of IUD . Ensure that the client does not have	1	2	3
		RTI or infection in reproductive organ Ensure that the client understood the advantages and disadvantages of	1	2	3
		IUD before she made the decision Ensure that she is still under regular menstrution, and not pregnant Other(Specify)	1 1	2 2 2	3 3
		(Specity)	Sponta- neous	Promp- ted	No/ DK
401h	(Post-counseling) What important advice/counseling should you	Give her the follow-up card Remind her about the probable side effects and discomfort and assure	1	2	3
	provide to a woman who just accepted IUD?	her of the follow-up Remind her the procedure of follow-up	1	2 2	3 3
		Encourage the client to contact with service provider if there is any side effects or complications Encourage the client to check the	1	2	3
		thread Advise the client to avoid sexual	1	2	3
		intercourse for 2-3 days Ensure that the client understood the	1	2	3
		main points of counseling Other(Specify)	1 1	2 2	3 3

401i	<i>Is it compulsory to follow up to IUD clients?</i>	Yes1 No2				
) 401j	<i>Do you or your facility do follow up to IUD clients?</i>	Yes1 No2				
) 401k	When is the timing of follow up? Multiple responses	Within 3 days Within 7 days After 1 month 2-5 months 6-11 months After 1 year When problem arises Other (Specify) DK	B C D E F G X			
			Sponta- neous	Promp- ted	No/ DK	
) 4011	What advice/counseling should you provide to a IUD user at the time of follow-up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications, discomfort Assure for any other service if she has no side-effects, complication or discomfort Other(Specify)	1 1 1 1	2 2 2 2 2	3 3 3 3	

Section 4c: Skills and Practices on Tubectomy

			Sponta- neous	Promp- ted	No/ DK
403a	What are the conditions under which a woman can accept tubectomy or can be recommended for adopting tubectomy?	Women who do not want to have any more children and have at least 1 living child Women who do not want to have any more children and the age of the	1	2	3
		youngest child is at least 2 years Women who have 2 nd time CS Husband agreed for tubectomy Other(Specify)	1 1 1 1	2 2 2 2	3 3 3 3
			Sponta- neous	Promp- ted	No/ DK
403g	A Wollian Collico to you loi	Explain advantages and disadvantages of tubectomy	1	2	3
	accepting tubectomy, what advice/counseling should be provided to her?	Explain probable side effects, discomfort and complications of Tubectomy Ensure that the client does not have	1	2	3
		any health conditions unfavorable to the operation Ensure that the client understood the	1	2	3
		advantages and disadvantages of tubectomy before she made the decision Other(Specify)	1 1	2 2	3 3
		(Specity)	Sponta- neous	Promp- ted	No/ DK
403h	(Post-counseling) What important advice/counseling would you	Give her the follow-up card Remind her about the probable side effects and discomfort and assure her of the follow-up	1	2	3
	provide to a woman who has just accepted tubectomy?	Remind her the procedure of follow-up Encourage the client to contact with	1	2	3
		service provider if there is any side effects or complications	1	2	3
		Remind her to take full rest for 2 days Encourage her to avoid heavy	1	2	3
		work or avoid lifting heavy weight for 3 weeks	1	2	3
		Reminf her to take medications that have been given to her Ensure that the client understood	1	2	3
		the main points of counseling	1 1	2 2	3 3
	1	(Specify)	1	1	1

)	<i>Do you or your facility follow up tubectomy clients?</i>	Yes1 No2				
)	When is the timing of follow up? Multiple responses	Within 3 days Within 7 days After 1 month 2-5 months 6-11 months After 1 year When problem arises Other (Specify) DK	B D E F G X			
			Sponta- neous	Promp -ted	No/ DK	
)	What advice/counseling would you provide to tubectomy acceptor at the time of follow up?	Provide counseling and treatment immediately if client complains of side effects, complications and discomfort Refer to appropriate place if client complains of side effects, complications, discomfort Assure for any other service if she has no side-effects, complication or discomfort	1 1 1 1 1	2 2 2 2	3 3 3 3 3	

Section 5: Postpartum IUD and Tubectomy

[Now, I would like to know about postpartum family planning from you.]

SI. #	Questions	
501	Are you aware of the government policy which encourages that IUD may be offered to those women who deliver at facilities, immediately after delivery?	Yes1 No2
502	Are you aware of the government policy which encourages that tubectomy may be offered to those women who deliver at facilities, right at delivery?	Yes1 No2
503	Are you aware of the government policy which encourages that IUD may be offered during C- section delivery?	Yes1 No2
504	Are you aware of the government policy which encourages that tubectomy may be offered during C-section delivery?	Yes1 No2
505	Do community-level providers such as FWAs (Family Welfare Assistants), FWVs, or others disseminate the postpartum IUD and postpartum tubectomy information to their catchment populations?	Yes1 No2
506	Have you conducted delivery at any public- sector or private-sector facility(s) in the last 6 months?	Yes1 No2
507	Do you offer the postpartum IUD to your delivery clients?	Yes1 No2

SI. #	Questions		
508	Do you offer the postpartum tubectomy to your delivery clients?	Yes1 No2	
509	Have you performed postpartum IUD or postpartum tubectomy or both in the last 6 months?	Yes1 No2	

Section 6: Policy changes or new policies

[Now, I would like to discuss with you about some policies regarding family planning services from you.]

SI. #			601a-609a. Is it being
			implemented?
601	DGHS staff nurses after being trained are	Yes1	Yes1
	permitted to provide IUD services	No2	No2
602	Nurses at private hospitals after being trained	Yes1	Yes1
	are permitted to provide IUD services	No2	No2
603	Women who have not yet given any birth of a	Yes1	Yes1
	child are allowed to accept IMPLANT	No2	No2
604	Post-partum family planning services has	Yes1	Yes1
	been added in the maternal health services	No2	No2
	and such services are available in the DGHS	•	
605	hospitals Postpartum family planning services have	No. 4	Yes 1
005	been added in private-sector facilities	Yes1 No2	No2
606	The DGHS facilities have not required		Yes 1
000	separate registration from DGFP to receive	Yes1 No2	No2
	family planning commodities and funds if they	₩02	NUZ
	want to provide family planning services		
607	The GOB-registered private or NGO facilities	Yes1	Yes1
	have not required separate registration from	No2	No2
	the DGFP to receive family planning	•	
	commodities and funds if they want to provide		
608	family planning services Fascial interposition in NSV is now mandatory		Vee 4
000	to ensure greater effectiveness of the	Yes1	Yes1
	procedure	No2	No2
609	DGFP approved the use of Tab Ibuprofen	Yes1	Yes 1
	after IUD insertion which will help prevent pain	No2	No2
	and bleeding among new users	↓ · · · · · · · · · · · · · · · · · · ·	
610	Ending time of Interview:	Hour	
		Minuto	
	n anding the interview here, if have you any gue	Minute	

Now, I am ending the interview here, if have you any question then you can ask me. Thank you for providing the information.

Appendix C.6. Facility Readiness Questionnaire

Mayer Hashi II (MH II) Baseline Survey 2015

Facility Readiness Questionnaire

(English)

Mitra and Associates

(Centre for Research and Consultancy)

2/17 Iqbal Road, Mohammadpur

Dhaka-1207, Tel: 8118065, 9115503, Fax:9126806

and

MEASURE Evaluation

Carolina Population Center

University of North Carolina at Chapel Hill

USA

Facility Readiness Questionnaire

Face Sheet

IDENTIFICATION	
DIVISION	
DISTRICT	
UPAZILA/THANA	
UNION/WARD	
CLUSTER	
TYPE OF THE FACILITY:	
1=District Hospital, 2=Medical College Hospital, 3=MCWC, 4=UHC, 5=UHFWC, 6=NGO Clinic, 7=Private Clinic,8=UPHCP, RD=9,	
10=Private medical college	
NAME OF THE RESPONDENT	

IDENTIFICATION								
GPS READING:					Degre	ees Minutes Thousandths		
			Ν	[
LATIT	UDE				Degre	es Minutes Thousandths		
			E					
LONG	ITUDE							
ALTIT	UTE/ELEVATION							
WAYPOINT								
	2							
	1	2		3				
						DAY		
DATE								
						YEAR		
INTERVIEWER'S								
NAME								
						RESULT		
RESULT**								
NEXT VISIT: DATE								
						—		
						OF VISITS		
TIME								
**RESULT CODES: 1	COMPLETED	3 P0	OSTP	ONED	5 PA	RTLY COMPLETED		
2	2 NOT AVAILABL	.E 4 RI	EFUS	ED	6 ОТ	HER		
						(SPECIFY)		

IDENTIFICATION					
SUPERVISOR	FIELD EDITOR	OFFICE EDITOR	KEYED BY		
DATE	DATE				

Mayer Hashi II Baseline Survey 2015

Informed Consent for Facility Readiness Questionnaire

(Verbal)

Title of Research: Mayer Hashi II (MHII) Baseline Survey 2015

Principal Investigator: S. N. Mitra

Participating Institute: Mitra and Associates

Introductory statement:

My name is ______. I have come from Mitra and Associates, a private research organization, located in Dhaka. To assist in the implementation of socio-development and health programs in the country, we conduct different types of surveys. We are now conducting a survey, a part of which aims to assess the facility readiness for providing IUD, implants, and female and male sterilization. The survey is paid for by the United States Agency for International Development (USAID). The survey is being coordinated by the University of North Carolina in Chapel Hill, North Carolina, USA. The data will be examined by Mitra and Associates and by researchers at the University of North Carolina in Chapel Hill, North Carolina, USA. I would very much appreciate your participation in this survey.

Why the study being done?

This part of the study will help understand the state and determinants of facility readiness for providing IUD, implants, and female and male sterilization in Bangladesh.

What is involved in the study?

This part of the study will collect information from this facility. You have been selected as a key informant for data collection from this facility. I would like to ask you some questions about your facility as a way of better understanding how to serve the population and to get a picture of services availability specially IUD, implants, and female and male sterilization methods. The survey usually takes between 50 and 60 minutes to complete.

What are the risks and benefits of this study?

By providing information you will not have any risk what so ever, rather this will help the government and policy planners to formulate policies and future plans leading to program improvement.

Confidentiality:

Whatever information you provide will be kept strictly confidential. It will be used for research purposes only and will be seen only by staff and researchers at the organizations mentioned.

Is there any compensation for participating in the study?

Your participation in the study is voluntary and promises no financial benefit; however, the Government particularly Ministry of Health and Family Planning (MOHFW) will be benefited from the study.

Right to refuse or withdraw:

Participation in this survey is voluntary and you can choose not to answer any individual question or all of the questions. However, we hope that you will participate in this survey since the information will help future program planning.

Who do I contact if I have questions or problems?

If you wish to know more about your rights as a participant in this study you may contact the Bangladesh Medical Research Council (BMRC), Mohakhali, Dhaka (Phone: 8819311, 8828396) or the Institutional Review Board (IRB) at the School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400, U.S.A. You can speak to an IRB person through "collect call" if necessary at the phone number 001-919-966-3012. You can also speak to the Dhaka-based UNC MEASURE Evaluation Advisor at the Phone: 01730-376458. If you have further questions regarding the nature of this study you may also contact Mitra Associates 2/17, Iqbal Road, Block-A, Mohammadpur, Dhaka-1207 or (phone 02-8118065, 02-9115053). At this time, do you want to ask me anything about the survey?

May I begin the interview now?	Yes 1	No 2	END			
Name of person obtaining consent:		_Signature:	Date:			
(Must be study investigator or individual who has been designated to obtain consent)						

Starting Time

Hours	
Minutes	

Instructions for interviewer:

• Please identify a key informant for data collection from the facility. Request the head of the facility or his/her representative to designate a key informant for the interview.

• Collect data through (a) person-to-person interview with the key informant, (b) direct observation of the facility rooms, equipment, and supplies, and (c) observation of facility records (such as service statistics, logbook, and forms).

• Request the key informant to show you the locations and rooms to be observed for filling up different sections of the questionnaire.

• In case of Upazilla Health Complex, District Hospital, or medical college hospital, locate (with the help of the key informant) the places or rooms where Long-acting and reversible Contraceptives (LARC) and Permanent Methods (PM) are served and records are available. Then, collect information through interview or observation.]

Name of the key informant: _____ Name of the second informant : _____

Designation of the key informant: ______ Designation of the second informant: ______

A: Information on service availability (TO BE COLLECTED FROM THE KEY INFORMANT)

Availa	bility of Family Planning Services		
A1	What Family Planning (FP) methods are	NSV A	If none of A-D is
	provided from the facility?	Female sterilizationB	circled end
		ImplantC	collection.
		IUDD	
		Injectables E	
		PillsF	
		CondomsG	
		No methods deliveredX	

A2	Does the facility provide NSV, female					
	sterilization (FS), implant (Impl), or IUD in any particular day/days of the week or month?		NSV	FS	Impl.	IUD
		Every working day	1	1	1	1
		2 days/week	2	2	2	2
		1 day/week	3	3	3	3
		2 days/month	4	4	4	4
		1 day/month	5	5	5	5
		Other	6	6	6	6
		No service	7	7	7	7
A3	When was the latest date NSV, female sterilization, implant, or/and IUD was provided? (THE KEY INFORMANT MAY CONSULT FACILITY RECORD TO FIND DATES) Write '98' if not provide any methods in the facility		_	1	1	
			NSV	FS	Impl.	IUD
		Day				
		Month				
		Year				
		NA				
A4	Does the facility provide the government	Yes				1
	permissible reimbursement for wage compensation and food/transport allowances to NSV, female sterilization, implant, and IUD clients?	No				2
A5	Does the facility provide additional incentive		NSV	FS	Impl.	IUD
	payments for any services beyond permissible reimbursement of compensation	Yes	1	1	1	1
	or allowances?	No	2	2	2	2
		NA	8	8	8	8

A6	Does the facility charge any fee for NSV,						
	female sterilization, implant and IUD?		NSV	FS	Impl.	IUD	
		Veg fixed for	1	1	1	1	
		Yes, fixed fee					
		Yes, scaled fee	1	1	1	1	
		No fee	2	2	2	2	
		NA	8	8	8	8	
Manage	ement /supervision / quality improvement						
A7	Does the facility have any written or unwritten	Yes, written reg	ulation			1	
	regulation that could limit clients' access to all or some FP services	Yes, unwritten r	egulati	on		2	
		No				3	
A8	Is there any mechanism at the facility to	Yes				1	
	assess the quality of service	No					Skip to Sec B
A8a	What is that mechanism?	DGFP-officer/Fa					
	Anything else?	Other external o					
		Internal quality teamC OtherX					
			^				
A8b	Is the mechanism occurs in regular interval or	Yes				1	
	not?	No				2-1	A9
A8c	How frequently does this happen?	Monthly				1	
		Quarterly				2	
		Six monthly				3	
		More than six month4					
		Other 7 -					•
			(Speci	fy)			

A9	Is there any filled-in checklist on the assessment of quality of service for the period of last time (mentioned in A8c)?	Yes1 (INTERVIEWER: COLLECT ONE SUCH FILLED-IN CHECKLIST FOR YOUR RECORD.) No2	
			A10
A9A	Are they recorded the quality assessment information of service on the check list/visit book during the last visit?	Yes1 No2	
A10	Is there any feedback from the supervisor? (DETERMINE THIS FROM THE CHECKLIST)	Yes, written feedback1 Yes, verbal feedback2 No	

	Provider designation	# of sanctioned	# of provider(s)	# of provider(s)
		post	available	at work today
B1	OB/GYN			
B2	Resident medical officer (RMO)			
B3	Medical officer (MCH)			
B4	Medical officer (CC-FW)			
B5	Medical officer (applicable for NGO or private clinic)			
B6	Clinic manager (applicable for NGO or private clinic)			
B7	Nurse (involved in FP work)			
B8	FWV			
B9	SACMO/MA			
B10	Paramedic (applicable for NGO or private clinic)			
B11	FWA/NGO Field Worker (applicable for NGO/FWC)			
B12	Aya (involved in FP work)			
B13	Cleaner/sweeper (involved in FP work)			

B. Information on service providers involved in the provision, supervision, or mobilization of LARC/PM services (TO BE COLLECTED FROM THE KEY INFORMANT)

C. Provision of postpartum female sterilization or IUD (TO BE COLLECTED FROM THE KEY INFORMANT)

C1	Does the facility provide delivery care?	Yes 1	
		No 2—	► Next section
C2	Is IUD service offerred at delivery?	Yes 1	
		No2—	•
C3	Is female sterilization offerred at delivery?	Yes1	
		No2	
C4	Does the facility provide C-section?	Yes 1	
		No 2	Next section
C5	Is IUD service offerred during or after C-section?	Yes1	
		No2	
C6	Is female sterilization offerred after C-section?	Yes1	
		No2	

D. Facility characteristics (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

No.	QUESTIONS	Coding Categories	
D1	Are there any signs or directions available in the neighborhood or outside of the facility which	Yes 1	
	help to locate the facility?	No2	
D2	Does the facility have signboard that is visible?	Yes 1	
		No	
D3	Is there any client/visitor waiting room, area, or space in the facility?	Yes 1	
		No	▶ D5
D4	Is there any visible sign that indicates the waiting room, area, or space?	Yes 1	
		No	
D5	Is there a Citizen Charter displayed in the facility?	Yes 1	
		No	
D6	Is there a list of services available in the facility	Yes 1	
		No	
D7	Is there a price-list of services	Yes 1	
		No	
D8	Are performance statistics (Monthly/Yearly) of the facility displayed?	Yes1	
		No	
D9	Are comprehensive FP wall-charts are displayed in the clients waiting/counseling	In waiting roomA	
	room?	In counseling roomB	
	(May be multiple responses)	Both roomD	
		No whereE	
D10	Is there a box/place where clients/patients can drop notes/letters with their	Yes 1	
	comments/suggestions	No	► E1
D11	Is the box/place easily visible?	Yes 1	
		No	

E.	Availability of BCC materials (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)					
#	Question	IUD	Implants	Female	Male	More than
				sterilizatio	sterilizatio	one
				n	n	method in

						one material
E1	Are there any billboard(s)/ banner(s) in the premise of the facility?	Yes1	Yes1	Yes 1	Yes1	Yes 1
		No2	No2	No 2	No2	No 2
E2	Are there any posters at the facility?	Yes1	Yes1	Yes 1	Yes1	Yes 1
		No2	No2	No 2	No2	No 2
E3	Are there any leaflets/booklets are kept in easily visible places?	Yes1	Yes1	Yes 1	Yes1	Yes 1
		No2	No 2	No2	No 2	No 2 ₁
		E5 🔶	E5 🗲		E5 🔶	E5 🔶
E4	Are the clients/visitors allowed to take the leaflets/booklets with them?	Yes1 ◀	Yes1	Yes 1	Yes1	Yes 1
		No2	No2	No 2	No2	No 2
E5	Are there any job-aids which are used by the service provider?	Yes1	Yes1	Yes 1	Yes1	Yes 1
	, ,	No2		No2	No 2	No 2
		E7 🗲	E7 🔶	E7 🔶	E7 🔶	E7 🗲
E6	Circle the job-aid that you observed.	Flip	Flip	Flip	Flip	Flip
		chart A	chart A	chart A	chart A	chart A
	(Devices or tools (such as instruction cards, memory joggers,	Wall	Wall	Wall	Wall	Wall
	wall charts) that allow	chart B	chart B	chart B	chart B	chart B
	an individual to quickly access the information he or she needs to	Booklet C	Booklet. C	Booklet. C	Booklet.C	Booklet. C
	perform a task.)	OthersD	OthersD	OthersD	Others D NAE	OthersD NAE
E7	Any materials from Mayer Hashi?	Yes1	Yes1	Yes 1		Yes 1
		No2	No2		Yes1 No2	
	(Code '8' if none of 'Yes' circled in E1 to E5)			No2		No2
		NA8	NA8	NA 8	NA8	NA8

F. E	F. Enabling infrastructure (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)			
	QUESTIONS F3-F7 RELATE TO TOILET FOR CLIENTS			

50			F 1
F3	Is there a functional toilet for clients?	Yes 1–	► F4
		No2–	► F8
		Yes, locked3	
F3a	Does the authority of the health facility open the locks for clients, if needed?	Yes 1	
		No2	
F4	Is the toilet clean?	Yes1	
		No2	
F5	Is there piped/tap water or running water for hand washing?	Yes1	
		No2	
F6	Is there water in bucket/drum/etc. for hand washing?	Yes1	
		No2	
F7	Is there a soap/liquid soap at hand washing place?	Yes1	
		No2	
F8	Is there a space with privacy for counseling	Yes 1	
		No2	F9
F8a	Is it possible to maintain privacy during counseling?	Yes 1	
		No2	► F9
F8b	What type of privacy is maintained for counseling?	Audio and visual privacy1	
		Audio privacy2	
		Visual privacy3	
FOR OF	PERATION THEATRE (OT) AND RELATED LOCATIONS		
F9	Is there a pre-operative preparation room?	Has pre-operative room1	
		Has room but name is different (for multiple use)	
		No room	▶
			F11a
F10	Does the pre-operative preparation room have sufficient space?	Congested 1	
	sumorent space :	Comfortable only for one person2	
		Comfortable for two person	
		Enough space4	
F11	How is the lighting condition of the pre-operative preparation room?	Low visibility1	
		Visible2	
		Bright 3	
		1	1

F11a	Is there a changing room adjacent to OT?	Yes 1
1 ⁻ 11d		
		No2
F12	Is there a separate Operation Theater (OT)?	Yes1
		No2
F14	Is there an instrument processing room/space close to OT?	Yes1
		No2
F15	Is there any toilet adjacent to OT?	Yes1
		No2
F16	Is there a functional standard OT table in the OT?	Yes1
		No2
F17	Is there a functional OT light in the OT?	Yes, Standard1
		Altervative light system, not standard 2
		No3
F18	Is there a post-operative recovery area?	Yes1
		No2
F19	Are there any functional beds in the post-operative	Yes1
	recovery area?	No2
F20	Are there functional seating arrangements in the	Yes1
	post-operative recovery area?	No2
G. Eq	uipment and Supplies (INFORMATION TO BE COLLE	L I I I I I I I I I I I I I I I I I I I
G1	Does the facility have <i>basic equipment</i> for a physical	BP InstrumentA
	exam (BP Instrument, Stethoscope, Thermometer, Height & weight scale, etc)?	StethoscopeB
		ThermometerC
		Height & weight scaleD
		Height scale (traditional)IE
		Weight scale onlyF
		Gloves for service providersG
		NoneH

Equipment and supplies required for physical/pelvic/simple laboratory examinations (general or OT) (INTERVIEWER: PLEASE NOTE YOUR OBSERVATIONS IN THE DESIGNATED COLUMNS) (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

	Name of Items	Min. No. required	No. found at facility	No. working (or in good condition)	Remark
G2.1	OT Table	1			
G2.2	OT light	1			
G2.3	Instrument Trolley	1			
G2.4	Autoclave	1			
G2.5	Sterilizer drum	4			
G2.6	Autoclave test tape	1			
G2.7	Instruments for PV exam	3 sets			
G2.7.1	I. Kuskos bi-valve Vaginal Speculum	1(3)			
G2.7.2	II. Kidney tray	1(3)			
G2.7.3	III. Gully pot	1(3)			
G2.8.	Surgical Apparel	20 sets			
G2.8.1	I. Makantchos (Gown)	5			
G2.8.2	II. Surgeon's or assistant's Gown	20			
G2.8.3	III. Tubectomy Sheet	20			
G2.8.4	IV. Vasectomy Sheet	20			
G2.8.5	V. Trolley Sheet	20			
G2.8.6	VI. Draw sheet	20			
G2.8.7	VII. Mask	20			
G2.8.7a	VIII. Cap	20			
G2.8.8	IX. Gloves cover	20			
G2.8.9	X. OT sandal	5			

	Name of Items	Min. No. required	No. found at facility	No. working (or in good condition)	Remark
H1	NSV Kit	6			
	Contents of NSV kit				
H1.1	Ring forceps	1 (6)			
H1.2	Vas dissecting forceps	1 (6)			
H1.3	Small surgical scissor	1 (6)			

H. NSV instrument kits (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

I. Functional tubectomy kits (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

	Name of Items	Min. No. required	No. found at facility	No. working (or in good condition)	Remark
11	Tubectomy Kit	10			
	Contents of the kit				
11.1	Small curved Mosquito Artery forceps	4 (40)			
11.2	Long straight Medium Artery forceps	2 (20)			
l1.2a	BP Handle	1 (10)			
l1.2b	Plain Detecting Forceps	1 (10)			
11.3	Needle Holder	1 (10)			
11.4	Surgical scissors straight	1 (10)			
l1.5	Surgical scissors curve	1 (10)			
11.7	Alley's tissue forceps	2 (20)			
11.8	Babcock tissue forceps	1 (10)			
11.9	Retractor	1 (10)			
11.10	Sponge holding straight forceps	1 (10)			
11.11	Tooth dissecting forceps	1 (10)			
l1.12	Other instruments				
	Functional for NSV and Tubectomy				
11.12.1	Large scissors for cutting gauge	2			
11.12.2	Large scissors for cutting thread	2			
11.12.3	BP machine	2			
11.12.4	Stethoscope	2			
l1.12.5	Weight machine	1			
11.12.6	Gully pot	5			
11.12.7	Kidney tray	5			
11.12.8	Lifter	5			

	Name of Items	Min. No. required	No. found at facility	No. working (or in good	Remark
				condition)	
J1	Implant				
J1.1	Table to examine client	1			
J1.2	Rest/Side Table (same height of the examining table) to keep hand of client	1			
J1.3	Soap for hand washing	1			
J1.4	Marker pen	1			
J1.6	Surgical drape	2			
J1.7	Povidon-iodine solution	1			
J1.8	Galipot to keep Anti septic mixture	1			
J1.9	Cotton balls	3-5			
J1.10	Surgical blade	1			
J1.11	Disposable anti septic syringe with needle for one time use	1			
J1.12	Medicine for Local anesthesia (1% lidocaen, without adrenalin)	1			
J1.13	Sterile Gauze	1			
J1.14	Normal bandage/butter fly bandage/ Band aid/ Elastomeric dressing	1			

J. Functional Implant kits (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

	Name of Items	Min. No. required	No. found at facility	No. working (or in good condition)	Remark
K1	IUD (in antiseptic packet)				
K1.1	Speculum (medium)	1			
K1.2	Tenaculum	1			
K1.3	Uterine sound	1			
K1.5	Straight Artery forceps	1			
K1.6	Long placenta/kali forceps	1			
K1.7	Sponge holding forceps	1			
K1.8	Straight Cutting Scissor	1			
K1.9	Sponge cotton ball (6 wet with povidon-iodine and 2 dry)	8			
K1.11	Povidon lodine mixture	2			
K1.12	Macintosh	1			
K1.12a	Mask	1			
K1.13	Torch light	1			
K1.14	Draping sheet	1			
K1.15	0.5% chlorine mixture and red bucket with cover	1			
K1.16	Blue bucket for waste disposal	1			
K1.17	IUD table with plastic sheet	1			
K1.18	High tool for sitting	1			
K1.19	Table for keeping instruments	1			

K. Functional IUD kits (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

L. Basic necessary supplies and equipment to manage emergencies at the operation theater (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

	Name of Items	Min. No. required	No. found at facility	No. working (or in good condition)	Remark
L1	Consumable Equipment				
L1.1	Oxygen Therapy Unit	1 set			
L1.2	Oxygen cylinder	2			
L1.3	Cylinder Stand	2			
L1.4	Therapy set	1 set			
	Pressure meter, flow meter, control valve, Mask-tube, water bottle				
L1.5	Airway Tube (3 diff. size)	1 set			
L1.6	Suction Machine (Electric and Manual)	1			
L1.6a	MR Syringes/ Catheter	1			
L1.7	AMBU bag	1			
L1.8	Emergency torchlight	1			
L1.9	Metallic catheter	2			
L1.10	Laparotomy Set (Venesection kit with vein flow)	1			
L1.11	Non-Consumable Equipment				
L1.11.1	Atraumatic Catgut 0	5			
L1.11.2	Ryle's tube	2			
L1.11.3	Foley's catheter	2			
L1.11.4	Rubber catheter	2			
L2.	Medicines and supplies			Expired drug?	
				Yes No	
L2.1	Inj. Naloxone injection (0.4 mg/ml)	3 Amp		1 2	

L2.2	Ini Epipophrino (adropalino 1:1000	2 4 mn	1	2	
	Inj. Epinephrine (adrenaline 1:1000 mixture) 1 mg/ml injection	2 Amp		Z	
L2.3	Inj. Hydrocortisone (100mg)	2 Amp	1	2	
L2.4	Inj. Promethazine (25mg/ml)	2 Amp	1	2	
L2.5	Inf. DNS 5% Dextrose in normal salaine (500ml bag)	3 Bag	1	2	
L2.6	Inf. Normal Saline(500ml bag)	2 Bag	1	2	
L2.7	Inj. Diazepam (10 mg/ml)	2 Amp	1	2	
L2.8	Inj. Calcium Gluconate injection 10% (10 ml/ample)	5 Amp	1	2	
L2.9	Inj. Sodi-bi-carbonate injection (25ml/ample)	5 Amp	1	2	
L2.10	Inj. Aminophylline injection (250mh/10ml)	5 Amp	1	2	
L2.11	Inj. Atropine injection (0.6 mg/ml)	5 Amp	1	2	
L2.12	Inj. Physostigmine injection (1mg/ml)	5 Amp	1	2	
L2.13	IV canola /Butterfly needle set	5 sets	1	2	
L2.14	Disposable Syringes (2ml, 5 ml, 10 ml, 50 ml)	2 sets each	1	2	

M. Infection prevention (IP) practice (TO BE OBSERVED AND RECORDED)

[IN CASE OF UPAZILA HEALTH COMPLEX, DISTRICT HOSPITAL, OR MEDICAL COLLEGE HOSPITAL, FIND FROM THE KEY INFORMANT THE FACILITY OF PART OF THE FACILITY WHERE LAPM ARE SERVED. THEN, COLLECT INFORMATION THROUGH INTERVIEW OR OBSERVATION.]

M0	Are there any Infection prevention (IP) protocol	Yes 1	
	charts or IP posters to guide staff	No	

SI. #	IP Steps	Yes	No	Remarks
	Hand Washing for facility staff			

M1	Does the facility have provision of hand washing	1	2-	
	washing		M5	
M2	Does the facility have running water supply or storage of water	1	2	
M3	Does the facility have soap	1	2	
M4	Does the facility have antiseptic for hand-rub	1	2	
	Gloving			
M5	Are there <i>examination</i> gloves kept in autoclave drum?	1	2	
M6	Are the decontaminated examination gloves kept in boxes?			
M7	Are there utility gloves kept in autoclave drum?	1	2	
M8	Are the decontaminated <i>utility</i> gloves kept in boxes?			
M9	Are any gloves recycled here in this facility	1	2	
	Decontamination			
M10	Is there any document describing protocol for decontamination?	1	2	
M11	Is there at least one bucket for the purpose of decontamination?	1	2>M13	
M12	Does the bucket have a cover?	1	2	
M13	Are there any handle(s) for stirring the materials to be decontaminated?	1	2	
M14	Are there any mugs?	1	2	
M15	Are there any weighing/measuring devices?	1	2	
M16	Is there bleaching powder solution for decontamination?	1	2	
M17	Is there 0.5% chlorine powder solution for decontamination?	1	2	
	Cleaning			
M18	Is detergent available?	1	2	
	Sterilization and High Level Disinfection			
M19	Is there a functional autoclave for sterilizing instruments?	1	2	

M20	Is there a functional electric sterilizer?	1	2	
M21	Is there a functional saucepan that is used for instrument sterilization?	1	2	
	House keeping			
M22	Are there disinfectant solutions used for cleaning floor sink and examination table?	1	2	
	Storage			
M23	Is there a designated storage area?	1	2>M26	
M24	Is the storage area clean?	1	2	
M25	Is the storage area dry?	1	2	
M26	Are instruments stored in HLD/boiled container?	1	2	
	Waste management			
MA1	Is there a dedicated place for storage of waste materials	1	2>MA4	
MA2	Is the waste-storage site properly labeled?	1	2	
MA3	Is the waste-storage site fenced and out of animal or children?	1	2	
MA4	Is there a BLACK bin for collection of general wastes?			
MA5	Is there a RED bin for collection of sharp wastes?	1	2	
MA6	Is there a YELLOW bin for collection of infectious wastes?	1	2	
MA7	Are all the bins covered?	1	2	
MA8	Does any of the bins contain mixture of wastes (i.e., infectious waste, sharp waste, or general wastes kept together in a bin)?	1	2	
MA9	Is there any spillage of wastes on the ground?			
MA10	Are sharp objects disposed in non-penetrable container?	1	2	
MA11	Are there leak-proof containers for decontaminating soiled instruments?	1	2	
MA12	Is there a functional waste-disposal system?	1	2	

MA13	Are there protective gears for waste handlers in the facility store? (To be observed in the storage area)			
MA14	Is there an incinerator for burning of wastes	1	2	

N. CLIENT RECORD REVIEW (INFORMATION TO BE COLLECTED THROUGH OBSERVATION) (I: SELECT 5 RECORDS OF EACH OF NSV, FEMALE STERILIZATION, IMPLANT AND IUD. THEY SHOULD BE THE LATEST DELIVERED METHODS/PROCEDURES. NUMBER THEM FROM 1 TO 5. FOR THE ANSWER BOX 'Y N 8' CIRCLE 'Y' IF THE ANSWER IS YES, CIRCLE 'N' IF THE ANSWER IS 'NO' AND CIRCLE '8' IN CASE OF "NOT APPLICABLE. FOR THE ANSWER BOX IS BLANK, WRITE THE COMPLETED PROCEDURE NUMBERS IN THIS BOX. DO NOT LEAVE BLANK. WRITE 8 OR 88 IN CASE OF "NOT APPLICABLE. FOR THE ANSWER BOX IS BLANK,

			Fem	ale ster	Female sterilization	E		Ma	Male sterilization	ization	
		1	2	с С	4	5	-	7	°.	4	5
Z1	Informed consent form singed and attached	v ≻∞	N ≻∞	N × 8	N × 8	N ≻ ∞	z ≻∞	z ≻∞	v ≻∞	ΥN8	Y N 8
N2	Physical exam completed by physician WRITE THE NUMBERS OF COMPLETED PROCEDURE, WRITE 88 FOR NOT APPLICABLE										
N3	Client screening checked by physician	N ≻∞	v ≻∞	N × 8	N ≻ 8	N ≻ 8	Z ≻∞	z ≻∞	v ≻∞	× N 8	Y N 8
N4	Medications for pain given recorded								-		
N4a	Inj. Pathedrine (25 mg)	۲ N 8	× N 8	N × 8	× N 8	ΥN 8	N × 8	N ≻ 8	×Ν 8	Y N 8	8 N X
N4b	Inj. Pentazocin (30 mg)	N ≻∞	v ≻∞	N × 8	z ≻∞	N ≻ 8	Z ≻∞	z ≻∞	v ≻∞	×Ν8	Y N 8
N4c	Inj. Atropine (0.4-0.6 mg)	N × 8	N ≻∞	N ≻ 8	z ≻∞	N ≻ 8	Z ≻∞	z ≻∞	v ≻∞	×Ν8	Y N 8
N4d	Inj. Pomethazine (12.5 mg)	N ≻∞	v ≻∞	N × 8	N ≻ 8	N ≻ 8	Z ≻∞	z ≻∞	v ≻∞	×Ν8	Y N 8
N5	Local anesthesia	v ≻∞	v ≻∞	N × 8	z ≻∞	N × 8	Z ≻∞	z ≻∞	N ≻ ∞	×Ν8	Y N 8
NG	Intra-op vital signs checked by physician WRITE THE NUMBERS OF COMPLETED PROCEDURE, WRITE 88 FOR NOT APPLICABLE										
N7	Post-op vital signs checked by physician WRITE THE NUMBERS OF COMPLETED PROCEDURE, WRITE 88 FOR NOT APPLICABLE										
N8	Procedure notes recorded WRITE THE NUMBERS OF COMPLETED PROCEDURE, WRITE 88 FOR NOT APPLICABLE										
N9	Discharge status recorded										
N10	Post-op medication given (WRITE NUMBERS FROM N10A TO N10G)										
N10a	Paracetamol(500 mg)										
N10b	Ibuprofen (400 mg)										
N10c	Capsule doxycycline (100 mg)										
N10d	Ciprofloxacin (500 mg)										
N10e	Antibiotic (specify)										
N10f	Antibiotic (specify)										
N10g	Diazepam (10 mg)				LN.						
		-	2	3	4	5	-	7	3 22	4	5
			1								

۲	Physical exam completed by physician (WRITE THE NUMBERS OF COMPLETED PROCEDURE, WRITE 88 FOR NOT APPLICABLE)										
N2	PV Examination (WRITE THE NUMBERS OF COMPLETED PROCEDURE, WRITE 88 FOR NOT APPLICABLE)										
N3	Eligibility check for taking Implant/IUD	N ≻ ∞	v ≻∞	v ≻∞	v ≻∞	N ≻∞	z ≻∞	z ≻∞	N ≻ 8	ΥN8	ΥN8
N4	Informed consent form singed and attached	N ≻∞	z ≻∞	v ≻∞	v ≻∞	N ≻ ®	z ≻∞	z ≻∞	N ≻ ®	ΥN8	ΥN8
N5	Procedure notes recorded	ΥN 8	× N 8	У N 8	ΥN 8	× N 8	N Y 8	× № 8	ΥN 8	γN8	Y N 8
N6	Medications for pain given recorded (WRITE NUMBERS FROM N10A TO N10G)										
N6a	Paracetamol(500 mg)										
N6b	Tablet Ibuprofen (400 mg)										
N6c	Iron tablet with folic acid (200 mg + 0.20 mg)								_		
N6d	Capsule doxycycline (100 mg)										
N6e	Cap. Ciprofloxacin (500 mg)										
NGf	Antibiotic (specify)										

O. Service delivery data from the facility (INFORMATION TO BE COLLECTED THROUGH OBSERVATION)

COLLECT THE FOLLOWING INFORMATION FOR THE PERIOD JANUARY TO DECEMBER 2014 FOR THIS FACILITY [WRITE THE INFORMATION IN THE BOX, AND CIRCLE THE CODE '999'/'9999, IF INFORMATION IS NOT AVAILABLE OR '888'/'8888' FOR

NOT AP	NOT APPLICABLE				
No	Question	IUD	Implant	Tubectomy	NSN
0	# of clients referred to this facility for(methods name)	# of clients 9999 No information9999 Not applicable8888	# of clients9999 No information	# of clients9999 No information 9999 Not applicable8888	# of clients
02	# of clients who accepted method (methods name) from this facility	# of clients 9999 No information	# of clients 9999 No information	# of clients 9999 No information 9999 Not applicable8888	# of clients
02a	# of clients who were referred to other facilities for	# of clients9999 No information9999 Not applicable8888	# of clients 9999 No information	# of clients9999 No information 9999 Not applicable8888	# of clients
03	# ofacceptors who (methods name) were followed up from this facility	# of clients9999 No information	# of clients9999 No information	# of clients9999 No information 9999 Not applicable8888	# of clients 9999 No information 9999 Not applicable8888
04	 # ofacceptors who (methods name) received treatment on side effects or complications from this facility 	# of clients9999 No information99999 Not applicable	# of clients 9999 No information 9999 Not applicable8888	# of clients9999 No information 9999 Not applicable8888	# of clients

No	Question	anı	Implant	Tubectomy	NSN	
05	# ofacceptors who	# of clients	# of clients	# of clients	# of clients	
	(methods name)	No information9999 Not applicable8888	No information9999 Not applicable8888	No information 9999 Not applicable8888	No information 9999 Not applicable8888	
	were referred from this facility to					
	complications					
06	# of acceptors	# of clients	# of clients			
	(methods name)	No information9999 Not applicable8888	No information			
	Whose methods are removed in this facility					
	Ending time			Hours		
				Minutes		
SAY THAN	SAY THANK YOU AND END THE INTERVIEW					

MEASURE Evaluation

University of North Carolina at Chapel Hill 400 Meadowmont Village Circle, 3rd Floor Chapel Hill, North Carolina 27517 *Phone:* +1-919-445-9350 • measure@unc.edu **www.measureevaluation.org**

This publication was produced with the support of the United States Agency for International Development (USAID) under the terms of MEASURE Evaluation cooperative agreement AID-OAA-L-14-00004. MEASURE Evaluation is implemented by the Carolina Population Center, University of North Carolina at Chapel Hill in partnership with ICF International; John Snow, Inc.; Management Sciences for Health; Palladium; and Tulane University. Views expressed are not necessarily those of USAID or the United States government. TR-17-183; ISBN: 978-1-9433-6461-9



